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ABSTRACT 
Alzheimer's disease (AD), the most common form of dementia, is a 
devastating age-related neurodegenerative disorder. There is a growing body of 
evidence suggesting that leading a stressful lifestyle is associated with a 
heightened risk of developing AD. This is supported by preclinical evidence 
using transgenic mice over-expressing genetic mutations leading to overt ß- 
amyloid protein production, a pathological marker of AD; stress in such mice 
has been capable of exacerbating AD-associated pathologies, including 
accelerating memory impairments and elevating ß-amyloid levels. In contrast, 
a recent study from our group demonstrated that a repeated mild stress 
procedure, novel cage stress, improved a short-term memory deficit and 
reduced the normal age-related increase in (3-amyloid levels. This thesis aimed 
to further characterise the beneficial effects of novel cage stress on AD- 
associated pathology in the TASTPM mouse model (double transgenic 
hAPP695swe x PS-I. M146V) which exhibits overt, age-related ß-amyloid 
pathology. First, age-related changes in AD-associated pathology, with or 
without exposure to novel cage stress, were assessed using a multidisciplinary 
approach incorporating measures of cognitive performance, in vivo magnetic 
resonance imaging and post-mortem analysis of ß-amyloid levels. The aim was 
to detect an age where we observe the most robust effect of stress; this time 
window was subsequently targeted to investigate a potential underlying 
mechanism, namely signalling though the glutamate alpha-amino-3-hydroxy-5- 
methyl-4-isoxazolepropionic receptor (AMPAr). Studies described throughout 
this thesis, alongside previously published data, indicate novel cage stress 
appears to improve AD-associated pathology in TASTPM mice, but 
independently of AMPAr function. It is likely that novel cage stress is 
insufficiently severe to induce detrimental effects, but, rather, subsequent 
repeated stimulation and physical activity may improve pathological status. A 
better understanding of lifestyle risk factors of AD, such as stress, will aid in 
identifying those at risk of developing the disorder. Moreover, discovering the 
underlying mechanisms linking stress with AD may open novel therapeutic 
avenues to treat the disorder. 
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CHAPTER 1 
GENERAL INTRODUCTION 
8 
1.1. Alzheimer's disease 
1.1.1. The impact on society 
Alzheimer's disease (AD), a devastating age-related neurodegenerative 
disorder, was first described by, and later named after the German psychiatrist 
Alois Alzheimer in 1907, and documented in a paper translated into English to 
read "About a peculiar disease of the cerebral cortex" (Alzheimer., 1907). The 
prevalence of AD is increasing due to the aging of the human population, likely 
a result of improved healthcare and living standards, alongside better 
recognition of the disorder. In the USA, it is estimated that there are 5.2 million 
sufferers of AD, 13% of those over 65 years old have AD (Alzheimer's 
Association, 2008). In England and Wales it is estimated that 39,400 patients 
will be diagnosed with AD each year (Copeland et al., 1999). 
AD does not only affect the sufferer directly, but also causes severe emotional 
strain to family members and carers; it is estimated that 42% of the UK 
population is affected by the disease either directly, or indirectly (Alzheimer's 
Research Trust website, www. alzheimers-research. org. uk/info/statistics/). 
Indeed, the negative emotional impact of caring for a sufferer of AD, 
professionally or personally, is well recognised and has been described 
(Grossberg, 2008; Nichols et al., 2008; Roepke et al., 2008; Vellone et al., 
2008). For instance, caregiver anxiety and stress have been shown to be 
directly proportional to the degree of AD clinical severity (Ferrara et al., 2008; 
Tun et al., 2008). 
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This high prevalence is coupled with a severe economic burden with an 
estimated annual cost of over £14 billion in the UK during 2000. Despite this 
expense, investment into researching AD is comparatively lower than other 
major disorders including cancer and heart disease (Lowin et al., 2001). There 
is currently no cure for AD; pharmacological treatments are often aimed at 
alleviating the symptoms of AD rather than preventing, or slowing the disease 
process (current therapeutic strategies to combat AD are discussed further in 
Section 1.1.3). 
1.1.2. The neuropathology of AD 
Clinically, AD manifests first as subtle memory impairments, followed by a 
gradual cognitive decline ultimately leading to a total loss of cognitive capacity 
and, ultimately, death within approximately 5 to 6 years following disease 
recognition (Molsa et al., 1986). Only identification of known pathological 
markers, commonly post-mortem, can confirm the variant of dementia as AD. 
Brain atrophy is coupled with the presence of two forms of inclusion in the 
brain: first, senile plaques composed of the insoluble form of the ß-amyloid 
peptide and second, neurofibrillary tangles (NFTs) composed of 
hyperphosphorylated tau, a microtubule-associated protein. 
Unlike these neuropathological inclusions, severe brain atrophy can be 
routinely monitored throughout the disease process to assess pathological 
status, using magnetic resonance imaging (MRI) a tool allowing for the non- 
invasive imaging of brain tissue in a living subject. Such studies have 
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confirmed a correlation between a decline in cognitive performance and brain 
atrophy (Di Paola et al., 2007), and have demonstrated regional tissue loss in 
the brain associated with specific symptoms of AD including delusions and 
apathy (Bruen et al., 2008). The direct cause of the loss of brain tissue in AD- 
affected brain is not fully understood. One theory is that the excessive release 
of excitatory amino acids, such as glutamate, is a key contributing factor 
leading to excitotoxicity and ultimately cell death (Walton and Dodd, 2007). 
Moreover, the development of the neuropathological inclusions associated with 
AD, including senile plaques and NFTs, are believed to play a key role in the 
neurodegenerative processes of AD. 
Amyloid as a potential marker of pathology in AD was first documented in 
1984 (Glenner and Wong, 1984), and later confirmed as the main component 
of senile plaques (Masters et al., 1985); it is now known that senile plaques are 
composed of a highly insoluble form of ß-amyloid protein. The processing of 
(3-amyloid, (altered due to various genetic mutations described later), formation 
of plaques and subsequent detrimental effects on brain function was 
collectively referred to as the "amyloid cascade hypothesis" (Hardy and 
Allsop, 1991). 
Under normal, non-pathological conditions, amyloid precursor protein (APP), a 
membrane-bound protein, is cleaved by the enzyme a-secretase to release C83, 
which is subsequently cleaved by y-secretase releasing soluble peptide 
fragments which are non-pathological. However, in the pathological state of 
AD, APP is cleaved by ß-secretase to release the peptide C99, which is 
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subsequently cleaved by y-secretase leading to the eventual aggregation of 
neurotoxic ß-amyloid peptide which is fibrillogenic and forms ß-amyloid 
plaques. ß-amyloid can vary in length but is commonly 40 (Aß1.40) or 42 (Aß1_ 
42) amino acid residues in length, figure 1.1 (Nordberg, 2004). Typically, Aß1_ 
4o is the more common variant, unlike the rarer API-42 residue which aggregates 
more readily to form ß-amyloidal deposits associated with the disease. 
Although there is evidence demonstrating that ß-amyloid has a detrimental 
effect on neurons in vitro (Yankner et al., 1990; Malouf, 1992; Pike et al., 
1993), possibly through enhancing vulnerability to insults (for review, (Cotman 
et al., 1992)), the role of ß-amyloid in the neurodegenerative processes 
observed in vivo, during states of pathology, is unclear. One proposed 
mechanism is that ß-amyloid can modulate cellular calcium homeostasis by 
affecting the function of synaptic ion channels. Indeed, calcium dysregulation 
is a clinical feature of AD and can possibly lead to synaptic loss (for review, 
(Green et al., 2007)). Under normal conditions, APP cleavage products are 
secreted during neuronal function (Nitsch et al., 1993), but such products may 
act to suppress neuronal activity given application of ß-amyloid to cultured rat 
hippocampal cells reduced long-term potentiation (Lambert et al., 1998); 
therefore, ß-amyloid secretion following synaptic activity might act via 
negative-feedback thus attenuating synaptic activity. Synaptic deregulation due 
to APP cleavage products, and subsequent impaired memory formation, may 
be due to the ability of soluble APP to activate potassium channels, which 
would further suppress synaptic transmission (Furukawa et al., 1996). Some 
reports have indicated a direct correlation between ß-amyloid levels and brain 
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atrophy levels (Archer et al., 2006) and, with cognitive performance in AD 
sufferers (Naslund et al., 2000), these findings are not consistent, given that ß- 
amyloid levels have been shown not to be correlated to brain atrophy (Josephs 
et al., 2008). It is worthy of note that ß-amyloidal deposits are not exclusive to 
AD; for instance, inclusions have been identified in Parkinson's disease (Braak 
and Braak, 1990). It remains unclear, however, whether 0-amyloid in AD, and 
other neurological disorders, acts as a cause, or a result of the brain atrophy. 
Under normal conditions tau proteins stabilise microtubules within neurons. 
During certain pathological states tau can become hyper-phosphorylated 
forming the intracellular inclusions NFTs. Tauopathies, a term used to describe 
neurological disorders associated with the formation of NFTs, include AD 
(Iqbal et al., 2005), progressive supranuclear palsy (Webb et al., 2008) and 
Downs syndrome (Hanger et al., 1991). The role that NFT formation plays in 
the pathogenesis of these disorders is not fully understood. Interestingly, NFTs 
are not expressed during states of disease only, but occur during normal aging 
(Geschwind, 2003), as are ß-amyloid plaques (Coria et al., 1987), which, 
together, suggest that disorders like AD may represent an accelerated form of 
normal aging. 
13 
APP 
n wMMM MMM 
C83 
ll 
a-secretase 
Soluble 
fragments 
Alzheimer's 
disease 
UUU 
Normal 
conditions 
Figure I. I. Processing of APP to release neurotoxic ß-amyloid. 
Membrane-bounded APP can be cleaved by either 0- or a-secretase, releasing 
peptide fragments C99 and C83 respectively. These are subsequently cleaved 
by y-secretase to release 3-amyloid and soluble peptide fragments from C99 
and C83 respectively. 33-amyloid aggregates forming neurotoxic (3-amyloid 
plaques, a characteristic pathological marker of AD. 
The significance of the roles played by ß-amyloid and tau in AD is a matter of 
constant debate and a traditional division of opinion lead to two beliefs, first, 
that ß-amyloid was principally responsible (those in support of this hypothesis 
were termed "bap-tilts"), or second, that tau is the main cause of the disease 
14 
(those in support of this hypothesis were termed "tau-ists") (Mudher and 
Lovestone, 2002). Despite ß-amyloid and tau receiving much attention from 
researchers, other pathological marker proteins have been associated with AD; 
for instance the protein ubiquitin has been found associated with NFTs in AD 
(Lennox et al., 1988), the pre-synaptic protein a-synuclein has been observed 
in an aggregated state in AD (Arai et al., 2001) and the nuclear protein p62 has 
been found co-localised with NFTs (Kuusisto et al., 2002). 
Having introduced the major pathological markers found in AD sufferers and 
the hypothesis that the deposition of classical inclusions occurs in an 
accelerated aging-like manner, it is now important to establish the endogenous 
difference between those unaffected and those who suffer from AD. We know 
that some genetic factors can make individuals prone to developing AD and the 
relevance of these factors will be discussed in the following sections. 
1.1.3. Genetic basis of AD 
There are, principally, two forms of AD classified by the age of disease onset. 
The more rare variant comprising 5-10% of AD cases, named "early-onset", is 
typically developed under the age 65 years old. "Late-onset" or "sporadic" AD 
is observed in sufferers over 65 years old, and is the more common form of 
AD, comprising approximately > 90% of cases (Strobel G., 2005; Alzforum, 
http: //www. alzforum. org/eFAD/overview/essay2/default. asp). 
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Around half of patients suffering from early-onset AD possess a hereditary 
form of AD known as "familial" AD. Several genes which are mutated in 
familial AD have been identified; the first description of a missense mutation 
on chromosome 21, adjacent to the APP gene, possibly being linked with AD 
was in 1991 (Goate et al., 1991). On the APP gene itself, there are mutations at 
positions 692/693 leading to decreased a-secretase cleavage, positions 670/671 
causing enhanced ß-secretase cleavage, and 717 resulting in enhanced y- 
secretase cleavage, all resulting in enhanced production of pathological 13- 
amyloid (Rubinsztein, 1997). Presenilins, proteins which are part of the 
complex forming y-secretase, also pose genetic risk factors for developing AD, 
first described in 1996 (Scheuner et al., 1996). Mutations on chromosome 14 
and chromosome 1 have been linked with mutated presenilin 1 and 2 (PS-1 and 
PS-2) respectively (Rubinsztein, 1997). 
Until recently, there was only one known genetic risk factor for the "late- 
onset" AD. Apolipoprotein (apoE), involved in lipid metabolism, has three 
splice variants, apoE2, apoE3 and apoE4. Those expressing the apoE4 allele 
are at a higher risk of developing AD, as first described in 1993 (Corder et al., 
1993; Saunders et al., 1993), and have higher ß-amyloid levels 
(Riemenschneider et al., 2000). Interestingly, those with apoE2 have a lowered 
risk suggesting this allele provides some protective effect (Corder et al., 1994). 
It has been suggested that the negative effects of possessing apoE4 are actually 
due to not possessing the more protective apoE3 or E2 alleles (Esler et al., 
2002). More recent studies, however, have revealed novel genetic risk factors 
which are likely to be associated with sporadic AD, including CLU (the gene 
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which encodes clusterin), PICALM and the complement component receptor I 
(CR1) (Harold et al., 2009; Lambert et al., 2009). 
A better understanding of this area of AD genetics may aid identification of 
those at risk of developing AD in later life, and such improved diagnosis will 
in-turn lead to earlier treatment of the disorder. Much research has been put 
into improving the diagnostic tools used to detect AD at the early stages to 
allow for early pharmacological intervention. These methods of diagnosing 
AD, and the current status of treatments are now discussed. 
1.1.4. Diagnosis and treatment 
The clinical stages of AD are believed to be preceded, in many cases, by mild 
cognitive impairment (MCI), but a comparably lower level of cognitive 
decline, affecting 5-6% of the aged population. Other strategies are aimed at 
recognising and identifying MCI due to the damage that occurs to the brain at 
this stage before progression to AD, and the high transfer rate; one study 
showed 41% of MCI sufferers progress to AD (Geslani et al., 2005). One of the 
major problems is the lack of, or misdiagnosis of AD, given that complete 
confirmation of AD at present, requires post-mortem identification of the 
pathological markers described in Section 1.1.2. Current diagnosis of AD does 
not rely on one single test, instead a battery of tests is commonly used to 
determine pathological status. 
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One of the first clinical manifestations of AD is a disturbance in episodic 
memory performance (the ability to recall specific details, such as events or 
facts), (Backman et al., 2001), followed by a gradual decline in all cognitive 
domains. Therefore, one of the first stages involves assessment of cognitive 
performance through memory tests including the Clinical Dementia Rating, 
Mini Mental State Examination and the Functional Assessment Staging, the 
outcomes of which have been proven to correlate with AD-associated 
pathological changes (for review, (Thind and Sabbagh, 2007)). Despite this 
reasonably robust correlation between cognitive performance and disease 
status, more specific tests for direct, quantifiable measures of pathology, for 
instance, measuring levels of biomarkers in both the periphery and CNS, would 
present a useful avenue to aid diagnosis (for review, (Borroni et al., 2006)). 
Measuring ß-amyloid, and APP forms, in both the blood plasma (Sundelof et 
al., 2008), and platelets (Borroni et al., 2003), respectively, has been shown to 
be capable of predicting the development of AD. Alterations in CSF ß-amyloid 
have been identified; a lower API-42 level was found in AD sufferers 
(Riemenschneider et al., 2000), possibly due to an ineffective clearance of the 
peptide from the brain. Potential biomarkers are not exclusive to ß-amyloid- 
related systems, but the total levels of tau protein in the CSF of sufferers of 
MCI may act as a predictor of AD (Maruyama et al., 2001). Despite evidence 
for such biomarker-aided diagnosis of AD, these approaches are still at the 
evaluation stage. As mentioned above, diagnosis often requires a variety of 
tests, and imaging of the brain has been used to identify early changes as 
markers of the disease state. 
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Two commonly used, and extensively researched, imaging methods to study 
AD pathology include positive emission tomography (PET) and magnetic 
resonance imaging (MRI). The principle of the former, PET, involves the 
introduction of a tracer that binds and allows the identification of the location 
of the protein of interest. Several compounds have been produced which bind 
to brain (3-amyloid, and these have been tested in AD sufferers. The aim of 
these is, therefore, to quantify ß-amyloid in a living subject (for 
review, (Nordberg, 2004)). MRI is a powerful tool capable of identifying early, 
non-invasive biomarkers of AD, and also allowing for monitoring disease 
progression. Given that it is recognised that reductions in particular brain 
region volumes occur in AD patients, structural MRI may predict the 
progression from MCI to AD (Karas et al., 2008). Further studies into 
morphological changes in AD and MCI sufferers may provide a better 
knowledge of surrogate markers of disease, thus aiding disease diagnosis (for 
review, (Kantarci and Jack, 2004)). A detailed description of MRI, and its use 
as a tool for studying AD-associated pathologies can be found in Section 2.3. 
As mentioned above, research is put into improving the diagnosis of AD in 
order to provide appropriate therapeutic intervention as early as possible. At 
present there is no cure for AD; however, agents designed to improve 
symptoms of AD are currently used. The classes of treatment available, and 
currently being researched, are described below (Helmuth, 2002). The most 
common therapy at present targets neurotransmitter systems which are affected 
in AD. For example, cholinesterase inhibitors, such as donepezil, slow the 
breakdown of the neurotransmitter acetylcholine, levels of which are decreased 
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in AD (Garcia-Alloza et al., 2005). Pharmacological routes to target 
neurotransmitter systems are not exclusive to the cholinergic pathways, drugs 
which block the receptors for glutamate, such as memantine, aim to prevent the 
detrimental effects of excitotoxicity due to elevated activity of these receptors 
in states of AD (Wenk, 2006). Treatment with donepezil and memantine have 
been shown to improve the symptoms of AD (Evans et al., 2000; Reisberg et 
al., 2003). Another potential therapy involves compounds which can inhibit 
the 0 and y-secretases, thus lowering the production of pathological 0-amyloid. 
Such secretases modulators are in clinical trials (Wolfe, 2008). Furthermore, 
metal ions such as copper and zinc in the CNS are thought to exacerbate AD 
through interactions with 0-amyloid and chelators of these ions, reducing free 
ion concentrations, could provide a novel therapeutic strategy (for review 
((Cuajungco et al., 2000)). There is, also, evidence to suggest that high levels 
of cholesterol are a risk factor for AD; statins, drugs which lower cholesterol, 
could potentially lower the risk of AD. However, there is insufficient evidence 
of any therapeutic value of statins at present (Eckert et al., 2005). Another 
promising area of treatment is through immunisation against 0-amyloid. 
Immunotherapy can be achieved actively, or passively. Active immunisation 
involves inducing the body's immune system to target 0-amyloid reducing its 
deposition, whereas passive immunotherapy involves constant exposure to an 
exogenous antibody to target 0-amyloid and lower its aggregation (Wisniewski 
and Konietzko, 2008). Unfortunately there were problems associated with early 
clinical studies of active immunotherapy with the unexpected development of 
meningoencephalitis in a small proportion of the subjects; this, however, has 
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not impeded more recent progress as both passive and active immunotherapies 
are currently in clinical trials (Brody and Holtzman, 2008). 
Research into effective diagnosis and therapies has been dependant largely on 
gaining a better understanding of the mechanisms underlying AD pathology. 
Much of what we know about such mechanisms relies upon the various animal 
models developed. These models provide the means to test novel therapeutic 
strategies, as mentioned above, pre-clinically prior to taking compounds into 
the clinic. The various animal models that are currently available to study AD- 
associated pathology will be discussed in the next section. The extent to which 
the models recapitulate features of AD, and how the models can be used to test 
disease-modifying agents, will also be addressed. 
1.2. Animal Models of AD 
To study the disease pre-clinically pathological features of AD must be 
replicated. Animal models of AD expressing one or more of these features 
have been developed for this purpose. As one would expect, normal laboratory 
animals exhibit age-related cognitive deficits (Kadar et al., 1990; Shukitt-Hale 
et al., 2004; von Bohlen and Halbach et al., 2006), but they do not exhibit AD- 
associated pathologies, such as ß-amyloid or tau-based inclusions, even very 
late in life (Dayan, 1971). Therefore normally aging animals do not directly 
model this disease state. It is, therefore, necessary to turn to animals which 
have had some form of manipulation to induce a disease-like phenotype. 
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Below, the range of animal models currently used to study AD-like pathology 
is discussed; these have been divided into three groups: 
1) Animals which have site-specific neurotoxic brain lesions to induce 
cognitive deficits. 
2) Models in which ß-amyloid has been exogenously introduced into the 
brain. 
3) Genetically manipulated animals which express AD-associated 
pathologies endogenously. 
The validity of these three approaches have been summari sed in Table 1.1. 
1.2.1. Brain lesion animal models 
Selective lesions to particular brain regions can induce cognitive impairments; 
for instance, bilateral lesions to rat entorhinal cortices with the excitatory 
amino acid ibotenate impaired spatial memory performance in the Morris 
Water Maze (Eijkenboom et al., 2000) and excitotoxic lesions to rat 
hippocampus result in conditional learning deficits and partial impairment in 
visual discrimination learning at the Y-maze paradigm (Murray and Ridley, 
1999). Interestingly, interactions have been observed when lesioning areas with 
cholinergic system involvement, which had subsequent effects on the levels of 
APP production. Selective lesions to the neocortex and hippocampus induced 
elevated expression of APP in these areas which provides evidence of possible 
links between neurodegeneration, cholinergic systems and APP expression in 
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AD (Leanza, 1998). Despite this subtle link between lesions and APP levels, 
this technique does not directly result in the production of the main 
pathological markers of AD, (3-amyloid plaques and NFTs, and only mimics 
neuronal loss that occurs in AD. In this respect, the model is of little value 
when attempting to study or manipulate the pathological mechanisms 
underlying AD, although donepezil partially reversed cognitive deficits 
induced by brain lesions in the rat demonstrating some predictive validity 
(Spowart-Manning and van der Staay, 2005). 
Another issue which needs to be addressed is the speed at which the brain 
damage occurs. During lesioning, the destruction of brain tissue occurs acutely, 
that is, shortly after the manipulation has taken place, which is not modelling 
the gradual long-tem loss of brain tissue that occurs in AD. Brain lesions 
therefore provide the means to study the effects of loss of brain material, 
although studies with this model appear to be modelling brain damage rather 
than AD per se. 
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1.2.2. ß-amyloid-infusion animal models 
The toxicity of ß-amyloid protein has been demonstrated by its direct 
introduction to the brain via a single intracerebroventricular (icv) injection, or 
though continuous infusion using an osmotic mini-pump, to induce memory 
impairments in rodents (Nakamura et al., 2001; Stepanichev et al., 2004). An 
early investigation demonstrated that continuous infusion of ß-amyloid into the 
cerebral ventricles induced deficits in spatial memory in the Morris Water 
Maze test (Nitta et al., 1994). Also, administration of ß-amyloid peptide into 
rodent brains has been shown to cause damage to neural tissue. Moreover, it 
has been shown that a bilateral icv administration of aggregated (3-amyloid 
induced decreased neuronal density, specifically in the CAI region of the 
hippocampus, which was coupled with working and reference memory 
impairments in the eight-arm radial maze (Stepanichev et al., 2004). Moreover, 
rats exposed to icv-infused ß-amyloid peptides showed a higher level of 
cognitive impairment 80 days after administration, which suggests that this 
model exhibits a slower, progressive decline in various behavioural paradigms 
(Nakamura et al., 2001). 
Rats infused with f3-amyloid, then treated with either donepezil or memantine, 
demonstrated improvements in deficits in the delayed-matching-to-position 
paradigm (Yamada et al., 2005). Despite the benefits of using ß-amyloid to 
replicate this disorder in animals it only models one aspect of AD, for instance, 
hyperphosphorylated tau, and thus NFTs, are absent. It is certainly arguable 
that, in this model, a continuous infusion of ß-amyloid provides a more 
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accurate reflection of AD compared to a single injection (Nitta et al., 1994). 
However, even this style of ß-amyloid administration does not replicate the 
gradual, increasing deposition that starts from a relatively early age in clinical 
AD, and the effects of the rapid, sudden appearance of ß-amyloid in the brain is 
likely to produce adverse effects which do not occur in AD. 
1.2.3. Genetically manipulated animal models 
As described in Section 1.1.3, genes have been identified which are implicated 
in the development of early-onset, familial AD. Knowledge of the genetics of 
AD has been used to model AD-like pathology in transgenic mice. The 
preclinical study of (3-amyloid-associated pathologies was revolutionised in 
1991 when the first genetically engineered animals were developed to 
endogenously over-express mutated human APP and, thus, exhibit extensive ß- 
amyloid pathology in the form of ß-amyloid plaque formation (Quon et al., 
1991). One of the earlier investigations in this area reported that these "p- 
amyloid overexpressing" transgenic mice developed deficits in alternation and 
spatial memory in the Y-maze and Morris Water Maze tests respectively, 
which correlated with (3-amyloid plaque pathology (Hsiao et al., 1996). 
Interestingly, spatial memory deficits in the Morris Water Maze have been 
shown to precede 3-amyloid deposition in transgenic mice (Van Dam et al., 
2003). A distinct advantage that transgenic mice have over ß-amyloid-infused 
animal models is the slower progressive deposition of ß-amyloid, which does 
not require the animals to undergo surgery. 
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Transgenic mouse models of AD over-expressing ß-amyloid are most 
commonly either singly transgenic, over-expressing mutated human APP 
(Quon et al., 1991), or double transgenic, achieved by crossing transgenic mice 
expressing APP with mice over-expressing mutated PS-1 (Borchelt et al., 
1997). Triple transgenic mice have been developed which are positive for APP 
and PS-1 and tau mutations; these mice exhibit abnormalities in unconditioned 
behaviours such as altered startle responses and hyperactivity (Pietropaolo et 
al., 2008). Studies carried out by Borchelt et al. used the double mutant APP x 
PS-1 transgenic mice to demonstrate an elevation of (3-amyloid plaques. 9 
month old APP x PS- I were comparable to singly transgenic APP at 18 months 
of age (Borchelt et al., 1997). These double, or triple, transgenic mice with 
two, or more, traits have more face validity (a measure of how well the disease 
is mimicked) given that they express more of the characteristics of the disease. 
In addition, multiple transgenic mice are useful to researchers given their 
higher level of ß-amyloid pathology, making studies aimed at reducing ß- 
amyloid levels easier. This also reduces the age of fi-amyloid pathology onset, 
and thus reducing the length of studies and making them more ethically sound 
and economically attractive. 
Such ß-amyloid over-expressing mice provide effective tools in aiding research 
into improved diagnosis. For instance, they are used for optimising MRI as a 
diagnostic tool. Much work has been done to resolve individual plaques in vivo 
(Jack et al., 2005), as described in more detail in Section 2.3. ß-amyloid-over- 
expressing transgenic mice have also proved to be useful when screening for 
therapeutic agents and appear to demonstrate a degree of predictive validity; 
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for instance, ß-secretase inhibitors lower ß-amyloid levels in transgenic mice 
(Chang et al., 2004). One such ß-secretase inhibitor is currently in clinical trials 
(Ghosh et al., 2008). Moreover, ß-amyloid immunotherapy improved cognition 
and lowered ß-amyloid pathology in an ß-amyloid-over-expressing mouse 
model (Wilcock et al., 2004). Other evidence supporting the predictive validity 
of the transgenic mouse model exists. Memantine and donepezil, drugs used to 
treat AD which antagonise the glutamatergic and agonise the cholinergic 
system respectively, improved performance at the Morris Water Maze memory 
test in a ß-amyloid-over-expressing mouse line (Van Dam and De Deyn, 2006; 
Van Dam et al., 2008). 
Given that AD is a disease which expresses several pathological features, it is 
beneficial if an animal model expresses more than one pathological marker. 
Transgenic mouse models over-expressing ß-amyloid have been found to have 
tau-positive cells which surround (3-amyloid plaques in doubly transgenic mice 
(Samura et al., 2006). Also, some studies have demonstrated cell loss in double 
transgenic mouse models over-expressing ß-amyloid (Casas et al., 2004; 
Howlett et al., 2008; Liu et al., 2008). However, it has been argued that ß- 
amyloid expressing transgenic mouse models of AD are incomplete given that 
they lack key aspects of the disease, such as NFF formation (Schwab et al., 
2004) and neurodegeneration (Stein and Johnson, 2002). Another issue that is 
worthy of note is that transgenic mice currently available which over-express 
mutated APP and PS-1 model the rarer familial form of AD, whereas the vast 
majority of human cases are of the sporadic variety. Despite this, the closest 
model available to researchers at this time is the double, or triple, transgenic 
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mouse model, expressing two or more known genetic risk factors for AD and 
providing information on 0-amyloid-associated cognitive dysfunction. These 
models have improved our understanding of the pathological mechanisms 
underlying AD and have provided the means to screen potential therapeutic 
agents pre-clinically. 
The principles of AD, its pathologies, how it is diagnosed and current therapies 
to combat its symptoms have been described above. A variety of animal 
models have been introduced and their relevance in modelling AD has been 
discussed. The conclusion was then drawn that the most effective model of ß- 
amyloid-based pathology seen in AD, in terms of validity, was the transgenic 
mouse model over-expressing ß-amyloid. This thesis deals with interactions 
between environmental and pharmacological interventions, and ß-amyloid 
pathology in the ß-amyloid over-expressing mouse line, TASTPM. The next 
section provides a description of what is currently known about TASTPM 
mice. 
1.2.4. The TASTPM mouse line 
This mouse line was created by crossing TASIO mice, positive for human 
mutated APP (hAPP695swe), with TPM mice, over-expressing a PS-1 
mutation (M146V); the resulting mouse line is the double transgenic (APP x 
PS-1) TASTPM mice (Howlett et al., 2004). Cognitive impairments have been 
observed in TASTPM mice from 6 months of age which correlates with 
increasing brain ß-amyloid pathology. Co-expression of PS-I mutation with 
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APP accelerates the onset of the pathology as levels of ß-amyloid pathology 
between 6 and 8 months of age were comparable to those observed in 16 month 
old singly transgenic TASIO mice (Howlett et al., 2004). Disturbances in 
unconditioned behaviours have also been described in the TASTPM mouse 
including heightened aggression, lowered body weight and hyperactivity, 
which are reminiscent of abnormalities observed in clinical AD (Pugh et al., 
2007). Further investigation, using microdissection, into the composition and 
localised effects of ß-amyloid plaques revealed phosphorylated tau and 
localised cell loss surrounding the inclusions (Howlett et at., 2008). 
The TASTPM mouse recapitulates ß-amyloid-based pathologies seen in AD 
and bears a resemblance to other psychological factors associated with the 
disorder, and is, therefore, an appropriate model for the studies described in 
later chapters. Given that this thesis deals with the issues of the effects of 
environmental manipulations on ß-amyloid-associated pathologies in a 
transgenic mouse model of AD it is important, firstly, to introduce and describe 
interventions such as exposure to a stressful or an enriched environment. 
1.3. The stress response and environmental enrichment 
1.3.1. The stress response 
The definition of stress is the strain placed on an individual resulting in 
subsequent adaptive physiological changes, or responses, which can be either 
beneficial (resulting in enhanced performance), or harmful potentially leading 
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to the development of psychiatric disorders (for review, (Ehlert and Straub, 
1998)). Stressors in the laboratory rodent commonly include environmental 
manipulations, such as restraint, forced-swim, exposures to temperature outside 
of the normal range and exposure to novelty. Below, the stress response is 
introduced and the beneficial and detrimental effects of stress reviewed. 
During states of stress the hypothalamus releases corticotrophin releasing 
hormone (CRH) which acts upon the pituitary gland. which subsequently 
releases adrencorticortropic hormone (ACTH) into the blood. This activates the 
adrenal glands which secrete the corticosteroid cortisol in humans or 
corticosterone in laboratory rodents 
- 
these corticosteroids belong to the 
glucocorticoid (GC) family (Papadimitriou and Priftis, 2009). Corticosterone is 
responsible for mediating many of the physiological responses to stress; for 
example, increasing core body temperature and normal weight gain in rodents 
(Bhatnagar et al., 2006), as well as providing negative feedback to the pituitary 
and hypothalamus to "switch-off' the pathway. Collectively this pathway is 
known as the hypothalamic-pituitary-adrenal (HPA) axis, figure 1.2. 
As described above, acute stressors induce a transient rise in GCs which is 
rapidly reversed after the stressor has been removed; this can actually be 
beneficial in humans by improving memory performance (Duncko et al., 2007; 
Smeets et al., 2007). This effect of acute stress has also been observed in the rat 
(Bangasser et al., 2005), and the mouse (Weiss et al., 2005). Long-term 
inappropriate or uncontrollable stress, such as a stressful working life, is linked 
with the development of affective disorders such as depression (Pittenger and 
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Duman, 2008), and has been shown to impair memory performance in humans 
(Lupien et al., 1998), the rat (Conrad et al., 1996; Mizoguchi et al., 2000) and 
the mouse (Song et al., 2006). 
Stress 
t... fý. 
Hypothalamus 
Adrenal 
glands 
Figure 1.2. HPA axis. The hypothalamus releases corticotrophin-releasing 
hormone (CRH) in response to emotional or environmental stressors. Upon 
activation by CRH. the pituitary gland secretes adrenocorticotropin hormone 
(ACTH) into the blood which acts on the adrenal glands on the kidneys. 
These adrenal glands release cortisol or corticosterone (CORT) which 
induces various physiological responses to stress and acts to inhibit activity 
of the hypothalamus and pituitary in a negative-feedback loop. Green arrows 
represent activatory pathways, red arrows indicate inhibitory pathways. 
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The effects of stress, and thus GCs, on memory performance are largely 
dependent on its impact on the hippocampus. The hippocampus provides 
negative regulatory control over the HPA axis and, due to its large 
concentration of GC receptors, is sensitive to the presence of 
cortisol/corticosterone (for review, (Kim and Diamond, 2002)). One suggestion 
is that a brief elevation of corticosterone, following acute stress provides 
stimulation to the hippocampus, thereby enhancing performance in 
hippocampal-dependant memory tasks (Beylin and Shors, 2003). However, 
long-term exposure to GCs can cause hippocampal atrophy possibly leading to 
further dysregulation of the HPA axis (for review, (Raber, 1998)). 
Interestingly, stress appears to have a negative impact on normal aging (for 
review (Pardon and Rattray, 2008)). Moreover, changes in the function of the 
HPA axis occur during aging (for review (Meaney et al., 1995)). Much 
evidence in this field focuses on the effects of early-life/post-natal stress on 
cognitive impairments which occur as part of the normal aging process (see 
(Pardon and Rattray, 2008) and references therein). However, evidence to 
suggest that mid-life stress can exacerbate age-related cognitive impairments is 
sparse; one particular study demonstrated that chronic unpredictable stress, 
applied during adulthood in the rat, worsened the age-related decline in spatial 
cognition that occurred later in life (Sandi and Touyarot, 2006). It is clear from 
such existing studies that stress can interact negatively with the formation of 
age-related cognitive impairments. 
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An important factor to consider when looking at the positive versus the 
negative effects of stress is the intensity of the stressor. Severe or traumatic 
stressors are thought to have more detrimental effects to cognitive function 
such as amnesia (for review, (Joseph, 1999)), whereas mild stressors are 
believed to be beneficial in aging (for review, (Minois, 2000)), probably by 
providing the stimulation needed for enhanced attention. The boundaries 
dividing a mild stressor, and thereby enriched environment, (a manipulation 
which is generally beneficial in various states of pathology (for review see, 
(Laviola et al., 2008)), is sometimes poorly defined. There appears to be, at 
least, some overlap between mild stressors and environmental enrichment 
which is thought to be beneficial in disease states - the principles of these 
beneficial effects of enrichment will now be briefly described. 
1.3.2. Environmental enrichment 
A large body of evidence exists to indicate a positive effect of an active. life- 
style, including physical exercise cognitive function in normal aging (Anstey 
and Christensen, 2000; Newson and Kemps, 2005; Angevaren et al., 2008). 
Moreover, exercise has been proved to improve symptoms in sufferers of 
psychiatric disorders such as depression (for review, Environmental 
enrichment has been shown to improve cognitive deficits induced by brain 
damage in the rat (Passineau et al., 2001), and age-related cognitive 
impairments in the mouse (Frick et al., 2003). 
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Several lifestyle risk factors are thought to modulate the risk of developing AD 
including diet, exercise and mental activity (for review, (Weih et al., 2007)). 
Stress and environmental enrichment both interact with psychiatric disorders 
and memory performance, as described above, and the interactions of these 
environmental manipulations with pathologies associated with AD, both 
clinically and pre-clinically, are reviewed in the next section. 
1.4. Environmental manipulations and AD-related pathology 
1.4.1. Stress and AD-associated pathologies 
There is emerging evidence supporting a role of stress as a risk factor in the 
development of age-related neurodegenerative disorders, including AD. As 
described above, a wealth of evidence exists associating stress with, for 
instance, hippocampal dysfunction and associated memory loss, supporting the 
hypothesis of a role of stress in the development of dementia. Indeed, 
individuals likely to experience stress are at over double the risk of developing 
AD, and experience a more rapid decline in cognitive performance and worse 
episodic memory deficits during AD (Wilson et al., 2003; Wilson et al., 2004; 
Wilson et al., 2005; Wilson et al., 2006). Proneness to suffering distress 
throughout life was also found to be associated with increased incidence of 
developing MCI (Wilson et al., 2007). Moreover, a study revealed that aged, 
non-demented subjects who experience stress, and harbour the apoE4 allele, 
perform worse at certain memory tests (Peavy et al., 2007), although 
expression of apoE4 was not found to be associated with distress proneness 
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(Wilson et al., 2007). This association between a stressful life and increased 
risk of AD does not appear to correlate directly with characteristic pathological 
markers such as ß-amyloid plaques and NFTs (Wilson et al., 2003; Wilson et 
al., 2006; Wilson et al., 2007). 
This relationship is also supported by studies examining the effects of 
emotional and environmental stressors on AD-associated pathologies in animal 
models of the disorder, these are summarised in Table 1.2. Chronic mild 
psychological stress was found to accelerate the age-dependent accumulation 
of cortical and hippocampal ß-amyloid plaques, soluble ß-amyloid in 
hippocampal interstitial (ISF) fluid, and memory deterioration in ß-amyloid 
over-expressing transgenic mice (Dong et al., 2004; Kang et al., 2007). 
Moreover, repeated stress enhanced localised tau accumulation, ß-amyloid 
plaques and degenerated neurons in the hippocampus of ß-amyloid over- 
expressing transgenic mice (Jeong et al., 2006). Treatment with the synthetic 
GC dexamethasone in APP x PS-1 x tau triple transgenic mice enhanced f3- 
amyloid levels and elevated tau accumulation (Green et al., 2006). In addition, 
treatment with the synthetic GC prednisolone, elevated ß-amyloid levels in the 
cortex of the ß-amyloid-infused rat brain, indicating a reduced clearance of ß- 
amyloid (Harris-White et al., 2001). 
Although, as mentioned in Section 1.2, normal rodents do not form AD-like 
pathology with physiological aging, the effects of stress on normal animals 
have provided information linked to changes observed in AD. For instance, 
severe acute and repeated stress enhanced localised APP mRNA production in 
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normal rat brain (Rosa et al., 2005). Unlike most rodents, non-human primates 
develop ß-amyloid plaques as part of normal aging. Cortisol administration to 
macaque monkeys resulted in an increased Aß(1_42): Aß(1.40) ratio in the brain, 
and a reduction in plasma Aß(1_42), changes similar to those observed in AD. 
However no effect on (3-amyloid plaque deposition was observed (Kulstad et 
al., 2005). Changes with stress relevant to AD are not restricted to ß-amyloid; 
acute and repeated stress in normal mice induced phosphorylation of tau 
protein, a precursor stage to NFT formation (Okawa et al., 2003; Feng et al., 
2005; Ikeda et al., 2007), which appears to be mediated by CRF receptor 
signalling (Rissman et al., 2007). Despite such findings not being directly 
relevant to AD given the lack of associated pathology, they aid understanding 
of the mechanisms connecting stress and the formation of pathological markers 
similar to those in AD. 
As described in Section 1.1.3, mutations in APP and PS are risk factors for the 
rare familial AD variant, but a known genetic risk factor in development of the 
common, sporadic late-onset AD is the possession of apoE4 allele. Variations 
in CSF cortisol levels in AD sufferers have been reported to be dependent on 
apoE genetic status, with subjects possessing the apoE4 allele presenting the 
highest CSF cortisol levels, while aopE2 expressers had the lowest cortisol 
levels (Peskind et al., 2001). Although links between the apoE genotype and 
effects of stress remain to be understood, it has been speculated that different 
variants of apoE may enhance the susceptibility to stress-related insults (Peavy 
et al., 2007). Despite transgenic mice expressing human apoE4 being available, 
no studies have looked into effects of stress on these animals to date. 
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Dysfunctional allostasis of the HPA-axis is a widely accepted clinical feature 
of AD (for review, (Pomara et al., 2003)). Although there are conflicting 
findings as to whether transgenic mice expressing 0-amyloid exhibit HPA-axis 
dysregulation some studies have reported enhanced measures of basal 
corticosterone levels in APP over-expressing mice (Touma et al., 2004). This, 
however, is not a consistent observation (Gil-Bea et al., 2007). Elevated basal 
plasma corticosterone levels in APP x PS-1 x tau triple transgenic mice were 
observed from 9 months of age (Green et al., 2006). An altered stress response 
in APP over-expressing mice has been reported, appearing prior to the onset of 
plaque development, which is indicative of a detrimental role of soluble ß- 
amyloid in HPA-axis dysregulation (Pedersen et al., 1999). HPA-axis 
hyperactivity and subsequent sensitivity in transgenic mice for AD may, 
therefore, be a modulating factor in the severity of the response to stress. 
The limited number of pre-clinical and clinical studies into stress effects on AD 
does not yet allow for a good understanding of how stress can impact upon 
AD. Interestingly, stress effects on AD appear to occur apparently 
independently of neuropathological markers in humans, but enhance similar 
markers modelled in animals. There is an emerging link between stress and the 
production/degradation of 0-amyloid; it is important to understand how GC 
responses to stress affect the ß-amyloid cascade, along with other underlying 
mechanisms linking stress with AD since this may provide novel avenues for 
therapeutic intervention. For example, through targeting the GC stress response 
systems it might be possible to slow or prevent neurodegenerative diseases, an 
issue that has been recently discussed (Dhikav and Anand, 2007). An ongoing 
study of this type investigating the effects of the GC-antagonist mifepristone 
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could provide information on the therapeutic potential of targeting this system 
to enhance cognitive performance in AD sufferers (Belanoff et al., 2002). 
As described in Section 1.3.1, stress can have a negative effect on cognitive 
function and, as described above, appears to exacerbate AD-associated 
pathology. Another environmental manipulation, enrichment can improve 
cognitive decline associated with normal aging, its effects on AD-like 
pathology will therefore be described briefly in the next section. 
1.4.2. Environmental enrichment and AD-associated pathologies 
Literature exists indicating that a lifestyle which involves more exercise, social 
and leisure activities lowers the risk of developing dementia or AD 
(Fabrigoule, 2002; Fratiglioni et al., 2004; Perez and Cancela Carral, 2008). 
Furthermore, heightened education levels were seen to be negatively correlated 
with AD severity (Roe et al., 2008). The notion of living in an "enriched 
environment" lowering the risk of AD is supported by studies with ß-amyloid 
over-expressing transgenic AD mouse models. It has been reported that 
environmental enrichment, such as access to several play items, attenuated 
cognitive impairments (Jankowsky et al., 2005) and reduced ß-amyloid 
pathology (Lazarov et al., 2005) in a double transgenic mouse model of AD. In 
addition, one study using ß-amyloid over-expressing single transgenic mice 
showed that exposure to home cages enriched with items to encourage exercise 
and stimulation improved anxiety-related behaviour in the elevated plus maze 
test (Gortz et at, 2008). Although this connection is not fully understood, one 
likely explanation for these effects is the associated increased level of 
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enhanced exercise which has been shown to lower brain ß-amyloid in 
transgenic mice (Adlard et al., 2005), and to improve performance in a variety 
of behavioural tests in normal mice (Clark et al., 2008). Interestingly, 
corticosterone was elevated in mice as an acute response to exercise (Girard 
and Garland, 2002). As discussed above in Section 1.3.1, mild or acute 
stressors can improve brain function. Additionally, the evidence cited above 
supports a potential link between HPA-axis function and environmental 
enrichment, ultimately providing benefit to cognitive function. 
There is significant evidence, summarised above, to suggest that changing 
lifestyle appears to be capable of modulating the pathologies associated with 
AD. Being subject to inappropriate / uncontrollable or living a stressful 
lifestyle appears to worsen AD-associated pathologies, whereas an active 
lifestyle with an appropriately stimulating environment seems to provide some 
benefits in relation to the disorder. Improving our understanding of the 
mechanism underlying such associations will not only guide us to improve our 
lifestyles and therefore lower the risk/burden of AD, but may also open novel 
therapeutic avenues to combat the disorder. 
1.5. Aims and objectives 
The overall aim of this thesis is to investigate further the interactions between 
stress and AD-associated pathology in the TASTPM double transgenic mouse 
model over-expressing ß-amyloid. This will be achieved using a 
multidisciplinary approach incorporating in vivo measurements of cognitive 
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performance, and pathological status using in vivo MRI, alongside ex vivo 
determination of ß-amyloid burden using a variety of analytical techniques. 
The specific objectives of the studies are listed below: 
1. To characterise the main behavioural paradigm used in this thesis to 
assess cognitive functioning in mice, and to set-up small animal in vivo 
MRI acquisition, and to optimise the MRI and immunohistochemistry 
image analysis tools used. 
2. Once these experimental procedures have been established they will be 
used to describe the TASTPM mouse model. More specifically, the 
effects of a repeated mild stress procedure on AD-associated 
pathologies in TASTPM mice at a variety of ages during early-to- 
moderate stages of pathology will be investigated. From these findings, 
a time-window in TASTPM mouse pathology when we see the largest 
effects of stress will be identified. 
3. This time window will then be used to study a potential underlying 
mechanism responsible for the relationship between stress and the AD- 
like pathologies in TASTPM mice, by targeting the glutamatergic 
system pharmacologically. 
Overall, the studies should provide a profile of early AD-like pathologies in 
TASTPM mice, furthering our understanding of interactions with lifestyle risk 
factors, such as stress, and will clarify the mechanisms through which these 
effects are exerted. 
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CHAPTER 2 
OPTIMISATION OF METHODS 
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2.1. Introduction 
Studies into the effects of stress on AD-like pathology in (3-amyloid 
overexpressing mice often rely on changes in the behavioural end-point of an 
animal as an indicator of modulation of AD-associated pathology by 
environmental or pharmacological intervention in vivo. Throughout studies 
reported in this thesis, a behavioural test was used consistently to identify 
changes to mouse memory performance with such challenges. This behavioural 
measure was used in combination with in vivo magnetic resonance imaging 
(MRI) applied, in this instance, to study changes in brain region structure and 
morphology, as well as providing an indicator of changes in the properties of 
brain tissue in the early stages of ß-amyloid deposition. These in vivo markers 
of pathological status of the TASTPM mouse were supported by post-mortem 
quantification of ß-amyloid; one method used for this purpose was 
immunohistochemistry to identify the protein. 
The purpose of this chapter is to introduce various methods which were used 
throughout this thesis; suitability and optimisation of the methods implemented 
are described with particular reference to the following: 
1. The optimisation of a behavioural paradigm to assess memory 
performance in mice. 
2. The development of MRI image acquisition protocols, and a semi- 
automated image analysis tool to extract data from these scans. 
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3. The formulation of a semi-automated image algorithm to quantify f3- 
amyloid burden from immunohistochemistry sections. 
2.2. Memory performance test optimisation 
2.2.1. Introduction 
Contextual fear conditioning (CFC) is a tool capable of studying the memory 
performance of laboratory rodents. The test relies upon the development of a 
classical Pavlovian association between a conditioned stimulus (CS) and an 
unconditioned stimulus (US). Typically, the CS is a memory cue, such as a 
sensory stimulus or novel context, and the US is commonly a series of 
footshocks administered as a negative associated cue (for review (Maren, 
2001)). When the US is presented in the presence of the CS the animal 
develops a CS-US association and exhibits a conditioned response (CR); when 
the US is a footshock, the CR is often an emotional fear-like response, 
exhibited in rodents as immobility (Maren, 2001). This represents a training 
stage when the memory is acquired, and is referred to as "memory acquisition" 
in the following studies. The intensity of the CR can be tested at a later time 
point by presenting the CS in the absence of the US; the strength of the CR is 
indicative of memory retained and thus immobility of the animal is a measure 
of "memory retention". During the memory retention test, the animal is 
exposed to the CS without the US (footshocks), therefore the CS-US 
association becomes weaker, the animal anticipates the footshock less with 
continued exposure to the CS, and the CR declines. This process is known as 
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"memory extinction" and represents a form of re-learning that the CS is no 
longer aversive, which can be tested multiple times following the memory 
retention trial, figure 2.1. 
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Figure 2.1. Contextual memory acquisition, retention and extinction. 
During CFC conditioning learning is expressed as immobility exhibited by 
the mouse during memory acquisition. The level of immobility increases with 
repeated application of the footshocks (US) in the presence of the CS, a novel 
context. If the animal has learnt, and can successfully remember the CS-US 
association, during the memory retention test the mouse will anticipate the 
US and exhibit a high level of immobility when presented with the CS alone. 
During the memory extinction trial(s), if the mouse learnt to no longer 
associate the CS with the US during the memory retention trial, the 
immobility levels decline. 
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Similar paradigms have been well described in the literature and have been 
used to study memory deficits in ß-amyloid-overexpressing transgenic mice for 
AD (Comery et at, 2005; Saura et al., 2005; Jacobsen et al., 2006; Quinn et al., 
2007; Riddell et al., 2007). For example, the test has proven to be sufficiently 
sensitive to identify an accelerated onset of memory deficit with chronic stress, 
and attenuated cognitive impairments with pharmacological intervention in 
such mice (Dong et al., 2004). 
Unlike many behavioural paradigms one can use to study memory systems in 
rodents, CFC conditioning provides the potential to test both short, and long- 
term memory retention and extinction. Briefly, the nature of these two forms of 
memory, and how they are tested, is important when specifically studying AD- 
associated pathology. Clinical symptomology of AD show an age-related 
profile of memory loss; for instance, remote memory, those memories formed 
and retained over relative longer periods of time, appears to be affected later in 
the disease process (Sartori et al., 2004). 
CFC memory tests provide a robust measure of cognitive performance, which 
is essential when studying potential loss of memory in a mouse model for AD. 
Therefore, CFC in mice was optimised, as described below, for the first-time at 
the University of Nottingham. 
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2.2.2. Methods 
Animals 
Male C57B1/6 mice (Charles River Laboratories, UK) were used. Mice were 
divided into two main groups, shocked and non-shocked; non-shocked mice 
were used in this study to confirm the negative CR expressed during this test 
was due to the shocks, and not an unconditioned response to the novel operant 
chamber. Mice were then further divided into two subgroups depending on the 
form of memory tested (either short-term or long-term memory); short-term 
memory shocked mice (n=4), short-term memory non-shocked mice (n=2), 
long-term memory shocked mice (n=4), long-term memory non-shocked mice 
(n=3). Animals were individually housed with food and water available ad 
libitum. Animals were kept in a constant environment, on a 12h light: dark 
cycle, temperature and humidity were controlled automatically. All procedures 
were carried out according to the Animals (Scientific Procedures) Act 1987, 
under license PPL 40/2715 granted to Professor Charles Marsden. 
Memory testing 
There is variation of CFC protocols used between different groups. The CFC 
protocol used in the following studies was adapted from a previous study 
(Frankland et al., 2004). In that study the authors used CFC to identify regions 
of the mouse brain involved in both short and long-term memory retention. The 
protocol involved 5 footshocks (0.75 mA, 2 seconds, once per minute) as the 
US, and memory retention was tested 24h later for short-term memory, and 36 
days later for long-term memory. 
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In this optimisation, the protocol described above was adapted to suit our 
requirements, the US involved 10 footshocks (0.4mA, I second, once per 
minute) delivered by a shock generator (Campden Instruments, Loughborough, 
UK); the mouse was placed into the "Skinner box" operant chamber (CS) and 
the first shock was administered 60 sec later. The operant chamber measured 
25cm x 25cm x 38cm. Footshocks were administered through alternate steel 
bars, spaced 1 cm apart, at the base of the chamber. The CFC box was 
thoroughly cleaned with 20% ethanol solution between sessions to remove any 
scent markers which may act as confounding associative olfactory cues. Mice 
were placed individually into the operant chamber during all trials and their 
behaviour was video-taped, by a camera suspended above the experimental 
apparatus, and subsequently scored using Ethovision (Noldus, Wageningen, 
Netherlands), figure 2.2. This software allows for the simultaneous recording 
of manually scored immobility as well as activity (distance moved by the 
mouse); for a large cohort of 3 month old mice (both WT and TASTPM, total 
n=29), activity (cm) and immobility (sec) exhibited by the mice during CFC 
memory acquisition were found to be highly correlated (R2=0.96, figure 2.3), 
therefore, automatically recorded activity was used as a general indicator of 
fear memory acquisition throughout the remainder of this thesis. 
In this optimisation, short- and long-term memory retention was assessed 24 h 
and 33 days later respectively, which involved re-exposure for 3 mins to the CS 
(operant chamber) in the absence of the US; immobility was manually scored. 
Although several memory extinction trials can be performed during a CFC 
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experiment, only one extinction trial (identical to the memory retention trial) 
was performed for both the short- and long-term memory tests 48 h following 
the memory retention test. 
Figure 2.2. CFC apparatus. Diagram representation of CFC experimental 
apparatus. Mice were placed individually in the "Skinner-box" operant 
chamber. Footshocks were administered from an electric shock generator via 
the steel rod floor. The mouse's immobility was recorded via a video camera 
and scored manually. 
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Figure 2.3. Correlation between activity and immobility as measures of 
fear memory acquisition. Mean activity (distance moved, cm) and mean 
immobility (sec) for each of the 10 minutes/footshocks during the CFC 
memory acquisition trial exhibited by a mixed population of 3 month old 
mice (both WT and TASTPM, n=29). The two measures of this conditioned 
fear response are highly correlated (R2 = 0.09551). 
All CFC conditioning results were analysed using the statistical software 
package SPSS 14.0, with a repeated measures ANOVA and Tukey's post-hoc. 
For "memory acquisition" Time (total distance moved, cm per minute over the 
10 minute trial) was the within-subject factor, and Shock (shocked vs. no 
shocked) was the between-subject factor. To analyse performance during the 
memory retention and extinction tests, Trial (performance at the memory 
retention test vs. extinction test) was the within-subject factor, Shock and 
Memory (short-term vs. long-term memory), were the between-subject factors. 
Values are expressed as mean immobility (sec) ± standard error of mean 
(SEM). 
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2.2.3. Results 
During contextual fear memory acquisition both groups showed a change in 
activity over the 10 minute trial (P = 0.026), a Time X Shock interaction did 
not quite reach statistical significance (P = 0.05). Mice exposed to footshocks 
showed an overall lower level of activity (P < 0.0001), figure 2.4. 
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Figure 2.4. CFC memory acquisition. Mean (± SEM) activity (distance, cm) of 
mice exposed to either no footshocks (n=5) or footshocks (n=8) over the 10 min 
training period. Both shocked and non-shocked mice showed a decline in activity 
as a function of time (P = 0.026); mice exposed to repeated footshocks show a 
progressive decrease in activity as a function of time, as compared to non- 
shocked mice, which did not quite reach statistical significance (P = 0.05). Non- 
shocked mice had, overall, a higher level of activity compared to shocked mice 
throughout the trial (P < 0.0001). 
During the memory retention tests, there was a difference between non- 
shocked and shocked immobility for both the short- and long-term memory 
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performance (P < 0.0001); shocked mice in both the long and short-term 
memory groups exhibited high levels of immobility, indicative of a conditioned 
fear response, figure 2.5. Reduced immobility between the memory retention 
and extinction trials was observed in the shocked short-term memory group 
only (P = 0.004), but did not quite reach statistical significance in the long- 
term memory group (P = 0.083). During both the memory retention and 
extinction trials, there were no differences between the short- and long-term 
memory groups, figure 2.5. 
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Figure 2.5. Short- (24 h) and long-term (33 days) memory retention and 
extinction. Mean (± SEM) level of immobility expressed by mice in the 
short-term memory group (left, non-shocked (NS, open bars, n=2) shocked 
(S, closed bars, n=4)) and long-term memory (right, non-shocked (NS, open 
bars, n=3) and shocked (S, closed bar, n=4)). During the memory retention 
trial non-shocked mice expressed lower immobility (***P < 0.0001) 
compared to shocked mice in both the short and long-term memory tests. A 
significantly (**P = 0.004) lower level of immobility from the memory 
retention to the extinction trial was exhibited by shocked mice in the short- 
term memory studies. This, however, did not quite reach statistical 
significance for the long-term memory group (P = 0.083). 
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2.2.4. Discussion 
CFC was optimised to allow for the study of both short and long-term memory 
performance in mice. Mice successfully acquired and retained aversive 
contextual memory for up to 33 days, and appear to have successfully 
exhibited memory extinction. 
Mice acquired an aversive contextual memory with repeated footshock 
exposure in a novel context as demonstrated by the suppression of activity in 
the shocked mice, this is consistent with the well described classical 
conditioning behaviour (Maren, 2001). Collectively, both groups showed a 
change in activity over time; however, while the non-shocked mice remained 
relatively active throughout the 10 min trial, shocked mice showed a constant 
reduction upon repeated shock, indicative of enhanced immobility behaviour. 
Retention of this aversive contextual memory was intact at similar intensity 
both 24h and 36 days following training, similar to findings described 
previously (Frankland et al., 2004). 
Many studies have been aimed at identifying the brain regions involved in 
processing contextual memories. A molecular imaging study revealed 
involvement of the anterior cingulate cortex in the consolidation of long-term 
contextual memory in mice (Frankland et al., 2004). However, the majority of 
studies have been aimed at identifying brain areas responsible for expression of 
conditioned fear responses by localised damage to brain structures. For 
instance, damage to the basolateral amygdala, hippocampus and prefrontal 
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cortex in rats have disrupted conditioned memory performance in the rat 
(Kjelstrup et al., 2002; Berlau and McGaugh, 2003; Sierra-Mercado et al., 
2006). Such studies provide an indication of the brain anatomy involved in 
memory retention expression, which is dependent on the type of memory 
involved, be it short or long-term memory, (for review, (Wiltgen et al., 2004)). 
During this optimisation the short-term memory group expressed significant 
memory extinction, whereas the long-term memory group only showed a 
general trend towards extinction. A higher number of subjects in the long-term 
memory study may have provided higher statistical power to reach a significant 
level. Alternatively, another theory is that this may represent a known 
difference between short and long-term memory. Molecular pathways 
underlying short-term memory are thought to be less robust and believed not to 
involve structural changes in brain architecture, whereas long-term memory 
relies upon semi-permanent structural protein changes (for review, (Wiltgen et 
al., 2004)). Such robustness may lead to elevated resistance to the process of 
memory extinction. Similar studies to those described above have revealed the 
brain circuitry involved in fear memory extinction. Similar to the memory 
retention circuitry, extinction appears to involve interactions between 
amygdala and prefrontal cortex, while the hippocampus appears to play a more 
regulatory role (for review, (Ji and Maren, 2007)). 
In this experiment, the optimisation of CFC was successful as the aversive cue, 
footshock, was sufficient to induce a conditioned memory (CR) which was 
evident for at least one month following training. Further to this, mice were 
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capable of extinguishing this fearful contextual memory upon re-exposure to 
the CS in the absence of the US. This protocol was therefore used throughout 
the following studies as a measure of cognitive function and memory 
performance in TASTPM mice, along with wild-type controls, and to assess 
the effects of various treatments on cognitive performance. 
2.3. Magnetic resonance imaging (MRI) 
2.3.1. Introduction 
A behavioural endpoint such as CFC provides a tool to study memory 
performance in transgenic mouse model of AD; this information can be 
correlated with in vivo imaging methods to provide a more complete picture of 
pathological status. MRI is a tool which allows the non-invasive imaging of the 
brain in a living subject. 
The basic principal allowing for the imaging of tissue by MRI relies upon the 
magnetic properties of hydrogen protons. Protons spin along an axis, and these 
axes of multiple protons are randomly aligned in tissue. When placed inside a 
strong magnetic field, for instance within an MRI magnet, hydrogen ions, and 
the precession of these ions, align either in a high-energy, or low-energy state. 
A radiofrequency (RF) pulse is administered and the axes, and their precession, 
flip to a new angle, termed the "flip-angle". The flip-angle is commonly 90°. 
As the axes and precession relax back to the original spin state and direction, 
aligned with the magnetic field, a signal is released called Ti relaxation. The 
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signal released by the precession of the ions during the relaxation is called T2 
relaxation, see figure 2.6. TI and T2 relaxation reflect tissue composition, for 
instance the rate of relaxation can be dependent on tissue water content, as 
described in more detail below. Relaxation can then be received using a 
specially designed coil, transferring the signal to data in order to create an 
image. High resolution images, from such scans, are routinely used by 
clinicians to study changes in brain characteristics, such as morphology, 
associated with degenerative diseases observed in AD. 
Figure 2.6. Diagrammatic representation of the principles of MRI. 1. 
Hydrogen protons (blue circles) are randomly aligned and spin on their axis 
(precession, green arrow) in tissue. 2. When placed in magnetic field, the axis, 
and precession align. 3. A radiofrequency pulse causes all ions, and their 
precession, to align to a new flip-angle (commonly 900). 3. Relaxation of the 
proton axis, and its precession, from this aligned state, back to the original spin- 
states, provides signal (TI and T2 relaxation respectively). Signals can be 
received by a coil and subsequently converted into an image. 
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Thus, in vivo MRI offers a potential diagnostic tool to aid the identification of 
AD at the early stages, during disease development, to allow for earlier 
therapeutic intervention. Preclinical research using ß-amyloid-overexpressing 
transgenic mice for AD have shown that MRI can be an appropriate tool to 
monitor changes associated disease progression through a variety of methods 
(see below, and references therein). 
MRI clinical studies have shown changes in specific brain region volumes, 
such as the hippocampus and entorhinal cortex (Fox et al., 1996), have been 
associated with an increased risk of conversion from MCI to AD (Apostolova 
et al., 2006). Monitoring specific brain area volume loss through MRI during 
the early stages of AD can, therefore, provide the potential to predict the 
conversion of AD from MCI (for review, (Chetelat and Baron, 2003)), which 
may allow for early pharmacological treatment. Similarly, this tool has been 
exploited to study alterations to brain morphology in ß-amyloid-overexpressing 
transgenic mouse models for AD. Histological examination of 3.5 month old 
PDAPP mouse line showed substantial reductions in corpus callosum and 
hippocampal volumes (Gonzalez-Lima et al., 2001); this finding has been 
supported by ex vivo MRI on cadavers of the same mouse line at a similar age 
where hippocampal volume was reduced prior to ß-amyloid deposition, but no 
significant differences were found for whole brain volume (Redwine et al., 
2003). In vivo MRI has been used to identify changes in brain region volumes 
in transgenic mice over-expressing ß-amyloid (Weiss et al., 2002; Van Broeck 
et al., 2008). 
58 
Another tool available to monitor disease progression is T2 relaxometry. This 
is calculated by repeated measurements following the RF pulse, at a number of 
time points during the ion precession relaxation stage, figure 2.6(4). T2 
relaxation times are reflective of tissue composition, changes of which are 
associated with certain disease states. Elongation of T2 relaxation time has 
been associated with clinically diagnosed AD, and has been shown to be 
correlated with clinical severity (Laakso et al., 1996) and declines in cognitive 
performance (Kirsch et al., 1992). This, however, is not universally observed; a 
similar study found no change in 72 relaxation in the hippocampus of subjects 
suspected to have AD (Campeau et al., 1997). In contrast to prolonged T2 
relaxation in clinical AD, shortened T2 relaxation times have been observed in 
various transgenic mouse models of AD overexpressing (3-amyloid (Helpern et 
al., 2004; Falangola et al., 2005b; El Tannir El Tayara et al., 2006; El Tayara 
Nei et al., 2007; Falangola et al., 2007). The reason for the fundamental 
difference in T2 relaxation times clinically and preclinically is unknown. T2 
relaxometry, nevertheless, offers a non-invasive in vivo approach to monitor 
pathological changes when studying AD, clinically or preclinically, and is 
sufficiently sensitive to detect early changes before overt onset of pathology. 
Another tool made available by MRI to aid accurate diagnosis of AD is the 
imaging of individual ß-amyloid plaques in vivo. Work has been done to 
achieve this by application of an exogenous contrast agent, for instance 
Pittsburg compound B, and applying positive emission topography (PET), as 
discussed in Section 1.1.3. The non-invasive identification of ß-amyloid 
plaques through high-resolution MRI has not, as yet, been accomplished in 
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human AD sufferers. However, a wealth of evidence showing that this can be 
achieved in ß-amyloid-overexpressing transgenic mice is available. Early 
studies involved the application of an exogenous contrast agent to aid the 
visualisation of ß-amyloidal deposits, which has proven successful (Poduslo et 
al., 2002; Wadghiri et al., 2003; Higuchi et al., 2005). Subsequently, ß-amyloid 
plaques have been successfully imaged in various transgenic mouse brains in 
the absence of an exogenous contrast agent both ex vivo (Lee et al., 2004; 
Zhang et al., 2004), and in vivo (Jack et al., 2004; Jack et al., 2005; Vanhoutte 
et al., 2005; Borthakur et al., 2006; Braakman et al., 2006; Dhenain et al., 
2007; Faber et al., 2007; Wengenack et al., 2008). It is clear that resolving, and 
thus identifying, ß-amyloid plaques presents a potential method of assessing 
pathological burden in these mice and, ultimately, clinical AD. This method 
may be less appropriate, however, when studying the early stages of ß-amyloid 
deposition given its inability to identify inclusions prior to 5 months of age in 
double transgenic mice known to exhibit deposits as early as 2.5 months old 
(Dhenain et al., 2007). 
MRI-based studies aimed at assessing early pathological changes which occur 
in ß-amyloid-overexpressing mice may lead to improved identification of more 
sensitive and subtle neurological changes that could potentially be transferred 
to the clinic. In the following studies in vivo MRI was used to study regional 
brain volumes (volumetry) with the aim of detecting changes in TASTPM 
mice. Given changes in T2 relaxation times can be observed in transgenic mice 
at earlier stages, as compared to imaging individual plaques, regional T2 
relaxometry was used as a measure of pathological status. Here, the 
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optimisation and acquisition of the in vivo MRI scans (volumetry and 
relaxometry) in mice, and the development of an analytical data-extraction 
method, were carried out for the first time on a 7T magnet (Bruker Biospin, 
Germany) at the University of Nottingham. 
2.3.2. Acquisition of images 
The optimisation of acquiring high-resolution (T2-weighted) images for 
studying volumetry, and T2 relaxometry scans of the mouse brain was 
performed in collaboration with Prof. Dorothee Auer, Dr. Mirjam Schubert, 
School of Medical and Surgical Sciences, and Dr. Malcolm Prior, Brain and 
Body Centre, University of Nottingham. Scanning was performed on a 7T 
magnet, with a 31cm bore diameter for rodent studies. 
To develop the T2-weighted rapidly acquired refocused spin echo (RARE) 
image to study volumetry, preliminary scans were carried out on a mouse brain 
ex vivo. The mouse brain was placed into the magnet, and a fast-gradient echo 
(FLASH) sequence was applied to determine the anatomical position of the T2- 
weighted slices. A variety of multi-slice, multi-echo T2-weighted spin-echo 
sequences were applied to the ex vivo mouse brain. The image with the greatest 
clarity and contrast, determined visually, was chosen. For T2 relaxometry 
scans, again, the slices were established using a FLASH sequence, and multi- 
slice, multi-echo T2-weighted spin-echo sequences were performed, although 
with different TEs, as described below. The final protocol for acquisition of 
T2-weighted volumetric images, to study volumetry, was as follows: echo 
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time (TE) 
= 
9.266 ms; effective TE = 29.54 ms; repetition time (TR) = 5.259 s; 
RARE factor 
= 
8; FOV 
= 
16.64 mm; in plane resolution 0.13 mm; slice 
thickness = 0.5 mm, 16 repetitions (manually realigned and averaged post- 
acquisition), 15 coronal slices were taken; for an example image see figure 
2.7A. The protocol for the acquisition of T2 relaxometry scans, with the aim of 
creating a map of T2 relaxation values for the whole brain, was as follows: TE 
= 
10.187 ms; effective TE = 21.65,62.40,103.14,143.81,184.64 and 225.39 
ms; TR = 19.743 s; RARE factor = 4; FOV= 14.976 x14.976 mm; in plane 
resolution = 0.234 mm; 4 averages, slice thickness of 1 mm (15 coronal slices 
taken). 
Figure 2.7. Representative T2-weighted volumetry images, and semi- 
automated image analysis tool. A: In vivo T2-weighted volumetric coronal 
scan of 5.5 month old TASTPM mouse. B: Registered brain atlas with 
example MRI scan following neuroanatomical-landmarking: the digital 
mouse brain atlas was superimposed over the scan. C: Following image 
registration the ROI (anterior cingulate cortex) was delineated onto the 
mouse brain atlas, and then projected back onto the MRI scan to demonstrate 
the accurate positioning of the ROI. 
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In vivo scanning time took, in total, approximately 2 hours 30 mins per mouse, 
during which time the mouse was under gaseous anaesthesia using a purpose- 
built mouse holder, figure 2.8. For in vivo scans mice were initially 
anaesthetised in an anaesthetic-induction chamber under a mixture of 5% 
isoflurane and oxygen (0.7-0.9 litre/min). When fully anaesthetised mice were 
transferred to a purpose-built plastic mouse holder, figure 2.8. A tooth-bar and 
ear-bars were used to position the mouse in front of the anaesthetic lead. 
During the scanning mice were maintained under anaesthesia with a mixture of 
1.5-2% isoflurane, and oxygen (0.7-0.9 litre/min). Levels of anaesthesia were 
assessed by monitoring breathing rate via an automated system calculating 
breaths per minute; anaesthesia dose was adjusted when necessary to correct 
for changes in respiration. Core-body temperature was monitored through a 
rectal thermometer, and adjusted using the circulating hot water bath which 
warms the plastic holder and the body of the mouse. Core-body temperature 
was kept at 
--37.5°C (Lauda Ecoline Staredition 003, Harvard Apparatus), and 
respiration was monitored automatically with the depth of anaesthesia 
modulated to regulate breathing-rate (SA Instruments Inc., New York). To 
perform the scans the mouse was placed in a volume coil, from which the RF 
pulse signals were transmitted, and a receive-only head coil was placed closely 
over the skull to receive the signal (all scanning equipment from Bruker 
Biospin, Germany). This apparatus was then placed into the horizontal bore of 
the magnet and the scanning procedure started. Specific details of anaesthetic 
and scanning protocols will be described in greater detail in Chapter 3. 
63 
Anaesthetic lead 1 Entry/exit points 
for circulating 
hot water bath 
Face mask 4 
Mouth-piece and 
anaesthetic lead 
Ear bars 
Circulating hot 
water bath 
Tooth bar 
Water bath 
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lead 
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Figure 2.8. Mouse holder for MRI scans. Gaseous anaesthetic was 
administered through the anaesthetic lead, and warm water circulated through 
the holder by the entry-points to warm the mouse. A tooth-bar held the 
mouse's nose over the anaesthetic lead, and ear-bars held the head in place to 
reduce any movement artefact. A plastic cuff was fixed to the animal's head 
to further reduce any respiration-related movement. 
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2.3.3. Image analysis tool 
For the image analysis, a semi-automated method was developed in 
collaboration with Dr. Alain Pitiot, Brain & Body Centre, University of 
Nottingham. First, the volumetric scans were manually co-registered with a 
digital mouse brain atlas (Paxinos G, Franklin KBJ, The Mouse Brain in 
Stereotaxic Coordinates, Deluxe Edition of the Atlas Second Edition, 
Academic Press, San Diego, California, 2001). Registration was conducted 
using the Register program (Montreal Neurological Institute, Canada) and 
involved identification of, for each MR scan, a number of pairs of 
neuroanatomical land-marks on both the scans and mouse brain atlas. Land- 
marks were distributed throughout the brain to allow for precise registration. 
Once land-marking was complete, the program computed a flexible 
transformation to match these pairs of points using thin-plate-splines (a 
morphological tool) as a transformation model, ensuring both flexibility and a 
precise match of the two images. Registration was performed for each MRI 
brain slice. Once registration had been completed, the MRI scans were super- 
imposed onto the atlas, allowing one to assess the accuracy of the image 
correspondence, figure 2.7B. Next, the regions of interest (ROIs) that were 
studied in the brain were manually delineated onto the mouse brain atlas using 
the Display program (Montreal Neurological Institute, Canada). Delineations 
were then projected from the atlas onto the MRI image, figure 2.7C, using the 
transformation computed above, this was checked manually for all mice to 
ensure we obtained robust, accurate results. This method of ROI delineation, 
directly onto the mouse brain atlas, allows one to be confident that the results 
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are reproducible, as ROI delineation is consistent between mice. Each ROI was 
converted from a total voxel count and expressed as a volume in mm2. The 
volume for each ROI was then calculated as a percentage of the whole brain 
volume. 
To study brain volumetry and regional T2 relaxometry, ROIs were delineated 
and classified using the mouse brain atlas (Paxinos & Franklin, 2001); the 
inclusion criteria are described below. For the purpose of the investigations 
described in this thesis, the delineations were designed to allow for robust, 
consistent results which are easily reproducible. Anterior cingulate cortex 
(ACC) was taken from Bregma 2.34mm to Bregma 
-0.22mm. Retrosplenial 
cortex was taken from Bregma 
-0.34mm to Bregma -3.88mm. Thalamus was 
taken from Bregma 
-0.22mm to -3.88mm; from -0.22mm to -2.30mm a 
horizontal line was drawn from the most ventral part of the caudate putamen 
(striatum), any thalamus lying below this line was excluded (figure 2.9C); from 
-2.46mm to 
-3.16mm a horizontal line was drawn from the most ventral part of 
the fasciculus retroflexus, thalamus above this was included. Corpus callosum 
was taken from Bregma 1.10mm to Bregma 
-2.54mm; from Bregma 1.10mm 
to Bregma 
-0.34mm, the ROI included up to the lateral edge of the cingulum 
(figure 2.9B); from Bregma 
-0.46mm to Bregma -1.06mm the corpus callosum 
was characterised by a vertical line drawn at the lateral edge of the fibria; from 
Bregma 
-1.22mm to Bregma 
-2.54mm the corpus callosum was characterised 
by a vertical line taken at the most lateral edge of the thalamus, bisecting the 
ROI (figure 2.9C). The caudate putamen was taken from Bregma 1.94mm to 
Bregma 
-2.30mm; from Bregma 1.54mm to Bregma 0.62mm, the ROI was 
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taken above a horizontal line drawn at the most ventral part of the anterior 
commisure, anterior part (figure 2.9D); from Bregma 
-0.7mm to Bregma 
- 
1.70mm a horizontal line was drawn at the most dorsal pat of the basal lateral 
amygdaloid nucleus, anterior part, caudate putamen above this line was 
included. The hippocampus was taken from Bregma 
-0.94mm to Bregma 
- 
3.88mm. Subiculum was taken from Bregma 
-2.46mm to Bregma -3.88mm. 
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Figure 2.9. Example ROI delineations onto a digital mouse brain atlas to 
study volumetry and relaxometry. A. Bregma 
-3.28mm, hippocampus in 
green, and subiculum in red. B. Bregma 0.26mm, caudate putamen in green 
and corpus callosum in blue; corpus callosum within horizontal lines taken at 
the most lateral edge of the cingulum was included. C. Bregma 
-1.34mm, 
thalamus in red, corpus callosum in blue and caudate putamen in green; 
corpus callosum was included within horizontal lines drawn at the most 
lateral edge of the thalamus; thalamus was included above a vertical line 
drawn at the most ventral part of the caudate putamen. D. Bregma 0.62mm, 
caudate putamen in green, and corpus callosum in blue; caudate putamen was 
included above a horizontal line drawn at the most ventral part of the anterior 
commisure, anterior part. 
I 
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The MRI acquisition protocols for both the volumetry and T2 relaxometry 
studies were optimised to provide sufficient resolution, and intensity, in a 
realistic scanning time-frame required for in vivo studies, and were considered 
appropriate to determine the pathological status of TASTPM mice. The semi- 
automated image analysis tool was set up to produce consistent, robust results 
with a high level of accuracy, appropriate to study changes in the parameters 
described above. Moreover, T2 relaxation times acquired through the use of the 
semi-automated method were in a similar range to those achieved by manual 
ROI segmentation, further confirming the reliability of the analysis method. 
These MRI studies provide an assessment of pathological status in vivo; it is, 
however, important to correlate such findings, and findings from behavioural 
studies, with direct post-mortem quantification of a known pathological 
marker, such as detection of ß-amyloid through immunohistochemistry. 
2.4. Immunohistochemistry 
2.4.1. Introduction 
TASTPM mice start to deposit ß-amyloid in the form of extracellular plaques 
from as early as 3 months old, the occurrence of which increases with age 
(Howlett et al., 2004). Quantification of plaques, identified through 
immunohistological staining, is frequently used as a method of detecting 
pathological changes in such mice. Many studies rely on manual counting of 
plaques. However, this type of analysis can be problematic when the applied 
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pharmacologic and/or environmental interventions may result in subtle changes 
to ß-amyloid pathology. This can prove difficult if an inaccurate manual 
quantification is adopted, possibly leading to false-negative results. One option 
is to accurately assess ß-amyloid burden through the use of a semi-automated 
method of quantification. Here, a robust method to accurately and reproducibly 
measure TASTPM mouse ¢-amyloid plaques was developed to support data 
acquired through the MRI studies and behavioural endpoints mentioned above. 
2.4.2. Immunohistochemistry methodologies 
This method has been developed to assess levels of ß-amyloid pathology. 
Alterations to staining procedures specific to the antigen studied are described 
in each experimental chapter where appropriate. Brain sections were processed 
under standard procedures. The processing, sectioning and staining of tissue, 
described below, was principally performed by the laboratory of Prof. James 
Lowe, Department of Histopathology, Queen's Medical Centre, University of 
Nottingham. 
Brain tissue suspended in 4% PFA was refrigerated prior to processing. Tissue 
was subjected to paraffin wax infusion processing using a LEICA TP 1050 
apparatus, (Leica Microsystems, Milton Keynes, UK), and was paraffin wax 
block embedded using a LEICA EG 160 apparatus. Blocks were then sectioned 
using a LEICA RM 2135 rotary microtome. Variations in sectioning protocols 
will be described for each study, where appropriate. Sections for determining 
anatomical position acting as location markers within the brain were stained 
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using standard haematoxylin and eosin stain. Sections for immunostaining 
were de-waxed in xylene, which was removed by subsequent washing in 
alcohol (industrial methylated spirits (IMS)). Sections were then rinsed in tap 
water, followed by deionised water. For J3-amyloid plaque staining, sections 
were subjected to a concentrated (90-100%) formic acid pre-treatment (-5sec 
exposure), then washed thoroughly with tap water. The immunostaining 
procedure was conducted automatically using Dako Techmate 500 Plus (Ely, 
Cambridgeshire, UK), using a labelled streptavidin biotin technique. 
Immunostaining process worked through capillary action between two closely 
positioned sections, in which solution is drawn up between them. To ensure 
consistent staining, the slides were immersed in 0.1% Tween 20 for 20 mins 
prior to staining. Immunostaining was conducted according to standard 
procedures in the Department of Histopathology. Between all steps listed 
below, sections were washed with buffer (Dako REAL wash buffer 1). Briefly, 
primary antibody (Ab), (for ß-amyloid, ßA4 mouse mono-clonal primary Ab 
raised in QMC, commercially available from Leica Vision Biosystems), was 
diluted in Dako REAL Ab diluent (product S2022) at 1: 3000 concentration for 
60 mins. Antigen detection was achieved by 30 min exposure to dual link 
secondary Ab (Dako REAL link biotinilated secondary Ab, anti-mouse and 
anti-rabbit), followed by 30 min exposure to horseradish peroxidise (Dako 
REAL streptavidin peroxidise), horseradish peroxidise was stained for 10 min 
with chromogen diaminobenzadine exposure (reagents part of DAKO kit 
K5001). Sections were counter-stained with Gills3 haematoxylin for 30 sec, 
dehydrated with alcohol (IMS) methcol, and cleared with xylene. Slides were 
mounted with DPX glue. 
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2.4.3. Semi-automated image analysis 
In order to study subtle changes in regional ß-amyloid plaque pathology with 
various treatments, a semi-automated method was developed to allow for a 
robust and reproducible quantification of ß-amyloid. Technical assistance was 
provided by Mr. Trevor Grey, Department of Histopathology, Queen's Medical 
Centre, University of Nottingham. 
Brain sections chosen to present equal expression of ROIs were thoroughly 
cleaned prior to analysis. Sections were scanned by the Nanozoomer Digital 
Pathology slide scanner (Hamamatsu, Japan), at x20 magnification. ROIs were 
then individually captured at x5 magnification. The files were transported to 
AnalySIS Pro 3.1 Soft Imaging System (Munich, Germany), where they were 
analysed. First, preliminary studies were conducted to set-up colour thresholds 
to automatically detect, and detect the dark-stained ß-amyloid deposits against 
the background tissue. The detection of ß-amyloid deposits was further 
optimised by the development of inclusion criteria aimed to discriminate 
antigen from non-specific background staining. For this purpose, example ß- 
amyloidal deposits and non-p-amyloid artefactual inclusions were manually 
identified and criteria including object sphericity, elongation, convexity and 
shape factor were recorded. For these factors, exclusion criteria were 
established with the aim of excluding non-ß-amyloidal stain. For each section, 
ROIs were manually delineated onto the images. 
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Novel ROI exclusion criteria were established to ensure calculation of accurate 
assessment of ß-amyloid load. ROI delineation for IHC analysis was similar to 
that described for MRI analysis (Section 2.3). The following ROI delineations 
were used in experimental Chapter; half the brain was available for analysis. 
ROIs studied included the hippocampus, retrosplenial cortex, caudate putamen, 
thalamus and corpus callosum. The hippocampus was taken from Bregma - 
0.94mm to Bregma 
-3.88mm (figure 2.10A). The retrosplenial cortex was 
taken from Bregma 
-0.34mm to -3.88mm (figure 2.10A & B). The caudate 
putamen was taken from Bregma 1.10mm to 
-2.18mm (figure 2.10A & B); 
from Bregma 1.10mm to 
-0.82mm a vertical line was drawn from the most 
ventral part of the lateral vertical, all caudate putamen above this was included 
(figure 2.10B). The thalamus was taken from Bregma 
-0.22mm to Bregma - 
3.88mm (figure 2.10A & B); from Bregma 
-0.94mm to -2.30mm a horizontal 
line was drawn from the most ventral part of the caudate putamen, all thalamus 
above this was included (figure 2.10A). The corpus callosum was delineated 
from Bregma 1.10mm to 
-2.54mm where the ROI splits; 
from Bregma 1.10mm 
to 
-0.82mm corpus callosum was included up to the edge of the lateral ventricle 
(figure 2.10B); from Bregma 
-0.94mm to -2.54mm a vertical line was 
drawn at 
the most lateral edge of the thalamus, corpus callosum within this was included 
(figure 2.1OA). 
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Figure 2.10. IHC analysis, representative ROI delineations. A. Bregma 
- 
1.94mm: retrosplenial cortex (yellow), corpus callosum (orange, taken from 
the lateral edge of the thalamus), hippocampus (green), thalamus (red, taken 
from the most ventral part of the caudate putamen), caudate putamen (blue). 
B. Bregma 
-0.58mm; retrosplenial cortex (green), corpus callosum (red, taken 
up to the lateral edge of the lateral ventricle), caudate putamen (blue, taken 
from the most ventral part of the lateral ventricle), thalamus (yellow). 
Immunohistochemical analysis of ß-amyloid burden was also analysed in 
independent groups of TASTPM mice in Chapter 3. This was performed 
between Bregma 
-0.94mm to -3.88mm, the whole brain was available for 
analysis and subsequently only the retrosplenial cortex, thalamus and 
hippocampus were studied using the delineation criteria detailed above. In one 
study the whole brain was available for analysis which led to potential 
difficulties in ROI delineation. For example, if a vertical line is drawn down 
the midline of the brain section, splitting it into left and right hemispheres, the 
position of the section was not always the same on both hemispheres, i. e. the 
left side can be more anterior than right. Some ROls bisect, and were 
delineated across the left and right of the brain; using the thalamus as an 
example, where the thalamus was one whole unit across the brain the mean 
corresponding atlas plate number of the left and right side of the brain was 
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taken, and the thalamus was delineated as described on that plate number. 
Alternatively, when a ROI splits into two separate entities, for example 
thalamus splits at Bregma 
-2.18mm, and is expressed independently on both 
the left and right side of the brain, the ROI was treated as two independent 
units and delineated depending on the location on that specific side of the 
brain. Specific details, such as sections available for analysis for all studies, in 
the following experimental Chapters are described therein. 
Level of ß-amyloid, calculated as the percentage of ROI covered by the 
protein, for all ROIs were then collated; an overall mean percentage area of 
ROI covered by ß-amyloid was calculated allowing for direct comparison 
between treatment groups. To ensure reproducibility of the ROI delineation, 
and resulting ß-amyloid quantification data, example brains were re-scored at 
random and ROI area and percentage ROl covered in ß-amyloid were 
compared with the original data set, where an acceptable level of confidence of 
reproducibility was achieved. Example reproducibility (% confidence) of % 
amyloid burden for particular ROIs are follows; hippocampus = 98%, 
retrosplenial cortex = 95%, thalamus = 92% and corpus callosum = 99%. 
Example reproducibility of ROI delineation are as follows; hippocampus = 
99%, retrosplenial cortex = 91 %, thalamus = 89%, caudate putamen = 74% and 
corpus callosum = 93%. This method has been designed to accurately quantify 
0-amyloid. Abiding by clear rules in delineating ROI, and maintaining strict 
self-assessment, ensures this image analysis algorithm was robust and 
reproducible. This will be applied throughout this thesis to assess, or aid the 
assessment of, ß-amyloid pathology in TASTPM mice with various treatments. 
74 
CHAPTER 3 
EFFECTS OF REPEATED MILD STRESS ON 
EARLY-TO-MODERATE STAGES OF 
PATHOLOGY IN TASTPM MICE 
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3. General Introduction 
A connection between emotional stressors and AD-associated pathology in ß- 
amyloid-overexpressing transgenic mice was discussed in detail in Section 
1.4.1. In the main, the evidence indicates that repeated and acute severe 
stressors have been shown to enhance ß-amyloid levels as well as accelerate 
memory deficits in such mice modelling AD. 
Contrary to these investigations, a recent study from our group demonstrated 
that a repeated mild stress procedure, called "novel cage stress", involving 
daily exposure to a novel environment for 5 weeks, applied from 4 months of 
age, had the opposite effects; first, it lowered brain ß-amyloid levels, and 
second, prevented the onset of a short-term contextual memory deficit in 5.5 
month old TASTPM mice, as assessed, using the contextual fear conditioning 
(CFC) paradigm described in Section 2.2 (Pardon et al., 2009). This study also 
revealed that TASTPM mice exhibited deficits in short-term contextual 
memory extinction from 4 months of age (Pardon et al., 2009), when the short- 
term memory retention was still intact. We do not know, however, whether 
stress, applied earlier, is capable of modulating milder states of AD-associated 
pathology exhibited by TASTPM mice. We also do not know whether stress 
can interfere with long-term memory performance. 
This chapter aims to further describe the age-related Alzheimer's-like 
pathology that occurs in the TASTPM mice, and to determine the effects of 
novel cage stress on these age-related pathological changes. For this purpose 
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these studies are described below in two parts grouped depending on the 
pathological status of the animals tested: 
1. The first part deals with time periods corresponding to mild 
pathological changes in TASTPM mice, between the ages 3 and 4.5 
months, (Section 3.1). 
2. The second deals with TASTPM mice exhibiting mild-to-moderate 
levels of pathology from the ages of 5.5 to 6.5 months, (Section 3.2). 
Understanding the progression of pathology in TASTPM mice, and how this is 
affected by stress, at a variety of time-points will identify a critical window in 
which the effects of stress on AD-related pathology are most abundant. This 
time-window will then be subsequently used in a later chapter to investigate a 
potential underlying mechanism connecting the pathological changes in 
TASTPM mice with repeated mild stress. 
3.1. Effects of stress during early stages of pathology in TASTPM mice 
3.1.1. Introduction 
There is a body of clinical evidence suggesting that stress throughout adult life 
poses as a life-style risk factor for the development of AD (see Section 1.4.1., 
and references therein). This evidence indicates that stress, either prior to 
pathological onset, or during the early stages, may enhance the risk or severity 
of AD. As described above the repeated mild stressor, novel cage stress, 
applied from 4 months of age in TASTPM mice, a time-point associated with 
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mild ß-amyloid burden, improved the AD-like pathology (Pardon et al., 2009). 
Interestingly, a deficit in contextual memory extinction was observed in 
TASTPM mice at 4 months of age, which remained unaffected by subsequent 
novel cage stress exposure when studied in 5.5 month old TASTPM mice. 
As demonstrated in Section 2.2., CFC can be used as an appropriate tool to test 
contextual fear memory performance in mice, and was used in the study 
described above as the behavioural endpoint. However, in order to determine 
pathological changes to unconditioned mouse behaviours not associated with a 
cue, learning paradigm or aversive environment, a suitable test is required. 
Spontaneous alternation, a behavioural test performed in a standard T-maze 
can allow one to study a form of working memory in a freely moving animal 
outside of a fearful environment. Spontaneous alternation in the T-maze has 
proven to be sufficiently sensitive to detect memory deficits in transgenic mice 
over-expressing a calcium-binding protein implicated in AD, named S l00ß, 
which exhibit neurological dysfunction (Gerlai et at., 1994) 
Here, we tested the hypothesis that the beneficial effects of novel cage stress 
may be dependent on the pathological status in TASTPM mice, by 
investigating the earliest stages of ß-amyloid deposition. We, therefore, aimed 
to establish whether the short-term contextual fear extinction deficit can be 
detected in TASTPM mice aged 3 months, corresponding to the first signs of 
insoluble ß-amyloid deposit formation (Howlett et al., 2004), and if repeated 
novel cage stress applied from 3 months onwards can prevent, or reverse, a 
deficit in extinction of contextual fear in 4.5 month old TASTPM mice. For 
this purpose we, first, compared 3 month old TASTPM and wild-type (WT) 
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mice for the acquisition, retention and extinction of contextual fear memory. 
These memory tests were supported with assessments of spontaneous 
alternation performance, a measure of unconditioned working memory 
performance. We, secondly, assessed the impact of 5 weeks exposure to novel 
cage stress, applied from 3 months of age, on age-related changes in short-term 
contextual fear behaviour, spontaneous alternation, and regional brain levels of 
soluble and insoluble ß-amyloid in TASTPM mice at 4.5 months of age. 
3.1.2. Methods 
Animals 
Male TASTPM (Transgenic Unit, Biomedical Services Unit, University of 
Nottingham) and control WT, C57B1/6 mice (Charles River Laboratories, UK) 
were used. Mice were grouped for experimentation purposes depending on the 
age at which they were studied; either 3 months old, or 4.5 months old. Mice in 
the 4.5 month old group were singly housed from 3 months of age due to the 
development of age-related aggression observed in the TASTPM mouse line 
(Pugh et al., 2007). Food and water were available ad libitum, a cardboard 
play-tube and bedding were available as part of standard environmental 
enrichment. Animals were kept under standard conditions in a constant 
environment, on a 12h light: dark cycle. Temperature and humidity were 
controlled automatically. All procedures were carried out according to the 
Animals (Scientific Procedures) Act 1987, under license PPL 40/2715 granted 
to Professor Charles Marsden. 
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Group & Experimental Design 
In the 3 month group, base-line measures of contextual memory performance, 
unconditioned exploration in the T-maze in 3 month old TASTPM (n=8) 
compared with WT mice (n=9); following behavioural assessments, mice were 
humanely killed and TASTPM brain ß-amyloid was quantified. An 
independent group of TASTPM mice was individually housed at 3 months, and 
half were exposed to novel cage stress from 3 months of age for 5 weeks (n=7 
for each stress condition). At 4.5 months of age short-term contextual memory 
performance, unconditioned exploration and ß-amyloid levels were assessed in 
these mice. At both 3 and 4.5 months short-term memory performance and 
exploration were tested using the CFC test and spontaneous alternation test 
respectively. Locomotor activity was tested in the 4.5 month old mice to 
determine any effects of 5 weeks repeated stress exposure on activity and 
reaction to a novel environment. For a simplified experimental design see 
figure 3.1 
. 
Novel cage stress 
In order to induce a state of repeated mild stress, novel cage stress was applied 
as previously described, (Pardon et al., 2004; Pardon et al., 2005; Pardon et al., 
2009), being performed once daily, four times per week over a5 week period. 
Stress was applied on days I to 4 of the working week and weekly home cage 
changes took place on day 5. 
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Figure 3.1. Experimental Design. A: 3 month groups were tested for 
spontaneous alternation, a full description of the protocol can be found in 
Section 3.1.2, followed by contextual fear conditioning. Mice were then 
humanely killed. B: Half of the 4.5 month old group were stressed from 3 
months of age for 35 days and tested for spontaneous alternation, locomotor 
activity (LMA) then performance in the contextual fear conditioning test. 
Mice were humanely killed 48h following T4. D= Experimental day number. 
The procedure involved mice being taken from their home cage and placed into 
a clean novel cage for I h. The novel cages were half the size of the home cage 
measuring 15 x 16 x 15 cm. To achieve this a normal cage was divided in the 
centre by a transparent perforated plastic divider. The novel cages had a thin 
layer of sawdust on the floor, but were devoid of all normal environmental 
enrichment stimuli (cardboard play-tube and bedding); food and water were not 
provided throughout the stress session. Mice were lifted in and out of the novel 
cages by the tail; to control for handling effects control non-stressed TASTPM 
81 
mice were similarly manipulated and lifted from the home cage by the tail, and 
replaced immediately back into the home cage at times corresponding to the 
start and the end of the stress procedure. Stressed mice were removed from the 
novel cage after lh exposure and placed back into their home cage. Between 
each stress session, sawdust was discarded and the novel cages were 
thoroughly washed with disinfectant wash to remove olfactory scent markers. 
Physiological measures 
Novel cage stress has been previously shown to reduce normal weight gain in 
mice (Pardon et al., 2004). To determine the effects of 5 weeks of novel cage 
stress on TASTPM mouse body weight, measures were taken both prior to, and 
after the stress period. Body weight changes over time were analysed using a 
repeated measures ANOVA with Stress as the between-subject factor. 
Faecal boli were counted for mice exposed to novel cage stress at the end of 
the lh stress session to provide an indicator of emotional reactivity to the novel 
environment, as previously described (Pardon et al., 2004; Pardon et al., 2005; 
Pardon et al., 2009). Changes in stress reactivity with repeated novel cage 
exposure were analysed using a repeated measures ANOVA with Stress 
Session as the within-subject factor. A post-hoc test was used comparing 
weekly mean defecation counts, using a series of paired samples t-tests 
comparing each weekly mean score with the score from the previous week (for 
example, week 1 vs. week 2, and week 2 vs. week 3). As seen previously 
(Pardon et al., 2004; Pardon et al., 2005), the handling procedure, which is very 
brief, rarely induced defecations; therefore, this analysis was solely performed 
on mice subjected to novel cage stress. 
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For all results described below, values are quoted as mean ± SEM, and Tukey's 
post-hoc test was used for multiple comparisons in the analysis where 
appropriate. 
Locomotor activity 
Locomotor activity was measured following the spontaneous alternation trials 
in the 4.5 months old TASTPM mice only (figure. 3.1) and was used to 
determine any differences in the activity of 4.5 month old non-stressed and 
stressed TASTPM mice. Mice were individually placed in one of 8 identical 
Plexiglas chambers measuring 13 x 17 x 20 cm, for 30 mins. Locomotor 
activity (distance moved, cm) was recorded and video-taped via a camera 
positioned above the boxes; the level of activity was recorded automatically 
using Ethovision software (Noldus, Wageningen, Netherlands). 
Resulting data was expressed, first, as total distance travelled throughout the 30 
min trial analysed using an independent samples t-test to determine any effects 
of 5 weeks of novel cage stress on total ambulation. Second, to study 
habituation to the novel environment, total distance travelled over 5 min time 
intervals (6 intervals in total) was analysed using a repeated measures ANOVA 
with Time as the within-subject factor, and Stress as the between-subject 
factor. 
Spontaneous alternation 
Spontaneous alternation was tested in all mice as a measure of spatial working 
memory performance. A standard T-maze was built in-house, (top horizontal 
arm 94cm x 8cm x 15cm, bottom vertical arm 40.5cm x 8cm x 16cm). The 
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mouse was placed in the vertical arm starting chamber, and held by a sliding 
plastic door for 
-10 sec; the door to the holding chamber was then removed. 
The mouse was free to explore the maze; at the T 
-junction the mouse then 
chose to explore either the left or right horizontal arm. Once the mouse had 
made this decision, and explored one arm, the opposite arm was closed off 
using a plastic sliding door thus preventing the mouse from exploring the 
opposite arm. The mouse was then returned to the starting chamber, held there 
for 
-10 sec, again released and allowed to explore the maze, figure 3.2. Mice 
were exposed to two spontaneous alternation trials, separated by 24h, the 
results from each trial were averaged for each mouse. During each trial, the 
mouse had the opportunity to undertake the decision making process, and 
explore, up to 6 times within 10 mins. Performance of the mice during this task 
was assessed by the number of successful alternations in arm directions 
between each attempt at exploration. As 6 alternations/trials were permitted per 
session the mouse could perform a maximum of 5 successful alternations 
during the session; the result was expressed as a percentage of successful 
alternations during the trial; for example, if the mouse alternated successfully 4 
out of the five possible times, it showed 80% alternation. This test was run 
similarly to that used previously by our group on NMRI mice (Pardon et al., 
2004), and was subsequently used to study age-related changes in spatial 
working memory in TASTPM mice during the PhD studies of Gillian Scullion 
(Scullion., 2008). Due to unexpected aversive responses to the apparatus 
exhibited by TASTPM mice, non-performance at this task, (i. e. the mouse not 
exploring the maze due to an anxiety-like behaviour), was quantified during the 
test. Mice that did not complete 6 decisions, and explorations, within both 10 
84 
min sessions were recorded as non-performers and were excluded from the 
analysis. Mice which made 6 alternations on one trial-day, only, were recorded 
as partial non-performers and the single value was subsequently used for 
analysis. Mice were habituated to the T-maze, and exposed to the plastic 
sliding doors for 10 mins, 24 h prior to the first trial (figure 3.1). T-maze 
equipment was thoroughly cleaned with 20% ethanol between all tests to 
reduce olfactory cues. 
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Figure 3.2. Spontaneous alternation trial protocol. 1. Mouse placed in the 
starting chamber. 2. Mouse released from starting chamber and explored 
either left or right arm, the opposite arm was closed off. 3. Mouse was 
returned to the starting chamber. 4. Mouse was, again, free to explore either 
the left or the right arm, the opposite arm was closed off (as in step 2). This 
protocol was repeated up to 6 times within a 10 min period. 
To determine any age-related changes in performance of TASTPM mice a 
paired samples t-test was used to compare TASTPM performance at 3 and 4.5 
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months of age, Age was the between-subject factor. An independent samples t- 
test was used to determine the effects of stress in 4.5 month old TASTPM 
mice, with Stress as the between-subject factor. 
Short-term memory tests 
CFC was used here to study short-term contextual memory performance; the 
protocol was conducted as described in detail in Section 2.2. In brief, during 
memory acquisition mice were exposed to 10 footshocks (1 sec duration, 0.4 
mA) in the CFC operant chamber over 10 mins (figure 3.1) 24 h later mice 
were returned to the operant chamber for 3 mins in the absence of shocks and 
immobility was scored as a measure of contextual memory retention (figure 
3.1); at two 48 h intervals after the memory retention test, mice were, again, 
exposed to the context for 3 mins and immobility was scored to study 
extinction (figure 3.1). Similar to the CFC optimisation (described in Section 
2.2) behaviour of the mice was video recorded and subsequently scored. For 
the 3 min memory retention and extinction trials behaviour was scored three 
times by the same experimenter who was blind to the treatment groups; the two 
values closest together were taken for an average value. On occasion, when the 
two values closest together were > 20 sec apart, this was considered 
unacceptable variation and the behaviour was rescored until two values were < 
20 sec different. This method of scoring was adopted for all further 
experiments described in this thesis to maintain consistency between studies. 
Activity (distance moved, cm) during the memory acquisition trial was 
compared using a repeated measures ANOVA with Time as the within-subject 
factor, and Strain or Group (comparing 3 month old, 4.5 month old non- 
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stressed and 4.5 month old stressed TASTPM mice) as the between-subject 
factor. Memory performance was analysed using two methods. First, mean 
immobility (sec) between groups was compared using a repeated measures 
ANOVA with Trial as the within-subject factor, and Strain or Group as the 
between-subject factor. Tukey's post-hoc test was then used for multiple 
comparisons where appropriate. The second analytical method to study 
contextual memory extinction involved the production of extinction indexes. 
Three extinction indexes for each group mice were created by calculating 
differences in immobility between the CFC trials. "Extinction" was calculated 
by subtracting performance (total immobility, sec) during the final extinction 
trial by that during the memory retention trial; "Extinction 1" was the first 
extinction subtracted by the memory retention trial; for "Extinction 2", the final 
extinction trial was subtracted by the first extinction trial. Negative scores 
arising from these indexes reflected a drop in immobility between trials, and 
therefore extinction, and data were compared to 0 (representing no extinction) 
using a one-sample t-test. 
Quantification of brain f-amyloid levels. 
Brain 13-amyloid was quantified to assess age-related changes in the 
pathological status of TASTPM mice and determine the effects of 5 weeks of 
novel cage stress on this parameter. For both the 3 month and 4.5 month old 
groups, mice were killed 24 or 48h following the final CFC extinction trial 
respectively. The brains were removed from the skull and the frontal cortex 
(defined as brain tissue above the corpus callosum near the anterior of the 
brain), hippocampus and cortex were dissected and immediately frozen using 
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dry ice and stored at 
-80°C. Upon tissue analysis, brain was defrosted and 
weighed to allow expression as pg ß-amyloid per milligram (mg) of wet tissue. 
Brain samples were kept on ice, added phosphate buffered saline (PBS) 
containing protease inhibitor cocktail solution, homogenised using a hand 
homogeniser, and then frozen at 
-80°C until analysis. Lysate was defrosted and 
centrifuged at 4°C, 14,000 rpm (13.5cm rotor, Sigma 3-18K) for 20 mins, 50µl 
of the supernatant was used to quantify A01.40 in the soluble fraction. The 
pellet was re-suspended in 100µI PBS and protease inhibitor cocktail solution, 
vortexed and spun at 4°C, 9000 rpm (13.5 cm rotor, Sigma 3-18K) for 20 mins; 
the supernatant was removed and the pellets frozen at 
-80°C. To quantify the 
levels of insoluble Aß1.42 associated with deposited 0-amyloid plaques, the 
pellet was re-suspended in 100µ1 of 5M guanidine HCl solution. Soluble Aß1.40 
and insoluble Aß1.42 levels were assessed using a solid phase sandwich 
enzyme-linked immunosorbant assay (ELISA) kit (Bioscience International, 
Inc., California, USA). Assays were performed following standard instructions 
included with the kit and have been successfully used previously in our group 
to monitor brain changes in (3-amyloid in TASTPM mice (Pardon et al., 2009). 
Briefly, wells of a 96-well plate were coated in a monoclonal antibody 
recognising the NH2-terminus of the 3-amyloid protein. 50 µl of sample, either 
the soluble or insoluble fraction of 3-amyloid, was added to the well, along 
with the detection antibody (Rabbit ant-Hu API-4o / A01.42). The resulting 
complex was recognised by a third antibody labelled with alkaline 
phosphatase. A fluorescent substrate solution was added to the wells, and 
fluorescence was quantified using a plate reader. All brain samples were run in 
duplicates and values were averaged during analysis. Resulting data were 
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calculated using a standard curve run with the sample and expressed as pg 
Aß(l_4o) or Aß(1.42) per mg of wet tissue. Previous optimisation of ELISAs has 
shown no detectable levels of human (3-amyloid in WT mice (Pardon et al., 
unpublished); therefore, analysis was only conducted on the TASTPM mouse 
brains. 
Levels of ß-amyloid in the ROIs studied were compared between 3 month old 
TASTPM and 4.5 month old non-stressed and stressed TASTPM mice using a 
one-way ANOVA with Group as the between subject factor. 
3.1.3. Results 
Physiological measures 
Overall, there was a significant Time effect (P < 0.0001) indicating increased 
body weight for both the non-stressed and stressed TASTPM mice before and 
after the novel cage stress period with age (figure 3.3A); however, there was no 
effect of repeated novel cage stress. 
Stressed TASTPM mice demonstrated a significant change in weekly 
defecation count over the 5 week stress period (P = 0.014) as revealed by a 
repeated measures ANOVA. Weekly defecation number during the 5 weeks of 
the novel cage stress period was then compared with the score from the 
previous; there was a significant increase in weekly defecation counts from 
week 2 to week 3 only (P < 0.0001); all other weekly comparisons were non- 
significant, figure 3.3B. 
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Figure 3.3. Physiological measures. A: Changes in mean (± SEM) body 
weight between (grams) non-stressed TASTPM (TASTPM, n= 7) and 
stressed TASTPM mice (TASTPM (S), n=7) between 3 to 4.5 months of age 
(prior to, and following the stress period respectively). Overall, both groups 
displayed a significant increase in body weight over time (***P < 0.0001), 
but stress had no effect on this weight gain. B: weekly mean defecation count 
(± SEM) for TASTPM stressed mice (n=7) (defecation count during the lh 
stress session could not be quantified in non-stressed mice residing in their 
home cages), over the 5 week stress period. There was a significant (P = 
0.014) change in defecation over time, but only one significant difference 
between weekly defecation counts, an increase in defecation from week 2 to 
week 3 (***P <0.0001). 
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Locomotor activity performance 
Throughout the locomotor activity trial, (distance moved, cm) was separated 
into six 5 min time intervals to determine habituation to a novel arena, there 
was an overall Time effect (P = 0.002) as activity of all mice declined over 
time, and a Time X Stress interaction (P = 0.013), figure 3.4. However, when 
analysing total activity (distance moved) throughout the 30 min trial there was 
no significant difference between non-stressed (4999.9 ± 332.0cm) and 
stressed (4983.0 ± 214.3cm) TASTPM mice. 
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Figure 3.4. Locomotor activity performance: Mean (± SEM) locomotor 
activity (distance moved, cm) over a 30 min trial expressed as 5 min time 
intervals for 4.5 month old non-stressed (TASTPM, n=7), and stressed 
TASTPM mice (TASTPM (S), n=7). Both groups displayed a decline in 
activity as a function of time (P = 0.002), and there was a difference between 
the two groups with time (P = 0.013), but no overall difference in total 
activity throughout the trial. 
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Spontaneous alternation performance 
At 3 months of age there was no difference between WT and TASTPM mice 
for spontaneous alternation performance. There were no significant age-related 
changes in performance of TASTPM mice from 3 to 4.5 months of age. There 
was no difference between non-stressed and stressed 4.5 month old TASTPM 
mice, although stressed TASTPM mice showed a trend towards a reduction in 
correct alternations compared to non-stressed TASTPM mice (P = 0.083), table 
3.1. 
Table 3.1. Spontaneous alternation performance. Mean (± SEM) 
performance (percentage correct alternation) of WT (n = 9), TASTPM non- 
stressed (n = 6) and stressed (n = 7) at two ages, 3 and 4.5 months old. There 
was no difference in spontaneous alternation performance between 3 month 
old WT and TASTPM mice, or any age-related difference between 3 and 4.5 
month old TASTPM mice. At 4.5 months TASTPM stressed mice appeared 
to display a lower performance at this task compared to non-stressed 
TASTPM mice, but this was not statistically significant (P = 0.083). 
In this task, non-performers were classed as mice which did not complete 6 
arm explorations within both two 10 min trials, and partial non-performers 
were mice which only performed 6 arm explorations in one of the two trials. It 
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is worthy of note that there was I non-performer, and three partial non- 
performers (completed 6 explorations on one test day only) in the 4.5 month 
non-stressed TASTPM mice. All WT and stressed TASTPM mice studied here 
performed this test fully; this is the reason for the variable number of subjects 
in the above analysis. 
Short-term memory tests 
An overall significant decline in activity (distance moved, cm) over time 
during the memory acquisition trial for mice in both 3 month and 4.5 month 
old groups was observed (P < 0.0001) indicating successful acquisition of 
conditioned fear. At 3 months of age a Time X Strain interaction did not quite 
reach statistical significance (P = 0.05), figure 3.5A. At 4.5 months of age, 
stress had no effect on the decline in activity during training, figure 3.5B. 
During the memory retention tests, immobility (sec) was similar in WT and 
TASTPM mice at 3 months of age. At 3 months of age, WT mice exhibited a 
reduced immobility from the memory retention to the last extinction trial (P = 
0.025), and had a significantly lower level of immobility during the final 
extinction trial compared to TASTPM mice (P = 0.004), figure 3.6A. There 
was no age-related change in TASTPM mouse immobility levels from 3 
months to 4.5 months of age during the memory retention test, and stress from 
3 months of age had no effect. At 4.5 months of age, TASTPM mice did not 
exhibit changes in immobility from the memory retention to the extinction 
trials, and there was no difference when compared to the performance of 3 
month old TASTPM mice. Pre-exposure to 5 weeks of novel cage stress had no 
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effect on 4.5 month old TASTPM mouse immobility levels across the 
extinction trials, figure 3.6B. 
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Figure 3.5. CFC memory acquisition performance. A: Mean (± SEM) 
activity (distance moved, cm) over 10 min memory acquisition trial, 3 month 
old WT (n=9) and TASTPM (n=8) both exhibited reduced activity upon 
repeated footshock exposure (once per minute). B: Mean (± SEM) activity 
(distance moved, cm) over 10 min memory acquisition, 4.5 month non- 
stressed (n=7) and stressed TASTPM mice (n=7) mice both displayed similar 
reductions in activity over the 10 min training period. 
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Figure 3.6. CFC short-term memory retention and extinction. A: Mean 
(± SEM) immobility (sec) of 3 month old WT (n=7) and TASTPM mice 
(n=8), immobility is similar between WT and TASTPM mice during the 
memory retention trial. WT mice demonstrated a significant reduction in 
immobility from the memory retention to the final extinction trial (*P = 
0.025). During the final extinction trial WT mice had a significantly lower 
level of immobility compared to TASTPM mice (**P = 0.004). B: Mean (± 
SEM) immobility (sec) of 3 month old TASTPM (3 month, n=8), and 4.5 
month old TASTPM mice non-stressed (4.5 month NS, n=7) and stressed 
(4.5 month (S), n=7) mice. There was no age-related change in immobility 
exhibited by TASTPM mice during the trials. 
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Three extinction indexes for each group mice were created based on the 
differences in immobility between the CFC trials. "Extinction" refers to the 
difference between the memory retention and final extinction trial, "Extinction 
1" refers to the difference between the memory retention and first extinction 
trial, and "Extinction 2" is the difference between the first and final extinction 
trial; results were compared to 0 using a one samples t-test. Significant 
differences in "Extinction were observed in 3 month old WT (P = 0.005) and 
TASTPM (P 
= 
0.001) mice only. During "Extinction 1" no significant 
differences were observed in any group. Significant differences were observed 
during "Extinction 2" in all groups (P < 0.05), with the exception of 3 month 
old WT mice where there was no statistical significance (P = 0.063), figure 3.7. 
Brain ß-amyloid levels in TASTPM mice 
Regional levels of Aß(I-4o) were compared between 3 month old, and 4.5 month 
old non-stressed and stressed TASTPM mice. There were significant Group 
effects in the hippocampus (P = 0.001) and frontal cortex (P = 0.026), but not 
the cortex. There was no significant difference between 3 and 4.5 month old 
AP(I 40) levels, but stressed 4.5 month old TASTPM mice had significantly 
higher levels compared to non-stressed mice in the hippocampus only (P = 
0.005), table 3.2. 
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Figure 3.7. Extinction indexes of 3 and 4.5 month old mice. Mean (± SEM) 
extinction indexes were calculated for 3 month old WT mice (3m WT, n= 7), 3 
month old TASTPM mice (3m TASTPM, n= 8), 4.5 month old TASTPM non- 
stressed mice (4.5m TASTPM, n= 7) and 4.5 month old TASTPM stressed mice 
(4.5m TASTPM (S), n= 7). A. There was a significant difference between the 
memory retention and final extinction trial in 3 month old WT and TASTPM 
mice only (**P < 0.01). B. No groups showed any difference between the 
memory retention and first extinction trial. C. Between the first and last 
extinction trial all mice exhibited significant differences (*P < 0.05), except 3 
month old WT mice which did not reach statistical significance (#P = 0.063). 
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TASTPM 
3 month old 4.5 month old 4.5 month old 
(non-stressed) (stressed) 
Aß(I-4o) Hippocampus 3.49 3.80 5.72 ** 
(0.32) (0.20) (0.46) 
Frontal 0.04 0.11 0.12 
cortex (0.01) (0.02) (0.03) 
Cortex 1.20 1.75 1.97 
(0.18) (0.27) (0.40) 
A(3(i. 42) Hippocampus 12.28 14.45 19.69 # 
(1.11) (3.13) (2.11) 
Frontal 12.72 17.28 20.75 ** 
cortex (1.18) (2.28) (1.21) 
Cortex 12.30 17.72 21.78 
(0.72) (2.07) (3.42) 
Table 3.2. Brain ß-amyloid levels in TASTPM mice. Mean (±SEM) levels 
of Aß(1.40) and Aß(t-42) (pg/mg wet tissue) in the hippocampus, frontal cortex 
and cortex of 3 month old TASTPM mice (n=8), 4.5 month non-stressed 
(n=6-7) and stressed (n=7) TASTPM mice. A1ß(1.40)/42 levels were compared 
across the three groups using a one-way ANOVA with Group as the within 
group difference, Tukey's post hoc test was used for multiple comparisons. 
For Aß(1.40) levels, there was a significant Group effect in the hippocampus 
(**P < 0.01) and frontal cortex (*P < 0.05); there were no significant age- 
related changes, but stress elevated levels in the hippocampus of 4.5 month 
old mice. For Aß(1-42) levels, there were significant Group effects in the 
frontal cortex (**P < 0.01) and cortex (*P < 0.05), but did not reach 
statistical significance in the hippocampus (*P = 0.05); however, there were 
no significant age or stress-related changes in levels between the three 
groups. 
When comparing A13( 2) levels between the three groups, there was a Group 
effect in the frontal cortex (P = 0.007), cortex (P = 0.023), but not quite in the 
hippocampus (P 
= 
0.05). There were no age-related changes between 3 and 4.5 
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month old TASTPM mice in Aß(l-42) levels in any brain region, nor any effect 
of stress on 4.5 month old TASTPM mice. 
3.1.4. Discussion 
The studies described herein were aimed, first, to determine base-line short- 
term memory retention and extinction of TASTPM mice at a pre-pathological 
age. Second, to assess the effects of 5 weeks of novel cage stress, applied from 
3 months of age, on age-related changes in memory retention and extinction 
between 3 and 4.5 month old TASTPM mice. The contextual memory 
behavioural endpoint was supported with assessments of working memory and 
brain ß-amyloid levels. 
Short-teen memory, and spontaneous exploration activity, remained intact in 3 
month old TASTPM compared to WT mice. Although TASTPM mice 
expressed short-term contextual memory extinction at 3 months of age, it 
appeared to be impaired when compared to age-matched WT mice. Stress from 
3 months of age had no effect on short-term contextual memory retention, 
memory extinction or spontaneous alternation performance, but increased Aß(1_ 
40) in the frontal cortex of 4.5 month old TASTPM mice, only. 
Our group has shown, in a similar previous study, that TASTPM mice develop 
a short-term contextual memory retention deficit between 4 and 5.5 months of 
age; consistent with this, we report here intact short-term memory retention in 
3 month old TASTPM mice. In the studies described above, we have shown 
that there was no age-related change in short-term memory retention from 3 
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months to 4.5 months of age in TASTPM mice, indicating that the short-term 
memory deficit described previously, (Pardon et al., 2009), likely occurs 
between 4.5 and 5.5 months of age. As demonstrated previously, 5 weeks of 
novel cage stress applied from 4 months of age reversed the memory deficit 
present in 5.5 month old TASTPM; an identical stress regimen applied from 
one month earlier (3 months of age) had no effect on short-term memory 
retention in 4.5 month old TASTPM mice. These results, combined, imply that 
effects of stress on short-term memory retention of TASTPM mice are age- 
dependant; this may implicate brain ß-amyloid, known to increase with age in 
TASTPM mice (Howlett et al., 2004), playing a role in this effect. Indeed, 
previously, a stress-induced reduction in brain ß-amyloid levels coincided with 
the reversal of short-term memory deficit (Pardon et al., 2009). In addition to 
evidence described in the current study, a body of research appears to support 
this hypothesis by linking environmental stressors with changes in brain f3- 
amyloid levels in similar ß-amyloid over-expressing transgenic mouse lines 
(Kang et al., 2007; Dong et al., 2008), which have also been linked with 
changes in behaviour (Dong et al., 2004; Jeong et al., 2006). 
We have previously demonstrated that TASTPM mice exhibit a short-term 
contextual memory extinction deficit from 4 months of age, prior to developing 
a short-term memory retention deficit (Pardon et al., 2009). It is worthy of note 
that two methods of analysing the CFC extinction performance were used, the 
first, referred to here as Analysis 1, was a repeated measures ANOVA 
assessing the change of immobility scores as a factor of time (repeated 
exposure to the context). The second, Analysis 2, involved a series of 
subtractions of scores between trials providing an extinction index, extinction 
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was represented by a negative score, and this was compared to 0. These two 
types of analysis allow for some different interpretations of the data. 
Here we demonstrated, using Analysis 1, that TASTPM mice at 3 months of 
age exhibited a memory extinction deficit when compared to age-matched WT 
mice. There was also no age-related change in TASTPM mice as a memory 
extinction deficit was also evident in 4.5 month old TASTPM mice, plus there 
was no effect of 5 weeks of repeated mild stress on memory extinction. The 
absence of a stress effect on TASTPM memory extinction deficit is consistent 
with a similar finding when studied in mice I month older, i. e. stress from 4 
months of age had no effect on extinction performance in 5.5 month old 
TASTPM mice (Pardon et al., 2009). Together, these findings suggest that, 
during periods corresponding to early-to-moderate pathological status in 
TASTPM mice, the deficit in short-term memory extinction is resistant to the 
effects of repeated mild stress, and can be observed from as early as 3 months 
of age in TASTPM mice. This extinction deficit was described for the first time 
by our group (Pardon et al., 2009), and may reflect a degree of cognitive 
inflexibility in the TASTPM mice, given their inability to extinguish a 
previously acquired memory, which may be independent of brain ß-amyloid 
deposits given its presence at the pre-pathological age of 3 months. 
The second method of analysis, Analysis 2 using extinction indices, revealed 
no extinction in any group between the memory retention and first extinction 
trial, but all groups demonstrated extinction between the first extinction trial 
and final extinction trial. Interestingly, only 3 month old WT and TASTPM 
mice exhibited full extinction from the memory retention trial to the final 
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extinction trial. These findings indicate that only 3 month WT and TASTPM 
mice exhibit overall extinction over three trials, whereas 4.5 month old 
TASTPM non-stressed and stressed mice posses a partially impaired contextual 
memory extinction. 
The major differences between the two analytical methods are that, first, using 
Analysis 2,3 month TASTPM mice appear to exhibit normal contextual 
memory extinction similar to that observed in age-matched WT mice. Second, 
using Analysis 2, both non-stressed and stressed 4.5 month TASTPM mice, 
although not exhibiting overall extinction, do display extinction in the later 
trials only. Both analyses indicate a decline in contextual memory extinction 
with age in TASTPM mice between 3 and 4.5 months, and reveal that stress 
has no effect on extinction, but findings from Analysis 2 indicate that a 
pathological change occurs between the ages 3 and 4.5 months in TASTPM 
mice which is responsible for the development of the partial impairment in 
memory extinction. Although not reaching statistical significance, there was a 
trend towards an increase in ß-amyloid in all brain regions studied between 3 
and 4.5 months of age, implicating the presence of ß-amyloid being, at least, 
partially responsible for the development of the extinction deficit in TASTPM 
mice. 
A body of evidence suggests ß-amyloid levels directly correlate with the 
development of memory deficits in transgenic mice over-expressing the 
protein, (for review, (Morgan, 2003)). Conversely, evidence also suggests that 
memory deficits in similar mouse lines can occur prior to overt ß-amyloid 
deposition (Holcomb et al., 1999; Dodart et al., 2000), indicating the cognitive 
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deficits maybe due to an ß-amyloid-independent mechanism such as brain 
atrophy or changes in synaptic density. Depending on whether the results from 
the study described here are to be interpreted as 3 month old TASTPM mice 
possessing a short-term memory extinction deficit, or not, in-turn dictates 
whether this likely occurs via a ß-amyloid-independent, or 0-amyloid- 
dependent manner respectively, and the literature cited above can support 
either argument. Analysis 1 indicated that the 3 month TASTPM mouse 
extinction deficit was evident when compared to age-matched WT mice; it is 
likely that extinction is still evident, but not detectable when compared to 
robust extinction observed in the control WT group. In summary, these data 
indicate a worsening of short-term memory extinction between 3 and 4.5 
months of age in TASTPM, as revealed by both analytical methods, but stress 
had no effect on this process. 
Several studies into the mouse neuroanatomy of contextual fear memory 
extinction implicate the hippocampus as a key structure (Fischer et al., 2004; 
Fischer et al., 2007; Lattal et al., 2007; Sananbenesi et al., 2007), and 
transgenic mice exhibiting hippocampal reduction are deficient in contextual 
memory extinction (Schimanski et al., 2002). Furthermore, evidence suggests a 
role for the prefrontal cortex (Herry and Garcia, 2002; Barrett et al., 2003; 
Sgobio et al., 2008) and the amygdala (Herry and Mons, 2004) in extinction of 
fear memory associated with a stimulatory cue. A model for the expression and 
regulation of memory extinction which involves communication between these 
three areas has been proposed; simply, hippocampal activity may feedback to 
the prefrontal cortex, which subsequently provides a regulatory input to the 
amygdala, overall affecting expression of memory extinction (for review, (Ji 
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and Maren, 2007)). One or more of these brain regions are likely to be affected 
as part of the early pathological changes that occur in the TASTPM mouse 
between 3 and 4.5 months of age; certainly (3-amyloid levels were seen to 
increase (although not statistically significant) in the hippocampus and frontal 
cortex of TASTPM mice between these two ages. 
Working memory in TASTPM mice, as assessed by spontaneous alternation 
performance, remained intact at 3 months of age when compared to age- 
matched WT mice. There was no age-related change in TASTPM mouse 
performance at this task between 3 and 4.5 months. Repeated mild stress from 
3 months of age showed a trend towards a reduced performance at this task in 
TASTPM mice, suggesting a detrimental role of stress on working memory 
performance; indeed mild stress has been shown to impair performance at this 
task in WT mice in a previous study (Bats et al., 2001). Mice which did not 
complete one or more trials at this test were recorded as non-performers. Non- 
performers at this task were within the 4.5 month old non-stressed TASTPM 
group only; all stressed 4.5 month old TASTPM successfully completed all 
trials, as did 3 month old WT mice. A similar study demonstrated that the 
number of TASTPM mice unable to perform at this task increased with age 
(Scullion et al., unpublished), suggesting this poor performance may be 
associated with pathological severity. The non-performers throughout this task 
appeared to demonstrate an aversive response to the experimental apparatus 
and environmental surroundings, which likely led to the reduced exploration 
observed. This theory is supported by the known age-related increasing 
aggression and anxiety-like behaviours in TASTPM mice described previously 
(Pugh et al., 2007). Interestingly, pre-exposure to stress in the 4.5 month old 
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TASTPM mice appears to have reduced this fearful phenotype in the T-maze 
despite nearly impairing performance. A more detailed account of 
unconditioned aversive behaviours of these groups, such as time periods spent 
immobile during T-maze exposure, are needed before any conclusions can be 
drawn. 
As mentioned above, there were non-significant increases in ß-amyloid in the 
hippocampus, frontal cortex and cortex of TASTPM mice with age from 3 to 
4.5 months, as one would expect. Repeated mild stress from 3 months of age 
had little effect on ß-amyloid levels, with the exception of significantly 
increasing Aß(, 
_, 
o) in the frontal cortex. Contrary to this, a previous study saw 
novel cage stress applied from one month later (4 months) being capable of 
attenuating the age-related increase in ß-amyloid levels of 5.5 month old 
TASTPM mice. It is, therefore, possible that the effects of stress on ß-amyloid 
levels depend on the age of testing; stress might only have a beneficial effect 
on ß-amyloid when a certain threshold level has been reached. This, in turn 
would reflect the behavioural findings of that previous investigation given 
stress improved memory performance at a later age of 5.5 months in TASTPM 
mice only. However, the reason as to why novel cage stress should increase ß- 
amyloid levels in the current study is unknown, but remains partly consistent 
with several findings that describe a variety of stressors being capable of 
increasing levels of this pathological marker in similar mouse models (Dong et 
al., 2004; Jeong et al., 2006; Kang et al., 2007; Dong et al., 2008) 
In summary, reported above is the presence of a short-term contextual memory 
extinction deficit which developed between 3 and 4.5 months of age in 
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TASTPM mice. However, short-term memory retention remained intact at 3 
months old, and was unaffected by age in TASTPM mice. Pre-exposure to 
repeated novel cage stress had no effect on either memory retention or 
extinction expressed by 4.5 month old TASTPM mice. Brain ß-amyloid levels 
appeared to increase with age but largely remained unaffected by novel cage 
stress. It is clear from this study, and the previous study from our group, that a 
short-term memory deficit developed in TASTPM mice between 4 and 5.5 
months of age, and a short-term memory extinction deficit develops around I 
month earlier. Novel cage stress had a positive effect on both memory and f3- 
amyloid levels between 4 and 5.5 months of age, but had little effect when 
applied one month earlier and, in fact, elevated levels in one brain region. It is, 
therefore, possible that these positive effects are only detectable when studied 
at a time-point associated with a higher level of pathological severity. 
3.2. Effects of stress on early-to-moderate stages of ß-amyloid pathology 
in TASTPM mice 
3.2.1. Introduction 
The previous section (Section 3.1) dealt with characterising the behaviour of 
TASTPM mice during early stages of ß-amyloid pathology, between 3 and 4.5 
months of age. These studies, alongside those conducted previously by our 
group, (Pardon et al., 2009), indicated that TASTPM mice develop a short-term 
contextual memory deficit between 4.5 and 5.5 months of age. Repeated novel 
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cage stress was capable of reversing this short-term contextual memory deficit 
as well as attenuating the increased brain ß-amyloid levels in 5.5 month old 
TASTPM mice, but had no effect in mice one month younger. We also 
observed a short-term contextual memory extinction deficit which developed 
between 3 and 4.5 months of age in TASTPM mice, and repeated stress 
exposure had no effect on this apparently robust impairment at all ages 
investigated. 
As described in Section 1.1.2, clinical AD is associated with memory loss, 
initially, as an inability to form and recall recent/episodic (short-term) 
memories (Backman et al., 2001; Ringman, 2005; Gauthier et al., 2006); this 
eventually leading to loss of remote (longer-term) memories later in the disease 
progression (Sartori et al., 2004). Interestingly, a similar pattern of deficits has 
been observed in an APP x PS-1 double transgenic mouse line; short-term 
memory was impaired during a radial-arm-water-maze memory paradigm 
(dependant on intact hippocampal function) in young (3 month old) mice, a 
time-point corresponding to mild pathology, but longer-term memory remained 
intact in these mice until 6 months of age (Trinchese et al., 2004), a time-point 
associated with more moderate pathological burden. The short-term memory 
deficit found during the earlier stages of ß-amyloid pathology in TASTPM 
mice supports these findings; however, we do not, as yet, know whether long- 
term memory performance and other AD-associated pathologies are affected in 
older TASTPM mice corresponding to stages of more moderate pathological 
severity. Moreover, the effects of novel cage stress exposure on the various 
pathologies exhibited by older TASTPM mice are currently unknown. 
Therefore, these issues are addressed herein by investigating the performance 
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of stressed and non-stressed TASTPM mice, between 5.5 and 6.5 months of 
age. 
The importance of MRI as a tool for monitoring pathological progression, both 
clinically and preclinically, is described in detail in Section 2.3. This tool is 
therefore used in the following study to determine pathological status of 
TASTPM mice, and to assess whether the effects of repeated mild stress can be 
detected. 
It has been suggested that the positive effects of repeated novel cage stress on 
TASTPM mice may be, in part, due to enhanced levels of environmental 
stimulation and exercise, discussed in Section 3.1.4. Although novel cage stress 
has been shown to elevate plasma corticosterone levels upon both acute and 
repeated exposure (Pardon et al., 2004; Pardon et al., 2005), it is possible that 
this is insufficient to induce a significant detrimental effect on TASTPM mice. 
In order to assess any detrimental effects of corticosterone, an independent 
group of TASTPM mice were administered high levels of corticosterone, 
behavioural phenotype, and pathological status was subsequently assessed and 
compared to that of TASTPM mice exposed to novel cage stress. 
This section is, therefore, separated into two experiments: 
1. Aimed to assess long-term memory performance of TASTPM mice at 
5.5 months of age, and determine whether pre-exposure to novel cage 
stress can affect the long-term memory performance at the contextual 
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fear conditioning (CFC) test. In vivo MRI was then used to study AD- 
associated pathologies in TASTPM mice, and whether they were 
modulated by stress. These studies were then supported with post- 
mortem quantification of ß-amyloid using immunohistochemistry. 
2. Aimed to assess long-term memory performance of TASTPM mice one 
month older than those in Experiment 1, at 6.5 months of age, and 
determine whether pre-exposure to novel cage stress, or corticosterone 
at a high dose, can affect long-term contextual memory and 
spontaneous alternation activity. Post-mortem studies, using both 
ELISA and immunohistochemistry, were then performed to assess brain 
ß-amyloid levels to compare between the various treatment groups. 
Long-term memory performance of mice in Experiment 1 and Experiment 2 
was also compared to determine any age-related changes or whether stress had 
a different effect at the two ages studied. 
3.2.2. Methods 
Experiment 1 
Animals 
Male WT (n=19) (C57B1/6) mice (Charles River Laboratory, UK) and 
TASTPM (n=18) (Transgenic Unit, Biomedical Services Unit, University of 
Nottingham) were used. All mice were group housed until 3 months of age 
when they were individually housed for welfare purposes, as described in 
109 
Section 3.1.2. Mice were kept under standard conditions, food and water 
available ad libitum, cardboard play-tube and bedding were available as part of 
standard environmental enrichment, temperature and humidity were controlled 
automatically and mice were kept on a 12h light: dark cycle. All procedures 
were carried out according to the Animals (Scientific Procedures) Act 1987, 
under license PPL 40/2715 granted to Professor Charles Marsden. 
Experimental design 
The aim of this experiment was to determine effects of stress during early-to- 
moderate stages of pathology in 5.5 month old TASTPM mice. WT and 
TASTPM mice were divided into two subgroups, non-stressed and stressed 
mice (WT non-stressed, n=10; WT stressed, n=8; TASTPM non-stressed, n= 9; 
TASTPM stressed, n=9); structural MRI revealed one stressed WT mouse had 
an enlarged, atrophied hippocampus; this mouse was removed from all 
analysis. Mice in the stressed groups were subjected to 5 weeks of repeated 
novel cage stress from 4 months of age until 5.5 months of age, at which point 
all mice were tested for long-term contextual memory performance at the CFC 
test (memory acquisition occurred prior to the stress period, at 4 months of 
age). Pathological status was determined by in vivo MRI, a terminal procedure. 
Post-mortem immunohistochemistry was then used to assess ß-amyloid 
burden; for experimental protocol see figure 3.8. 
Novel cage stress 
Novel cage stress was performed as described in Section 3.1.2. Briefly, mice 
were placed in a novel clean cage, half the size of their home cages, for lh 
daily, four times a week (days 1-4 of the working week, weekly cage changes 
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took place on day 5). Novel cages were thoroughly cleaned between stress 
sessions with standard detergent to remove olfactory cues between animals. 
Novel cage stress was conducted for a total of 5 weeks. Non-stressed mice, 
both non-stressed WT and TASTPM, were manipulated to control for handling 
effects at times corresponding to the start and end of the Ih stress session. 
Physiological measures 
Repeated novel cage stress has been previously shown to reduce normal weight 
gain in mice (Pardon et al., 2004), therefore body weight was recorded, prior to 
novel cage stress at 4 months of age, and following stress at 5.5 months of age, 
for all mice. Body weight changes were analysed using a repeated measures 
ANOVA with Time as within-subject factors, and Strain and Stress as the 
between-subject factors. For all results described below values are quoted as 
mean ± SEM, and Tukey's post-hoc test was used for multiple comparisons in 
the analysis where appropriate. 
Fecal boli were counted following each stress session for WT and TASTPM 
mice exposed to novel cage stress. This was used as an indicator of emotional 
reactivity to the novel environment. To determine reactivity to stress over 5 
weeks, a repeated measures ANOVA was used with the repeated Stress Session 
as the within-subject factor, and Strain as the between-subject factor. 
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Long-term memory tests 
CFC was used as a tool to study the long-term memory performance of all 
mice. The protocol was similar to that described in Section 2.2. Mice were first 
exposed to the contextual memory acquisition trial prior to the stress period, at 
4 months of age, figure 3.8. This involved individual placement in the CFC 
operant chamber for 10 min in which footshocks were administered (10 shocks, 
1 sec duration administered once per minute, 0.4mA intensity). Mice were 
returned to the operant chamber 35 days after memory acquisition to test for 
long-term contextual memory retention; novel cage stress was applied between 
the memory acquisition trial and memory retention trial, figure 3.8. During the 
memory retention trial, mice were placed in the chamber without footshocks 
for 3 min and immobility was scored manually. Mice were returned to the 
conditioning chamber 48h after the memory retention test to assess long-term 
contextual memory extinction. This trial was identical to the memory retention 
trial (3 min context exposure in the absence of foot shocks, immobility scored 
manually). Given this was the first study, chronologically, which applied this 
memory test to TASTPM mice during this PhD, only one extinction trial was 
performed; this is unlike the remainder of the studies described throughout this 
thesis where two trials were performed in order to investigate the unexpected 
extinction deficit previously described in Section 3.1.3. 
Contextual memory acquisition was measured automatically as activity (total 
distance moved, cm) over the 10 min trial. Activity was analysed using a 
repeated measures ANOVA with Time as the within-subject factor, and Strain 
as the between-subject factor. As with previous experiments, CFC memory 
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retention and extinction behaviour was recorded, and manually scored as 
immobility (sec) for each trial using the scoring criteria detailed in Section 
3.1.2. Memory retention and extinction were analysed using the two methods 
detailed and described in Section 3.1.2. First, memory performance between 
the retention and extinction trials was analysed using a repeated measures 
ANOVA with the different Trial as the within-subject factor, and Strain and 
Stress as the between-subject factors. 
The second method of analysis used involved calculating an extinction index. 
"Extinction" was calculated by subtracting performance during the memory 
extinction trial, by the memory retention trial. Negative values, therefore, 
represent extinction, i. e. a decrease in immobility from the memory retention to 
the extinction trial. Mean values for all groups were then compared to 0 using a 
one-sample t-test. 
In vivo MRI 
Scanning followed the CFC long-term memory extinction trial, figure 3.8. The 
MRI scanning protocol and procedures were described in Section 2.3. Briefly, 
mice were anaesthetised (gaseous anaesthesia _5% isoflurane, -0.7-0.9 
litre/min 02 flow rate) and placed in a plastic mouse holder throughout the 
scanning procedure, anaesthetic was delivered at -1.5-2% isoflurane, 0.7-0.9 
litre/min 02. Core body temperature and respiration rate were monitored, and 
adjusted with a circulating hot-water bath and anaesthetic modulation 
respectively. 
All scanning was conducted using a 7T magnet (Bruker Biospin, Germany) in 
the Brain & Body Centre, University of Nottingham. Mice were positioned 
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inside the magnet and scanned for volumetry and T2 relaxometry, both 
performed in a coronal direction. Scanning time was approximately 20 mins 
per mouse for each scan performed. Following scanning, mice were 
administered a lethal dose of pentobarbitone (i. p. ) and perfusion-fixed with 
saline followed by 4% paraformaldehyde (PFA). Brains were removed from 
the skull and stored in 4% PFA at 4°C for immunohistochemistry. 
Image analysis involved a semi-automated registration method (detailed in 
Section 2.3.3). Regions of interest (ROIs) studied by MRI included 
hippocampus, subiculum, anterior cingulated cortex (ACC), retrosplenial 
cortex, thalamus, corpus callosum and caudate putamen. Using the semi- 
automated image analysis tool (described in Section 2.3.3) volumtery scans 
produced a voxel count for each ROI in all mice which was converted to 
volume in mm2 and subsequently calculated as a percentage of whole brain 
volume. T2 relaxation times (msec) were calculated and averaged for each 
ROI. Volumetry and T2 relaxometry data for each ROI, in all groups, were 
analysed using a two-way ANOVA with Strain and Stress as the between- 
subject factors. 
In order to assess the level of accuracy obtained using the semi-automated 
image analysis tool, T2 relaxometry data were also calculated by manually 
overlaying identified ROIs directly onto the images using Paravision software 
(Bruker Biospin, Germany). Relaxation times were acquired directly via this 
method for all ROIs, similar to a method described previously (El Tannir El 
Tayara et al., 2006). Due to the slice thickness of the T2 relaxometry scans, 
representative examples of ROIs were limited, hippocampus (4 examples), 
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subiculum (2 examples), ACC (1 example), retrosplenial cortex (3 examples), 
thalamus (2 examples), corpus callosum (3 examples) and caudate putamen (4 
examples). All manually calculated T2 relaxation times available for each ROI 
were averaged and compared using a two-way ANOVA with Strain and Stress 
as the between-subject factors. Due to unexpected deaths during the scanning 
procedure, and poor image quality in some mice, the number of subjects for the 
MRI study was as follows: non-stressed WT (n=8-9), stressed WT (n=7), non- 
stressed TASTPM (n=9) and stressed TASTPM mice (n=8). 
Immunohistochemistry 
Following MRI, mice were perfusion-fixed with 4% PFA and whole brains 
were removed, stored in 4% PFA at 4°C and processed for 
immunohistochemical detection of (3-amyloid protein deposits. All sections 
were prepared and stained under standard conditions by staff in the Department 
of Histopathology, Queen's Medical Centre, Nottingham. The process of tissue 
embedding, sectioning and staining are described in Section 2.4.2. Briefly, 
brains were paraffin wax-embedded using a LEICA EG 160, sectioned on a 
LEICA RM 2135 rotary microtome, and immunostained for ß-amyloid using a 
Dako Techmate 500 Plus. Full brains were serially sectioned (404m thickness), 
and the ROIs studied were the hippocampus, retrosplenial cortex and thalamus; 
these were selected for study on the basis of having a sufficient number of 
representative examples of each; hippocampus (7-8 examples), retrosplenial 
cortex (6-7 examples) and thalamus (5-8 examples). 
Sections were taken for ß-amyloid quantification as described in Section 2.4.3., 
and were scanned using a Nanozoomer Digital Pathology slide scanner 
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(Hamamatsu, Japan) at 20x magnification. ROIs were manually delineated 
directly on the image and % ROI covered in ß-amyloid was calculated using 
AnalySIS Pro 3.1 Soft Imaging System (Munich, Germany). Details on ROI 
delineation and ß-amyloid quantification are described in Section 2.3. Amount 
of 3-amyloid for all ROIs, across the sections, were averaged giving a mean 
score of (3-amyloid cover per ROI for each mouse. Mean % 3-amyloid per ROI 
in non-stressed and stressed TASTPM mice was compared using an 
independent samples t-test with Stress as the between-subject factor. 
In addition to ß-amyloid load quantification, numbers of "dense core" plaques 
(for the purpose of these investigations these were classified as plaques with a 
clear centre indicating a dense core of ß-amyloid, figure 3.9A) and numbers of 
"diffuse" plaques (plaques without a dense-core indicating an earlier state of 
plaque maturity figure 3.9B) were manually counted in the retrosplenial cortex, 
hippocampus and thalamus. Mean values between stressed and non-stressed 
TASTPM mice were compared using an independent samples t-test for all 
ROIs. 
Experiment 2 
Animals 
Male TASTPM (n=26, Transgenic Unit, Biomedical Services Unit, University 
of Nottingham) were used. Mice were housed under identical conditions to 
those described above in Experiment 1. 
117 
Figure 3.9. ß-amyloid plaque morphology classification. 5.5 month old 
TASTPM mouse brain, x20 magnification A. Dense-cored plaque, defined as 
having a clear central core composed of dense ß-amyloid. B. Diffuse plaque, 
defined as having no clear central core. 
Experimental design 
The aim of this experiment was to determine effects of stress or corticosterone 
treatment during moderate stages of pathology in 6.5 month old TASTPM 
mice. There were no WT mice in Experiment 2a group of 5.5 month old 
TASTPM mice were tested for base-line working memory performance in the 
spontaneous alternation test. TASTPM mice were independently grouped 
depending upon the treatment given. Control non-stressed TASTPM (n=8), 
stressed TASTPM (n=9) and corticosterone-treated mice (n=7); two mice (one 
non-stressed and one in the corticosterone-treated group) died during the 
experiment and were subsequently removed from all analysis. Stressed 
TASTPM mice were exposed to 4 weeks of repeated novel cage stress and 
corticosterone-treated TASTPM mice were subjected to 3 weeks of chronic 
corticosterone treatment (followed by aI week wash-out period) both these 
treatments were administered from 5.5 months of age. After the treatment 
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period, TASTPM mice (then at 6.5 months of age) were tested for working 
memory, followed by assessments of locomotor activity. Mice were then tested 
for long-term contextual memory performance (memory acquired prior to 
treatment period, at 5.5 months of age). 48h following the final memory 
extinction test, all mice were humanely killed and brains removed for 
assessment of (3-amyloid levels. Half of each brain was used for 
immunohistochemistry and the other half for ELISA; see figure 3.8 for 
experimental protocol. 
Novel cage stress 
Novel cage stress was performed similar to that described above in Experiment 
1; conducted for lh once daily, four times per week, for a total of 4 weeks. 
TASTPM mice which were not in the stressed group, both control non-stressed 
and those treated with corticosterone, were manipulated to control for handling 
effects at times corresponding to the start, and end, of the Ih stress session. 
Physiological measures 
As with Experiment 1, body weights of all mice were monitored at 5.5 months, 
prior to both the initial spontaneous alternation testing and the treatment 
period, and again following the treatment period at 6.5 months of age. Body 
weight changes were analysed using a repeated measures ANOVA with the 
two time-points (Time) as within-subject factors and Group as the between- 
subject factor. 
Fecal boli were counted following each stress session for stressed TASTPM 
mice. Weekly mean defecation counts of stressed TASTPM mice were 
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compared using paired samples t-tests comparing mean score of each week, 
with the mean score from the previous week (as used and described in Section 
3.1.2). 
Corticosterone preparation and treatment 
As described above, one group of TASTPM mice were subjected to 3 weeks of 
chronic high dose corticosterone treatment administered orally in the drinking 
water. Corticosterone treatment was in parallel with the novel cage stress- 
treated group, figure 3.8.500mg of corticosterone (Sigma-Aldrich, Dorset, 
UK) was dissolved in 20m1 ethanol, using a sonic probe, and was made up in 
tap water to 1% stock ethanol solution, to deliver corticosterone at a 
concentration of 25mg/ml. For the treated TASTPM mice normal drinking 
water was replaced with the 25mg/ml corticosterone solution for 4 days (full 
24h periods) until day 5 when it is was then replaced with normal tap water for 
3 days (full 24h periods), until the treatment regimen started again the 
following week; non-stressed and stressed TASTPM mice water bottles were 
replaced with 0.1% ethanol solution during this treatment period for control 
purposes. This weekly routine continued for three weeks and was followed by 
a one week wash-out period prior to behavioural testing to ensure that any 
changes measured were a result of long-term effects of corticosterone 
treatment, rather than acute effects of high systematic levels of corticosterone. 
Water bottles were weighed daily for all mice (TASTPM non-stressed, stressed 
and corticosterone-treated mice), and mean fluid consumption per day over the 
3 week treatment period was calculated and analysed using a one-way 
ANOVA with Group as the between-subject factor. 
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Spontaneous alternation 
Spontaneous alternation was used as a measure of working memory 
performance. Performance in this test was assessed prior to the treatment 
period, at 5.5 months of age, and following the treatment period at 6.5 months 
of age, figure 3.8. Spontaneous alternation was performed as detailed in 
Section 3.1.2. In brief, mice were subjected to 10 min habituation to the T- 
maze 24h before the test trials. Test trials involved 10 min exposure once daily 
to the T-maze, for two days, in which mouse could explore either the left or 
right arms a total of 5 times; a correct alternation was defined as alternating 
from left-to-right between explorations. Results were expressed as % correct 
alternations, out of possible 5 decisions, throughout the trials. This value was 
then averaged between the two trials. Mice which did not complete 5 decisions 
in one of the two trials were recorded as partial non-performers (the single 
value was used for analysis) and mice which did not complete either trial were 
recorded as complete non-performers, and excluded from the analysis. To 
assess age-related changes in spontaneous alternation performance, the 
performance of non-stressed TASTPM mice at 5.5 months was compared to 
the performance of the same animals at 6.5 months of age using a paired- 
samples t-test. To determine the effects of various treatments on exploration, 
performance of 6.5 month old non-stressed, stressed and corticosterone-treated 
mice were compared using a one-way ANOVA, with Group as the between- 
subject factor. 
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Locomotor activity 
This was assessed following the treatment/stress at 6.5 months of age and was 
used to determine any effects of repeated novel cage stress, or chronic 
corticosterone exposure on mouse ambulation or habituation to a novel arena. 
Locomotor activity was tested as described in Section 3.1.2; briefly, mice were 
individually placed into the test chambers for 30 min and activity (distance 
moved, cm) was tracked automatically using Ethovision software. Data were 
expressed as either activity during 5 min time-intervals, to determine 
habituation to the novel arena, and analysed using a repeated measures 
ANOVA with Time-interval as the within-subject factor and Group as the 
between-subject factor. In addition, total activity over 30 min, assessing overall 
lcomotor activity, was analysed using a one-way ANOVA with Group as the 
between-subject factor. 
Long-term memory tests 
As with Experiment 1, CFC was used as a tool to study the long-term memory 
performance. The protocol was identical to that described above; memory 
acquisition occurred prior to stress/treatment period (at 5.5 months of age); 35 
days later memory retention was tested (at 6.5 months of age) and, 48h 
following this, memory extinction was assessed. There was one modification 
from the protocol used in Experiment 1. An extra extinction trial (3 min 
exposure to the context in the absence of foot shocks, see figure 3.8) 48h 
following the first extinction trial. 
Activity (distance moved, cm) during contextual memory acquisition was 
analysed using a repeated measures ANOVA with Time as the within-subject 
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factor and Group as the between-subject factor, to ensure there was no 
difference between the groups before the treatment period. Memory 
performance between the retention and extinction trials was analysed using a 
repeated measures ANOVA with the different Trial as the within-subject factor 
and Group as the between-subject factor. 
A second method of analysing these data from the memory tests involved 
calculating a series of extinction indices, introduced in Section 3.1.2. 
"Extinction" was calculated by subtracting performance during the final 
extinction trial by the memory retention trial; "Extinction 1" was calculated by 
subtracting the first memory extinction trial by the memory retention trial; 
"Extinction 2" was calculated by subtracting performance during the final 
extinction trial by the first memory extinction trial. All values for all groups in 
these extinction indices were compared to 0 using a one-sample t-test. 
To determine changes in memory performance with age, and whether stress 
had different effects at the two ages studied, non-stressed and stressed 
TASTPM mice from Experiment I and Experiment 2 were compared. 
Performance across the memory retention and first extinction trial was 
analysed using a repeated measure ANOVA with Trial as the within-subject 
factor and Age and Stress as the between-subject factors. 
Immunohistochemistry quantification of ß-amyloid 
Following the final CFC memory extinction trial, mice were humanely killed 
and half brains were taken, stored in 4% PFA at 4°C, and processed for 
immunohistochemical detection of ß-amyloid protein deposition. All sections 
were prepared and stained identically to that described above in Experiment 1. 
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On these brain sections the ROIs studied were hippocampus (4 examples), 
retrosplenial cortex (4 examples) and thalamus (4 examples), the relatively low 
number of representative sections for ROIs in Experiment 2 is attributable to 
only half a brain being available for analysis. 
Image analysis of brain sections, and detection of ß-amyloid, was performed as 
described for Experiment 1 ß-amyloid was compared between the three groups 
(TASTPM non-stressed, stressed and corticosterone-treated) using a one-way 
ANOVA with Group as the between-subject factor. The morphology of 1- 
amyloid plaques alters as the disease progression occurs with "diffuse 
plaques", characterised by a constant mass of (3-amyloid representing early 
plaque maturity, and "dense cored" plaques with a core of densely aggregated 
ß-amyloid representing later stages of plaque maturation (Harigaya et al., 
2006). Numbers of "dense core" plaques, and "diffuse" plaques, were manually 
counted in the retrosplenial cortex only and mean values between the three 
groups were compared using a one-way ANOVA with Group as the between- 
subject factor. 
ELISA quantification ofi-amyloid 
To quantify (3-amyloid levels in the non-stressed and stressed TASTPM mice 
only, half brains were dissected into three brain regions, hippocampus, cortex 
and frontal cortex. Within these regions, soluble Aß(1_4o) and insoluble A13(1-42) 
ß-amyloid were assessed using a solid-phase sandwich ELISA using kits from 
Biosource International, Inc., California, USA. The process of preparing the 
samples and performing the assay are described in detail in Section 3.1.2. In 
both instances 50 µ] of sample was added to wells lined with monoclonal 
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antibody (specific to (3-amyloid peptides). A secondary antibody was added to 
bind this complex, followed by a fluorescent substrate solution. Fluorescence 
was analysed using a plate reader. All brain samples were analysed in 
duplicate. Concentration of ß-amyloid was calculated, using a standard curve 
run with the sample, and expressed as pg Aß(1.4o) or Aß(l_42) per mg of wet 
tissue. Results were analysed using an independent samples t-test with Stress as 
the between-subject factor to compare between non-stressed and stressed 6.5 
month old TASTPM mice. 
3.2.3. Results 
Experiment 1 
Physiological measures 
All mice demonstrated an increase in body weight from the start to the end of 
the stress period (P < 0.0001); there was no difference in weight gained 
between WT and TASTPM mice, or with stress, and there was no Strain X 
Stress interaction. Overall, WT mice had a significantly higher body weight 
compared to TASTPM mice (P < 0.000 1), figure 3.1 OA. 
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Figure 3.10. Physiological measures, Experiment 1. A: Mean (± SEM) 
body weight (grams), prior to (4 months of age), and following the novel 
cage stress period (5.5 months of age) for WT non-stressed (WT, n=10) WT 
stressed (WT (S), n=8), TASTPM non-stressed (TASTPM, n=9) and 
TASTPM stressed (TASTPM (S) n=9). All mice demonstrated an increase in 
body weight with time (P < 0.0001), TASTPM mice had consistently lower 
body weight compared to WT mice (***P < 0.0001). Stress had no effect on 
the weight of either strain. B: Mean (± SEM) novel cage stress defecation 
count for stressed WT (n=8) and TASTPM (n=9) mice. TASTPM mice had a 
consistently higher level of defecation compared to WT mice (P < 0.0001). 
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Throughout the novel cage stress sessions, stressed TASTPM mice had a 
higher level of defecation compared to stressed WT mice (P < 0.0001), figure 
3.1OB. 
Memory performance 
Mice were subjected to CFC memory acquisition prior to 5 weeks of novel 
cage stress, at the age of 4 months; all mice demonstrated a decline in activity 
over the 10 min trial (P < 0.0001) in response to repeated footshocks. There 
was a Strain effect (P = 0.017) as WT mice, overall, had a lower level of 
activity during training (P 
= 
0.044), as compared to TASTPM mice, figure 
3.11A. 
At 5.5 months old, TASTPM mice did not exhibit a long-term memory 
retention deficit, stress had no effect on memory retention in either WT or 
TASTPM mice and neither group exhibited extinction (a reduction in 
immobility between the memory retention and extinction trials). Overall, there 
was a significant difference in immobility between WT and TASTPM between 
the CFC trials (P = 0.019), but there were no significant differences revealed 
by a multiple comparisons test, (figure 3.11B). 
An extinction index revealed that none of the four groups exhibited significant 
extinction, although TASTPM non-stressed mice did exhibit a significant 
increase in immobility between these trials (P = 0.003, figure 3.11 C). 
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MRI measures 
Volumetry and T2 relaxometry scans were performed on WT and TASTPM 
non-stressed and stressed mice at 5.5 months of age to provide an in vivo 
measure of pathological status in the ROIs investigated. WT mice had a lower 
caudate putamen volume overall compared to TASTPM mice which failed to 
reach statistical significance (P = 0.05). There were no differences with Strain, 
Stress, or a Stress X Strain interaction for the remaining ROI volumes studied 
(table 3.3). In addition, there were no differences in whole. brain volume 
between WT non-stressed (462.63mm3 ± 12.24), WT stressed (455.14mm3 ± 
9.79), TASTPM non-stressed (460.4mm3 ± 6.73), or TASTPM stressed mice 
(464.26mm3 ± 10.58). 
Manual assessments of T2 relaxation times revealed non-significant Strain X 
Stress effects in the subiculum (P = 0.05), hippocampus (P = 0.05). T2 
relaxation times, calculated using the semi-automated tool, revealed significant 
Stress effects in the thalamus (P = 0.046) and subiculum (P = 0.029). A Strain 
effect did not quite reach statistical significance for the caudate putamen T2 
relaxation (P = 0.05). There was a significant Strain X Stress interaction in the 
thalamus (P 
= 
0.041) and retrosplenial cortex (P = 0.025), table 3.4. A multiple 
comparisons test on those ROIs listed above revealed a significant difference 
between stressed WT and TASTPM mice in the thalamus (P = 0.048), and 
significant differences between non-stressed and stressed TASTPM mice in the 
thalamus (P 
= 
0.022), retrosplenial cortex (P = 0.030) and subiculum (P = 
0.025). 
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WT TASTPM Strain 
Non-stressed Stressed Non-stressed Stressed Effect 
Anreriorcingulare 0.85 0.85 0.86 0.80 
cortex (0.02) (0.05) (0.03) (0.04) 
Retrosplenial 1.47 1.47 1.45 1.50 
Cortex 
Thalamus 
(0.03) (0.03) (0.04) (0.05) 
3.89 3.89 3.85 3.84 
(0.09) (0.07) (0.07) (0.08) 
Caudate 4.67 4.88 4.61 4.61 
pUtamen (0.07) (0.11) (0.07) (0.09) 
Corpus 
callosum 
Subiculum 
0.62 0.64 0.62 0.62 
(0.02) (0.02) (0.02) (0.02) 
0.37 0.45 0.41 0.46 
(0.06) (0.04) (0.07) (0.06) 
Hippocampus 4.67 4.89 4.73 4.86 
(0.14) (0.07) (0.08) (0.07) 
*P 
= 
0.05 
Table 3.3. MRI volumetry results, Experiment 1. ROIs expressed as mean 
(± SEM) percentage of whole brain volume (± SEM) for 5.5 month old non- 
stressed WT (n=8), stressed WT (n=7), non-stressed TASTPM (n=9) and 
stressed TASTPM (n=8). There was no difference in whole brain volume 
between TASTPM and WT mice, stressed or non-stressed. There appeared to 
be a Strain effect on the caudate putamen volume which did not reach 
statistical significance (*P = 0.05). 
Immunohistochemistry quantification ofß-amyloid 
Levels of 0-amyloid plaque pathology were quantified using a semi-automated 
method to analyse immunohistochemistry sections stained for the protein. 
There was no difference in mean percentage of ROI covered in 0-amyloid 
between non-stressed and stressed TASTPM mice in the retrosplenial cortex 
(0.031 ± 0.01 vs. 0.018 ± 0.004, P=0.199), hippocampus (0.059 ± 0.019 vs. 
0.050 ± 0.010, P=0.675), and the thalamus (0.047 ± 0.016 vs. 0.041 ± 0.009, 
P=0.757). 
130 
Ii 
6ý V ýý 
GV 
"ý 
d 
Mý 
ýN 
ý 
ý 
a F 
Fý 
fA 
c ý 
Z 
I 
EF+ 
3 
V% N 
O 
* 
, It ý ý ý 
wl 
C:, 
* 
ý 
'0 0 
00 WM 0^ 
Ný 
ýý 
ýO 
`g O od Oj O 
nNV, 
--. 
1-: 
-" 
K r. ý: ýý a: ýý. 
-) iz ý; 
.ý ýý v°  C5 
I 
ý ýö 
r'n IM 
ý, 
"`- 
b ý ý 
w F 
gý 
y 
Q 
ý 
Z 
ý ý ý ý ýo 
I 
ý ý 
ý ý Vi 
d 
L 
ý 
F 
3ý 
ý d ý y 
C 
0 
z 
p 
00 ý 00 ý, ýý y7ý 
TN ýý rd 
ui 
a, a, 
00 WýÖýýWý 
7dhO 
00 
7ýVýV 
wa 'R N 
O "' ýn ý 
.N ýOýO 
ä°-Nä° 
ä°v°v° 
ol N 
Ö 
I 
a ý 
ý ý ý ý ý ý 
f+; MN 
1-N 00, 
r 
výä° 
ý 
.ý 00 ý; M (-f ^ý fJ 
_ý w 
-t " IT : 
ýý ýý ýý ýo 
ýý ýý ý 
_, 
.ý It `. ýzr ; 
0 ý ý h a 
Oý 
. 
r1 
ýO 
ýö 
.M ýO 
NN 
.N Rý 
CD ý r; ro O, h (V ý 00 ý 
rp o6 pýp 
ý 
cr, ö a, e 
ý°v° 
ö 20- 
MM ý: N 
rý 
7 
ö a, 
v6 
ö CO NNýýýNrý 
v°ýývýýý 
MN0 
NM 09 Rýý 
Oýýp -) p 
ý 
L ýaýz 
_ 
,ýý ,ýKý 
I 
ý 
.s ý 
ýý ö 
ýý 
ýNW 00 M 
ýÖýÖ 
7 
yC II 
ý I 
Next we assessed differences in levels of morphology of ß-amyloid plaques 
between non-stressed (n=6-7) and stressed (n=9) TASTPM mice, the lower 
number of subjects in the non-stressed group is due to a lower number of 
example ROIs available; mice with insufficient expression of ROI examples 
were excluded from the analysis. There was a trend towards a reduction in 
dense core plaques with stress in the retrosplenial cortex only (P = 0.088). 
There was no difference in diffuse plaque number in this ROI, and no 
significant differences found in the other ROIs for either plaque type, table 3.5. 
TASTPM 
Non-stressed Stressed 
Hippocampus Dense-core 1.63 1.58 
(0.57) (0.41) 
Diffuse 4.39 3.90 
(1.10) (0.78) 
Retrosplenial Dense-core 0.24 # 0.06 
cortex (0.10) (0.04) 
Diffuse 1.17 1.06 
(0.35) (0.23) 
Thalamus Dense-core 1.21 1.13 
(0.45) (0.29) 
Diffuse 2.49 1.75 
(0.72) (0.37) 
Table 3.5. Plaque morphology, Experiment 1. Mean (± SEM) dense-core 
and diffuse plaque number in non-stressed (n = 6-7) and stressed (n = 9) 5.5 
month old TASTPM mice in the hippocampus, retrosplenial cortex and 
thalamus. There was a trend towards reduction in dense-core plaques with 
stress but this failed to reach statistical significance (#P = 0.088). 
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Experiment 2 
Physiological measures 
From 5.5 to 6.5 months of age, all mice exhibited an increase in body weight as 
a factor of time (P < 0.0001); overall, there was a difference in body weight 
gain between control, stressed and corticosterone-treated mice (P = 0.002), 
although there was no significant difference between these groups from the 
multiple comparisons test, figure 3.12A. To determine changes in TASTPM 
mouse defecation during the novel cage stress exposure over the four week 
period, weekly mean defecation counts were compared to the score of the 
previous week. The only significant difference was an increase in defecation 
count between week 3 and week 4 (P = 0.025), figure 3.12B. 
Given that corticosterone was administered through the drinking water, the 
amounts drunk daily by each mouse averaged over the 3 week period was 
compared between all conditions (control, stressed and corticosterone-treated 
TASTPM mice). There was, overall, a difference in volume consumed between 
the three groups (P < 0.0001), and a multiple comparisons test revealed 
corticosterone-treated mice drank significantly more than control non-stressed 
TASTPM mice (9.54m1 ± 1.43 vs. 3.37ml ± 0.06, P<0.0001) and stressed 
TASTPM mice (9.45ml ± 1.43 vs. 4.33ml ± 0.24, P<0.0001). Average daily 
intake of corticosterone over the three weeks was 23.9 mg, equating to 
approximately 873mg/kg per day. 
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Figure 3.12. Physiological measures, Experiment 2. A: Mean (± SEM) 
body weight (grams) prior to the stress/treatment period at 5.5 months of age 
and following the stress/treatment period at 6.5 months of age for TASTPM 
non-stressed (n=8), TASTPM stressed (TASTPM (S), n=9) and TASTPM 
corticosterone (TASTPM CORT, n=7). All mice demonstrated an increase in 
body weight over time (***P < 0.0001). B: Weekly mean defecation counts 
for stressed TASTPM mice. The only significant difference between weeks 
was between week 3 and 4 (*P = 0.025). 
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Locomotor activity 
At 6.5 months of age, all mice tested demonstrated a decline in activity 
(distance moved, cm) over time (P = 0.001) throughout the trial; however, 
there was no difference in habituation to the novel arena between control, 
stressed and corticosterone-treated mice. In addition, there was no difference in 
total activity over the 30 min trial between the three groups. 
Spontaneous alternation performance 
Spontaneous alternation performance (mean % correct alternations throughout 
trials) was assessed in TASTPM mice at 5.5 months of age, prior to the 
treatment period, and at 6.5 months of age following the treatment period. 
First, comparing age-related performance of TASTPM mice from 5 months 
(n=3) to 6.5 months (n=3) there was no change in performance (66.67% ± 6.67 
vs. 60% ± 0) assessed using a paired-samples T-test. A one-way ANOVA 
comparing the performance of 6.5 month old non-stressed (n=4), stressed (n=7) 
and corticosterone-treated (n=6) TASTPM mice revealed no differences 
between the three groups (65% ±5 vs. 51.43% ± 5.08 vs. 65% ± 8.06). 
The reason for the low group numbers in the analysis of the spontaneous 
alternation tests is attributable to the number of non-performers in this task. 
TASTPM mice at 5.5 months of age had 4 full non-performers (did not 
perform in either trial). At 6.5 months old, non-stressed TASTPM had 1 partial 
non-performer (performed on only one trial, single value was used for analysis) 
and 4 full non-performers, stressed TASTPM mice had 2 full non-performers, 
and corticosterone-treated TASTPM mice had 2 full non-performers and 1 
partial non-performer. 
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Long-term memory test 
TASTPM mice were exposed to CFC memory acquisition at 5.5 months of age. 
Overall, all groups demonstrated a significant decline in activity as a factor of 
time, indicating successful conditioning (P = 0.008), and there was no 
difference between the three groups (non-stressed, stressed and corticosterone- 
treated TASTPM mice), figure 3.13. 
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Figure 3.13. CFC memory acquisition, Experiment 2. Mean (± SEM) 
activity (distance moved, cm) over time (10 mins) for the three groups non- 
stressed (TASTPM, n=8), stressed (TASTPM (S), n=9) and corticosterone- 
treated TASTPM mice (TASTPM (CORT), n=7) prior to the treatment period 
at 5.5 months of age. Overall, TASTPM demonstrated a decline in activity 
over time (P = 0.008), but there was no difference between the three groups. 
There was no difference between non-stressed, stressed or corticosterone- 
treated TASTPM mouse long-term memory retention. All three groups of mice 
demonstrated changes in immobility across the memory retention and 
extinction trials (P = 0.023). There was no Trial X Group interaction, although 
a multiple comparisons test revealed a significant difference, over the trials, 
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between non-stressed and stressed TASTPM mice only (P = 0.014). Stressed 
TASTPM mice had lower immobility levels compared to non-stressed 
TASTPM during the first extinction trial only (P = 0.033), figure 3.14. 
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Figure 3.14. CFC memory retention and extinction, Experiment 2. Mean 
(± SEM) immobility during the memory retention test and both extinction 
tests for non-stressed (TASTPM, n=8), stressed (TASTPM (S), n=9) and 
corticosterone-treated TASTPM mice (TASTPM (CORT), n=7). Overall, all 
groups of TASTPM mice showed a change in immobility over the three trials 
(P 
= 
0.023) and there was a difference between TASTPM non-stressed and 
stressed mice (P = 0.014). A multiple comparisons test showed a significant 
difference between non-stressed and stressed TASTPM mice during the first 
memory extinction trial only (*P = 0.033). 
A series of extinction indices were calculated to quantify changes in 
immobility levels between trials. Non-stressed TASTPM mice did not exhibit 
extinction between the memory retention and final extinction trial (Extinction), 
but demonstrated a trend towards a decrease in immobility between the first 
and final extinction trial (Extinction 2, P=0.083). Stressed TASTPM mice 
exhibited a significant drop in immobility from the memory retention and final 
extinction trial (Extinction, P=0.018), and between the memory retention and 
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first extinction trial (Extinction 1, P=0.028), but not between the first and last 
extinction trial (Extinction 2). Corticosterone-treated mice did not demonstrate 
a significant change in immobility between any of the trials, figure 3.15. 
Age-related changes in memory performance 
The performance of TASTPM mice from Experiment 1, at 5.5 months of age, 
and Experiment 2, at 6.5 months of age, were compared to determine any age- 
related changes in memory performance with or without stress; therefore in 
these analyses, Age and Stress are the between-subject factors. Given that in 
Experiment 1 there was only one memory extinction trial along with the 
memory retention trial, the analysis was only conducted on performance during 
these trials for both Experiments 1 and 2. 
During memory acquisition (data acquired 36 days prior to long-term memory 
tests), there was an overall decline in activity throughout the trial (P < 0.0001) 
exhibited by all mice, and there was an overall difference between the two ages 
(4 months vs. 5.5 months, P=0.002); mice in the older group had consistently 
lower levels of activity throughout the trial, figure 3.16. 
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Figure 3.15. Extinction indices of TASTPM mice, Experiment 2. Mean (± 
SEM) immobility (sec) for each extinction index of 6.5 month old non-stressed 
TASTPM (non-stressed, n=8), stressed (stressed, n=9), and corticosterone- 
treated mice (CORT-treated. n=7). Stressed TASTPM mice exhibited 
significant differences between the memory retention and final extinction trial, 
"Extinction" (A), and memory retention and first extinction trial "Extinction I" 
(B) (*P < 0.05). There was a trend towards extinction occurring between the 
first and last extinction trial, "Extinction 2" (C), exhibited by non-stressed 
TASTPM mice 
, 
but this did not reach statistical significance (4P = 0.083). 
Corticosterone-treated TASTPM mice did not show any changes in immobility 
between any Trials compared. 
I 
B. Difference between memory retention 
and first extinction trial 
C. Difference between first 
and first extinction trials 
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Figure 3.16. Age-related changes in TASTPM mouse memory 
acquisition. Mean (± SEM) activity (distance moved, cm) exhibited by 4 
month old (n=18) and 5.5 month old TASTPM mice (n=24). All mice 
demonstrated a decline in activity over the 10 minute trial (P < 0.0001), and 
5.5 month old TASTPM mice had an overall lower level of activity 
throughout the trial (P = 0.002). 
During the memory retention and extinction trials there was an overall effect of 
Stress (P 
= 
0.008), Age (P < 0.0001), and a Stress X Age interaction (P = 
0.028). There were no age-related differences during the long-term memory 
retention trial in either stressed or non-stressed TASTPM mice and no groups 
demonstrated a change in immobility between memory retention and 
extinction. During the memory extinction trial there was no age-related change 
in non-stressed TASTPM mice, but stressed 6.5 month old TASTPM showed 
lower immobility compared to age-matched non-stressed TASTPM mice (P = 
0.001), figure 3.17. 
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Figure 3.17. Age-related changes in TASTPM mouse memory 
impairment. Mean (± SEM) immobility (sec) of TASTPM mice at 5.5 
months of age non-stressed (5.5m TASTPM, n=9), and stressed mice (5.5m 
TASTPM (S), n=9), and 6.5 months of age non-stressed (6.5m TASTPM, 
n=8), and stressed mice (6.5m TASTPM, n=9). Immobility during the 
memory retention test was unaffected by age or stress. During the memory 
extinction trial 6.5 month old stressed TASTPM mice displayed a lower level 
of immobility compared to 6.5 month old non-stressed mice (**P = 0.001). 
Q-amyloid quantification 
In Experiment 2, brain ß-amyloid levels were quantified in 6.5 month old non- 
stressed and stressed TASTPM mice frontal cortex, cortex and hippocampus 
using an ELISA. This was supported by assessments of f3-amyloid in the 
hippocampus, retrosplenial cortex and thalamus of non-stressed, stressed and 
corticosterone-treated TASTPM mice using immunohistochemistry. 
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An ELISA assessing levels of Ap(I_40) revealed a trend towards a decrease with 
stress in the frontal cortex of 6.5 month old TASTPM mice which did not reach 
statistical significance (P = 0.062,0.74pg/mg ± 0.15 vs. 0.44pg/mg ± 0.05); 
there was, however, no difference in Ap(1_40) in the hippocampus or cortex with 
stress. In addition, there was no difference in Ap(1_42) with stress in 6.5 month 
old mice in any brain region studied. 
Immunohistochemical detection of ß-amyloid pathology, to assess the mean 
percentage of ROI covered in ß-amyloid in 6.5 month old non-stressed (n =6- 
5), stressed (n=9) and corticosterone-treated (n=6) TASTPM mice, was not 
found to be different for the hippocampus (0.29% ± 0.9 vs. 0.42% ± 0.06 vs. 
0.46% ± 0.07), retrosplenial cortex (0.19% ± 0.06 vs. 0.28% ± 0.07 vs. 0.24% 
± 0.09) or the thalamus (0.31 %±0.1 vs. 0.43% ± 0.1 vs. 0.41% ± 0.09). 
Due to a trend towards a change in dense core plaque number found in only the 
retrosplenial cortex of TASTPM mice with stress in Experiment 1, differences 
in the number of dense-core and diffuse plaques was assessed in this ROI for 
6.5 month old non-stressed (n=6), stressed (n=9) and corticosterone-treated 
(n=6) TASTPM mice. There was no significant difference in dense core 
plaques (0.67 ± 0.12 vs. 0.75 ± 0.23 vs. 0.96 ± 0.28) or diffuse plaques (2.04 t 
0.25 vs. 2.78 ± 0.48 vs. 3.79 ± 1.15) in the retrosplenial cortex. 
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3.2.4. Discussion 
The aim of the experiments described above was to assess the effects of 
repeated mild novel cage stress on the pathologies exhibited by the TASTPM 
mouse model of AD. Specifically, the question of how repeated mild stress 
might affect these mice during the early-to-moderate stages of ß-amyloid 
pathology, at both 5.5 and 6.5 months of age, was addressed. 
The major findings of these studies were as follows: 
1. TASTPM mice have an intact long-term contextual memory retention 
up to the age of 5.5 months. An absence of long-term contextual 
memory extinction is evident at all ages. 
2. Stress had no affect on memory performance at 5.5 months of age, but 
appears to have enhanced long-term contextual memory extinction in 
the oldest (6.5 month old) TASTPM mice only. 
3. In vivo MRI assessing volumetric changes and changes in brain tissue 
T2 relaxometry, appear to be capable of detecting AD-associated 
pathologies and effects of stress exposure in TASTPM mice. 
4. In general, there were no detectable effects of stress on brain ß-amyloid 
levels in the TASTPM mice at two ages studied, although pre-exposure 
to stress almost lowered At(140) in the frontal cortex of 6.5 month old 
TASTPM mice. 
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In the current study we found 5.5 month old TASTPM mice had an intact long- 
term memory retention, whereas we have previously shown that TASTPM 
mice at the same age have a short-term memory deficit (Pardon et a]., 2009). 
Contrary to this, a similar study demonstrated impaired remote memory (30 
days) expression of conditioned fear in a ß-amyloid overexpressing mouse 
model under 4 months of age (Kimura and Ohno, 2009). The difference 
between the nature of short- and long-term memory consolidation and storage 
should be addressed. Molecular pathways underlying long-term memories are 
thought to be robust and held in a consolidated state as compared to shorter- 
term memories, for instance, application of an amnesic agent directly after 
memory acquisition affects subsequent retention of that memory, whereas 
treatment with an amnesic agent several days later has no effect on retention as 
the memory has been consolidated into a more "permanent" state (for review, 
(Nadel and Land, 2000)). This robust nature of longer-term memories may be, 
in part, the reason why it is thought to be preserved until the later stages of 
clinical AD (Sartori et al., 2004). Moreover, clinical data are supported by 
preclinical evidence as longer-term, reference memory was intact until 6 to 8 
months of age in double transgenic ß-amyloid-overexpressing mice (Trinchese 
et al., 2004), a time point when, presumably, the brain regions responsible for 
storage of longer-term memories were compromised. Studies show long-term 
memories are stored in higher cortical areas (for review, (Wiltgen et al., 
2004)); for instance, one study demonstrated an important role for the anterior 
cingulate cortex in expression of long-term memory in mice at a similar 
paradigm to that described in the current study (Frankland et al., 2004). It is, 
therefore possible that higher cortical areas, such as the cingulate cortex, are 
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preserved until later stages of pathology in ß-amyloid overexpressing mice. 
Indeed, our in vivo MRI studies demonstrated no pathological changes 
occurred in the anterior cingulate cortex of these mice. Unlike its robust, 
beneficial effect on short-term memory, novel cage stress had no effect on 
long-term memory retention of TASTPM mice. Whether or not the beneficial 
effect of stress requires the pre-existence of a memory deficit remains to be 
determined. 
Our previous studies have shown that TASTPM mice develop a short-term 
memory extinction deficit between 3 and 4.5 months of age, which was 
resistant to novel cage stress, however, studies using another ß-amyloid 
overexpressing mouse line showed an intact short-term memory extinction in 
mice under 4 months of age (Kimura and Ohno, 2009). Consistent with our 
previous observations, in the current study we detected a lack of long-term 
memory extinction in TASTPM mice at 5.5 months of age. Interestingly, 
control WT mice also exhibited a lack of memory extinction during the long- 
term memory tests, suggesting that the lack of extinction by the TASTPM mice 
was not a deficit of the model per se, given it was observed in normal mice. As 
we do not have evidence as to whether this deficit also occurs in younger WT 
mice we cannot rule out the possibility that a long-term memory extinction 
deficit may represent a normal age-related change that occurs in mice. Indeed, 
it is believed that longer-term memories are more resistant to extinction (Lopez 
et al., 2008) possibly due to robust neurochemical pathways underlying such 
memories. 
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Novel cage stress had no effect on the long-term memory retention at either 5.5 
or 6.5 months of age. It is possible that the absence of a stress effect on long- 
term memory is due to the nature of memory being studied; short-term memory 
maybe more susceptible to change compared to longer-term memories; given 
the known differences between the two memory systems described above this 
is not unlikely. It is worthy of note that a fundamental difference between the 
current study and our previous study looking into short-term memory, is that 
here footshocks were administered prior to the stress procedure. It is, therefore, 
possible that pre-exposure to the severe stressor of footshocks may alter the 
stress-response to novel cage stress. An unpublished study by our group 
supports this hypothesis; pre-exposure to a footshock prior to novel cage stress 
elevated defecation level and unconditioned aversive behaviours during the 
stress sessions compared to non-shocked mice. This indicated pre-exposure to 
footshocks may change the perceived intensity of novel cage stress. 
Although stress had no effect on long-term memory retention, it did enhance 
extinction-like behaviour in 6.5 month old TASTPM mice. As discussed 
above, it is difficult to interpret whether this as a positive or a negative change. 
Extinction, the ability to re-learn that a stimulus is no longer aversive, is a 
natural response to deal with life trauma. When this is deficit it represents a 
lack of cognitive flexibility and, generally, a factor which induces a deficit in 
extinction is considered as a negative change to a normal memory processes. 
Novel cage stress appears to be inducing changes in the predicted direction, i. e. 
enhancing memory extinction, which supports the notion of a beneficial effect 
of this stressor. However, at 5.5 months WT mice did not exhibit long-term 
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contextual memory extinction, neither did TASTPM mice. Thus, enhancing 
extinction-like behaviour may, in fact, represent a negative change in memory 
performance. Novel cage stress is capable of affecting memory extinction in 
older TASTPM mice only, which suggests that a disease-related change 
evident in older mice only may underlie the effect of stress here. For instance, 
it may be that ß-amyloid levels, known to increase with age in this mouse line 
(Howlett et al., 2004), need to reach a certain "threshold" level before stress 
has a significant effect. Indeed, stress almost reduced brain P-amyloid levels in 
the oldest mice studied only, however, the effects of stress on ß-amyloid were 
not as robust as previously reported (Pardon et al., 2009), making these 
findings unclear. What is clear, however, is that stress was capable of affecting 
the long-term contextual memory extinction of 6.5 month old TASTPM mice. 
A high dose of corticosterone had no detectable effect on memory performance 
in TASTPM mice, it is therefore likely that any effect stress may be having on 
memory performance occurs through a corticosterone-independent mechanism. 
Corticosterone administration has been shown to be capable of facilitating 
memory performance when administered at an acute low dose of 250µm/kg 
(Brinks et al., 2009). However, corticosterone delivered at a high concentration 
of 26.8mg/kg, chronically for 3 weeks, has been shown to impair long-term 
memory performance (Coburn-Litvak et al., 2003). It is therefore surprising 
that high levels of exposure to corticosterone for 3 weeks in the current study 
had no effect on long-term contextual memory. Interestingly, corticosterone- 
treated mice consumed a significantly higher volume of fluid as compared to 
all other groups. This effect was unexpected. A separate study conducted by 
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our group to investigate this phenomenon further demonstrated that WT mice, 
free to drink corticosterone in solution, drank to excess. Such a high level of 
fluid consumption was not due to the ethanol in which the drug was 
solubilised, and these high doses of corticosterone had no effect on cognition 
(Pardon et al., unpublished). Interestingly, another study demonstrated that a 
lower dose of corticosterone was incapable of inducing a conditioned place 
preference in rats (Dietz et al., 2007), thus, corticosterone may only be 
rewarding when delivered at high doses. Indeed, chronic high dose of 
corticosterone appears to have enhanced the rewarding properties of brain 
stimulation in the rat (Barr et al., 2000), which supports this hypothesis. The 
reason underlying this apparent, addictive or rewarding property of high 
corticosterone administration is not known and would require further 
investigation. 
In Experiment 1, in vivo MRI was used to detect AD-associated changes in 5.5 
month old TASTPM mice, compared to age-matched WT mice with or without 
prior novel cage stress exposure. The results presented above indicate that, 
using a semi-automated tool, measurements of brain region volumetry revealed 
a smaller caudate putamen volume in TASTPM mice. To my knowledge, there 
have been no reports of caudate putamen volume changes in ß-amyloid over- 
expressing transgenic mice. However, previous studies have shown the 
striatum to be susceptible to developing ß-amyloid-based pathologies in similar 
mouse strains (Radde et al., 2006). Moreover, in clinical AD the striatum is 
subject to volume loss, determined by MRI (de Jong et al., 2008), providing 
further support of the face validity of this model. The reason for these volume 
148 
changes observed pre-clinically is not, as yet, clear given a general criticism of 
such transgenic AD mouse models is the apparent absence of gross 
neurodegeneration (Stein and Johnson, 2002). 
Tissue T2 relaxometry was used as an indirect method of assessing ß-amyloid- 
associated changes in tissue composition. Here, we were able to detect 
differences in T2 relaxation times between the two genotypes; although not 
reaching statistical significance, TASTPM mice appear to have shortened T2 
relaxation times compared to WT mice, which is consistent with previous 
findings in similar mouse models (El Tannir El Tayara et al., 2006; El Tayara 
Nel et al., 2007; Falangola et al., 2007). Stress elongated T2 relaxation times in 
TASTPM mice; to our knowledge there are no studies that have directly 
examined the effects of stress on brain tissue T2 relaxation times, although in 
humans an elongated T2 relaxation time has been associated with exposure to 
previous early-life extremely stressful events (Anderson et al., 2002). Despite 
the cause of the elongation of T2 relaxation with stress being unclear, one 
possibility is the heightened brain tissue water content that occurs following 
stress exposure (Duric and McCarson, 2005), which is known to elongate T2 
relaxation time (Laule et al., 2007). The ability to detect differences with stress, 
in addition to our observation of Stress X Strain interactions, supports the 
contention that stress can modulate AD-associated pathologies in TASTPM 
mice and that T2 relaxometry is an appropriate tool to assess such changes. 
The mechanism underlying the change in T2 relaxation times in AD sufferers 
and transgenic mouse models is not yet fully understood. Changes in 
relaxometry have also been found during normal aging (Chang et al., 1996), 
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and was thought to correlate to brain density and brain water content. T2 
relaxation is also sensitive to tissue iron levels; iron has been found to be co- 
localised with ß-amyloid plaques in transgenic mice (Falangola et al., 2005a), 
and, therefore, may play a role in the shortening of T2 relaxation observed in 
similar mice (El Tannir El Tayara et al., 2006; El Tayara Nel et al., 2007; 
Falangola et al., 2007). However, changes in T2 relaxation have been observed 
prior to deposition of the iron associated with ß-amyloid deposits (El Tayara 
Nei et al., 2007). Moreover, one group found changes in T2 relaxation in a ß- 
amyloid over-expressing transgenic mouse model prior to ß-amyloid 
deposition, and changes in relaxation times have been observed in PS 
transgenic mice devoid of ß-amyloid pathology (Falangola et al., 2007), 
indicating a factor independent of ß-amyloid can play a role. This is, in part, 
consistent with our findings given that repeated mild stress had no effect on ß- 
amyloid levels, but managed to alter T2 relaxation times in TASTPM mice. 
Moreover, our study confirmed that application of a semi-automated method to 
study T2 relaxometry in TASTPM mice heightened sensitivity as evidenced by 
harvesting more significant between-group differences compared to the values 
manually determined, consistent with a similar study (Falangola et al., 2005b), 
Contrary to our previous study, repeated mild stress, in the main, had no 
detectable effects on ß-amyloid levels in TASTPM mice at either 5.5 months or 
6.5 months of age. Interestingly, there was an trend towards a decrease of AP(j- 
40) in the frontal cortex of stressed 6.5 month old TASTPM mice (as 
determined by an ELISA) which was consistent with a previous study where 
we observed that novel cage stress reduced brain (3-amyloid levels in 5.5 month 
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old TASTPM mice (Pardon et al., 2009). However, the absence of a stress- 
effect at 5.5 months of age in the current study opposes these findings. 
Whether this lack of change with stress at 5.5 months of age, like the absence 
of behavioural effects, was due to the stress procedure being applied after pre- 
exposure to the stressful footshock (part of the CFC memory acquisition 
protocol) is not known. Immunohistochemistry, as a tool to determine 
pathological status, relies on the presence of ß-amyloid plaques; as these are a 
phenomena associated more with the later stages in pathological progression, it 
may be a tool better suited to studying later stages of pathology, when higher 
levels of ß-amyloid plaques are found. The semi-automated tool used to 
analyse the immunohistochemistry appears to be sensitive enough to detect 
age-related increases in brain ß-amyloid deposition; for example, the 
hippocampus of 5.5 month old TASTPM mice is 0.059% covered in ß- 
amyloid, whereas it is 0.29% covered in ß-amyloid in 6.5 month old TASTPM. 
However, the technique was incapable of detecting any changes associated 
with stress, or high corticosterone exposure in 6.5 month old TASTPM mice. 
Whether this is an issue associated with the level of resolution of the technique, 
or simply due to an absence of effect caused by the manipulations, is yet to be 
determined. However, the absence of any change in ß-amyloid using 
immunohistochemistry was in agreement with a similar, general lack of effect 
found by employing an ELISA. 
Immunohistochemistry did, however, allow us to detect a marginally lower 
number of "dense-core" plaques with stress in Experiment I (although not 
reaching statistical significance). Given that this form of plaque represents later 
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stages of pathology (Harigaya et al., 2006), these results indicate that stress 
maybe capable of slowing down the pathological progress. Indeed, there was 
no detectable change in diffuse plaque number with stress, suggesting that 
stress interacts with plaque maturity rather than formation. Although literature 
on this area is sparse, one study demonstrated that rats administered ß-amyloid 
along with the GC prednisolone had a higher level of dense-core plaques 
compared to diffuse (Harris-White et al., 2001). These findings may, therefore, 
suggest that mild stress exposure can be beneficial by lowering dense-core 
plaque number, whereas higher levels of GCs can increase the number of this 
type of plaque 
The method by which stress can modulate the morphology of ß-amyloid 
plaques, appears to affect Aß(l-4o) in the frontal cortex of the oldest TASTPM 
mice, and how stress was able to reduce ß-amyloid in our previous studies is 
still not known. Chronic high exposure to corticosterone had no effect on 
memory performance or ß-amyloid levels in TASTPM mice. Indeed, it has 
been previously shown that exposure to corticosterone does not mimic stress- 
induced elevations in hippocampal interstitial fluid in a ß-amyloid-over- 
expressing transgenic mouse line (Kang et al., 2007). It is, therefore, possible 
that a corticosterone-independent system is responsible for the various stress 
effects observed on brain ß-amyloid in transgenic mouse models (see Section 
1.4.1). 
In summary, the evidence above demonstrates that long-term memory 
remained intact in TASTPM mice up to 5.5 months of age and was unaffected 
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by repeated mild stress up to 6.5 months of age. In vivo MRI provided a means 
to study the early pathological markers of ß-amyloid-associated pathology in 
TASTPM mice and was sensitive enough to pick up effects of stress; 
lengthening T2 relaxation times in TASTPM mice. In the main, stress was 
incapable of modulating ß-amyloid levels in these animals, but may be capable 
of altering plaque morphology. The key findings, together with those 
describing the pathologies, and effects of stress on TASTPM mice during early 
stages of pathology (Section 3.1) are summarised below, figure 3.18. 
The aim of these studies was to determine a key point in the early-to-moderate 
pathology of TASTPM mice where we see the maximum effect of stress. This 
time-point appears to be at 5.5 months of age when stress reversed a short-term 
memory deficit and lowered brain ß-amyloid levels (Pardon et al., 2009). This 
time-window will therefore be used in the next section to explore a potential 
mechanism underlying this beneficial effect of stress on TASTPM mouse 
short-term memory performance and ß-amyloid pathology. 
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CHAPTER 4 
THE ROLE OF GLUTAMATE RECEPTOR 
SIGNALLING IN AD-ASSOCIATED 
PATHOLOGY, AND ITS INTERACTIONS WITH 
STRESS IN TASTPM MICE 
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4.1. Introduction 
Throughout Chapter 3 interactions between a repeated mild environmental 
manipulation, novel cage stress, and AD-related pathology in TASTPM mice 
were described. Effects of this stressor were investigated during both mild and 
moderate stages of ß-amyloid pathology. From these studies it was evident that 
TASTPM mice developed a short-term memory extinction deficit between 3 
and 4.5 months of age, but stress had no effect on memory performance or ß- 
amyloid levels between these ages. A previous study by our group 
demonstrated that stress between 4 and 5.5 months of age prevented the 
development of a short-term memory retention deficit and attenuated brain ß- 
amyloid accumulation (Pardon et al., 2009), but had no effect on memory 
extinction. A separate study showed an intact long-term memory in 5.5 month 
old TASTPM mice and pre-exposure to stress had little effect. Furthermore, 
stress between 5 and 6.5 months of age had no effect on long-term memory 
retention, but enhanced memory extinction. For a summary of these major 
findings see figure 3.18. 
The findings summarised above are, in part, consistent with the existing 
literature (see Section 1.4.1, and references therein) in that an environmental 
stressor was capable of modulating ß-amyloid levels in ß-amyloid over- 
expressing transgenic mouse models of AD. Unlike other findings in which 
stress exacerbated AD-like pathologies, our results indicated a beneficial role 
of repeated mild stress. The mechanisms through which this positive 
modulation of pathology occurs, remain unknown. In order to develop an 
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understanding of processes underlying this positive interaction, we must first 
take a time-point in TASTPM mouse pathology when we see the most 
significant effect of novel cage stress. In figure 3.18 the effects of stress on 
pathologies in TASTPM mice with increasing age are summarised. Novel cage 
stress applied between 4 and 5.5 months of age on short-term memory was the 
only occasion when a positive modulatory effect of stress was observed on 
both behaviour and ß-amyloid levels. Due to the robust, quantifiable change 
with stress at this time-point, it will be used to study the mechanisms linking 
repeated mild stress with the various pathological markers expressed in this 
model. To study a potential mechanism one must find an element that links 
processes occurring during progression of AD-like pathology with events 
which are known to be involved in the stress response. 
Levels of the excitatory amino acid (EAA) neurotransmitter, glutamate, have 
been correlated with cognitive impairment in normal aging (Zahr et al., 2008), 
and depletion of brain glutamate levels is a feature of clinical AD (Hyman et 
al., 1987). Glutamate levels have also been shown to decrease with age in 
double transgenic mice overexpressing ß-amyloid (Marjanska et al., 2005; von 
Kienlin et al., 2005; Oberg et al., 2008) and this neurotransmitter system is 
known to be involved in the processes of contextual fear memory learning (Lu 
and Wehner, 1997; Smith and Wehner, 2002) and extinction (Zushida et al., 
2007). Moreover, the glutamatergic system is known to play a key role in the 
stress response (for review, (Moghaddam, 2002)). Given its involvement in 
learning and memory, if glutamate levels decline with age in TASTPM mice, 
as reported in similar mouse strains, this may play a role in the development of 
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the short-term memory deficit between 4 and 5.5 months of age, and memory 
extinction deficit between 3 and 4.5 months, exhibited by TASTPM mice. 
Glutamate is the most abundant neurotransmitter in the brain and acts through 
EAA receptors, one of which is the alpha-amino-3-hydroxy-5-methyl-4- 
isoxazolepropionic receptor (AMPAr). AMPAr are tetrameric, comprised of 
four protein subunits (GIuR1_4), each of these subunits can be expressed as one 
of two splice variants termed "flip" or "flop", referring to an altered state of 
functioning, resulting in different receptor properties. For example, the 
expression of the "flip" variant has been linked to prolonged AMPAr 
desensitisation (Mosbacher et al., 1994), thus enhancing activity of these 
receptors with constant agonist exposure. AMPAr functioning has been 
previously shown to be important in conditioned memory performance 
(Woolley et al., 2009), for instance, a potentiator of AMPAr enhanced 
contextual memory extinction in mice (Zushida et al., 2007). AMPAr are also 
important in the stress response as blocking these receptors during 
immobilisation stress prevented increases in ACTH (Kusakawa et al., 2007), 
part of the HPA axis pathway (figure 1.2). Furthermore, complicated links have 
been demonstrated between AMPAr expression and corticosterone (Groc et al., 
2008). An association between AMPAr and AD-related pathology also exist; a 
reduction in AMPAr-mediated signalling was observed in APP x PS-1 double 
transgenic mice (Chang et al., 2006) and receptor subunit expression was 
reduced in vulnerable regions of the hippocampus of AD sufferers, an effect 
which correlated with the severity of pathological markers (Ikonomovic et al., 
1995). The findings summarised above suggest glutamate signalling through 
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AMPAr as a likely candidate for studying the underlying mechanism linking 
stressors with AD-related pathology in the TASTPM mice. Therefore, one 
hypothesis is that an age-related decline in glutamate leads to the development 
of behavioural abnormalities, which are reversed by repeated mild stress 
through providing daily stimulation via enhanced glutamatergic signalling 
through AMPAr. Indeed, elevated activity of AMPAr has been observed 
following an environmental enrichment paradigm (Gagne et al., 1998). 
A further connection between stress and glutamatergic signalling exists 
through the cellular splicing factor SC35. SC35, which is elevated during states 
of stress (Meshorer et al., 2005), can affect AMPAr function (Crovato and 
Egebjerg, 2005) and lead to the expression of a variant of acetylcholine 
esterase (AChE) (an enzyme responsible for the breakdown of the 
neurotransmitter acetylcholine), believed to be protective against (3-amyloid- 
related insults (Berson et al., 2008). 
Here we aimed to investigate the connection between stress and AD-associated 
pathology in TASTPM mice in relation to function through AMPAr and SC35 
protein expression. To achieve this, two experiments were conducted. 
Experiment I aimed to correlate changes in memory performance with changes 
in brain glutamate levels between 4 and 5.5 months of age, early stages of 
amyloid pathology of TASTPM mice. 
Experiment 2 investigated the involvement of glutamate signalling through 
AMPAr in the effects of repeated mild stress on TASTPM mice. A 
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pharmacological approach was taken to determine whether it was possible to 
mimic the effects of stress on TASTPM mice through daily administration of 
aniracetam. Aniracetam is a cognitive-enhancing, nootropic modulator which 
elevates AMPAr conductance, and has been previously reported to improve 
memory performance at a conditioning test in mice (Lu and Wehner, 1997; 
Smith and Wehner, 2002). This study was supported with a separate group of 
TASTPM mice being exposed to novel cage stress and administered the 
AMPAr antagonist 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7- 
sulfonamide (NBQX), known to disrupt conditioned memory in mice (Mead et 
al., 1999). Mice were treated with NBQX prior to each stress session in order 
to lower AMPAr signalling during the stress procedure with an aim of blocking 
the positive effects of novel cage stress. 
4.2. Methods 
Experiment 1 
Animals 
Male WT (C57B1/6, n=15) (Charles River Laboratories, UK) and TASTPM 
mice (Biomedical Services Unit, Transgenic Unit, Nottingham, n=16) were 
used. As with previous experiments mice were group housed until the age of 3 
months, after which they were singly housed. Food and water were available 
ad libitum, a cardboard play-tube and bedding were also available as part of 
standard environmental enrichment. Animals were kept under controlled 
conditions in a constant environment on a 12h light: dark cycle, temperature 
and humidity were maintained automatically. All procedures were carried out 
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according to the Animals (Scientific Procedures) Act 1987, under licence 
40/2715 granted to Professor Charles A. Marsden. 
Experimental design 
WT and TASTPM mice were divided into two subgroups depending on the age 
of behavioural testing: 4 months of age (n=8 per strain) and 5.5 months of age 
(n=7 WT and n=8 TASTPM mice). Short-term memory was assessed using 
contextual fear conditioning (CFC) at both ages for both strains. Mice were 
humanely killed by decapitation 48h following the final CFC extinction trial, 
their brains removed and half were stored in 4% PFA at 4°C until 
immunohistochemical analysis was performed for ß-amyloid in 5.5 month old 
TASTPM mice only. The other halves were dissected and the hippocampus and 
frontal cortex were used for glutamate quantification using HPLC to determine 
any age-related changes, or differences between the two strains, for the 
experimental protocol see figure 4.1. 
Short-term memory test 
CFC (contextual fear conditioning) was used to measure short-term memory 
performance as described in Section 2.2.2. Briefly, mice underwent CFC 
training (memory acquisition), receiving 10 foot shocks (0.4mA), once per 
minute for 10 mins. To test short-term memory retention, mice were returned 
to the CFC operant chamber 24h later, in the absence of shocks, for 3 mins 
during which behaviour was video-taped and immobility later scored manually. 
Two extinction trials were conducted 48h apart; again, mice were returned to 
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the operant chamber for 3 mins and immobility was scored. The experimental 
design is summarised in figure 4.1. 
I 
Group 1 Group 2 
4 months old 5.5 months old 
}1 I } 
D1 D2 D3 D4 D5 D6 D7 D8 Dl D2 D3 D4 D5 D6 D7 D8 
CFC CFC CFC CFC KILL CFC CFC CFC CFC KILL 
Ti T2 T3 T4 Ti T2 T3 T4 
Figure 4.1. Experimental design, Experiment 1. Contextual fear 
conditioning (CFC) was tested identically for WT and TASTPM mice in both 
age-groups, 4 and 5.5 months of age. CFC memory acquisition (TI) was 
conducted on day 1 (131), memory retention (T2) was conducted on day 2 
(D2), the first memory extinction trial (T3), was conducted on day 4 (D4) and 
the last extinction trial (T4), was conducted on day 6 (D6). At both 4 and 5.5 
months of age, mice were humanely killed 48h following T4, on day 8 (D8). 
Acquisition of conditioned fear was analysed using a two-way repeated 
measures ANOVA with Time as the within-subject factor, and Age and Strain 
as the between-subject factors. Performance across the memory retention and 
extinction trials was assessed in both experiments using a repeated measures 
ANOVA with the Trial as the within-subject factor, and Age and Strain as the 
between-subject factors. For all results described below, values are quoted as 
mean ± SEM, and Tukey's post-hoc test was used for multiple comparisons in 
the analysis where appropriate. 
As with previous studies, extinction of conditioned fear throughout the test was 
assessed using a series of extinction indexes, as described in Section 3.1.2. 
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Briefly, "Extinction" was calculated by subtracting immobility scores during 
the memory retention trial from the final extinction trial; "Extinction I" was 
calculated by subtracting performance during the memory retention trial from 
that during the first extinction trial; "Extinction 2" was calculated by 
subtracting immobility in the first extinction trial from the final extinction trial. 
Extinction is therefore represented by a negative score, and this was compared 
to 0 using a one-sample t-test for each group. 
Brain glutamate levels 
Reverse-phase HPLC was used to quantify brain regional glutamate levels in 
WT and TASTPM mice at 4 and 5.5 months of age. 48h following the final 
memory extinction trial, mice were killed and brains were removed. The 
hippocampus and frontal cortex were dissected out, snap-frozen on dry ice and 
stored at 
-80°C until they were analysed. Brain samples were weighed, hand 
homogenised in 500µl methanol, left on ice for 10 mins, then centrifuged at 
4°C, 10,000rpm (13.5 cm rotor, Eppendorf 5417R) for 10 mins. The pellets 
were discarded, and supernatant used for HPLC analysis. Samples were run at 
x200 concentration (sample diluted in methanol), 100 µl of the sample used for 
analysis was added to a derivitisation reagent, and held at room temperature for 
20 mins prior to injection. Before analysing experimental samples a standard 
curve was run to prove linearity between glutamate concentration and 
chromatogram peak height, which proved to be highly correlated (data not 
shown, R2 = 0.98). Alongside each daily batch of samples, a glutamate 
standard was run at the beginning, and at the end of each day and this was 
subsequently used for analysis. Results were calculated as nmoles glutamate 
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per mg wet tissue and were compared between groups using a two-way 
ANOVA with Strain and Age as the between-subject factors. 
Immunohistochemistry 
Quantification of ß-amyloid in 5.5 month old TASTPM mice was performed 
using immunohistochemistry similar to that described in Section 3.2.2. All 
mice were killed 48h following the final memory extinction trial. Half brains 
were removed, fixed in 4% PFA and kept at 4°C for subsequent 
immunohistochemistry processing. The processing of brain samples was 
conducted as described previously in Section 2.4.2. In brief, brain tissue was 
embedded in paraffin wax. Blocks were sectioned using a LEICA RM 2135 
rotary microtome. Sections were then immunostained for ß-amyloid using the 
ßA4 antibody with a concentrated formic acid pre-treatment. Representative 
sections were taken between Bregma 1.10mm and Bregma 
-3.88mm allowing 
sufficient expression of regions of interest (ROIs): hippocampus (5-7 
examples), thalamus (5-8 examples), retrosplenial cortex (5-8 examples), 
corpus callosum (5-10 examples) and caudate putamen (5-9 examples). 
Sections were then scanned using the Nanozoomer Digital Pathology slide 
scanner at x20 magnification. ROIs were delineated using the AnalySlS Pro 
3.1 Soft Imaging System. Deposited ß-amyloid was automatically detected 
and results were averaged for each ROI to give a final value as a percentage of 
ROI covered in ß-amyloid. Levels of ß-amyloid in 5.5 month old TASTPM 
were compared to groups of mice in Experiment 2; the reason for this 
comparison and the type of analysis used is described later. 
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Experiment 2 
Animals 
A total of 15 WT mice were used, separated into two subgroups: non-stressed 
vehicle-treated (non-stressed WT, n=7), stressed vehicle-treated (stressed WT, 
n=8). A total of 32 TASTPM mice were used and separated into four 
subgroups: non-stressed vehicle-treated (non-stressed TASTPM, n=8), stressed 
vehicle-treated (stressed TASTPM, n=8), non-stressed aniracetam-treated 
(aniracetam-treated TASTPM, n=8), and stressed NBQX-treated mice (NBQX- 
treated TASTPM, n=8). As described above, all mice were individually housed 
at 3 months of age and kept under standard housing conditions. 
Experimental design 
The aim of Experiment 2 was to determine effects of various treatments on 
memory performance and ß-amyloid pathology in the groups of TASTPM 
mice detailed above. Further details on the drug preparation, dosage and stress 
procedure are described in detail below. The various treatments were applied 
between the ages 4 and 5.5 months in WT and TASTPM mice. Following the 
stress and treatment period, at 5.5 months of age, all mice were tested for 
locomotor activity and short-term memory performance in the CFC paradigm. 
48h following the final CFC memory extinction trial, mice were killed and 
their brains removed to quantify ß-amyloid levels. For experimental design, see 
figure 4.2. 
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Figure 4.2. Experimental design, Experiment 2. Various treatments (drug 
administration and/or stress) were started on experimental day I (D1) at 4 
months of age. After the 5 week "treatment" period, locomotor activity was 
tested on day 33 (D33). Memory acquisition during the CFC test ( TI) was 
conducted on experimental day 36 (D36), memory retention (T2) was tested 
24h later on day 37 (D37). Two 48h intervals later extinction trials (T3 and 
T4) were conducted on days 39 and 41 (D39 and D41) respectively. 48h 
following the final extinction trial (T4), mice were humanely killed and 
brains removed for analysis on day 43 (D43). 
Drug preparation and administration 
Both aniracetam (NIMH, Bethesda, USA & Tocris Bioscience, Bristol, UK) 
and NBQX (Ascent Scientific, Western-Super-Mare, UK) were solubilised in 
sterile vehicle (10% hydroxypropyl-ß-cylcodextrin), all injections were made 
at 0.25ml volume and delivered intraperintoneally. Aniracetam was 
administered at 100mg/kg (i. p. ), a dose previously reported capable of 
disrupting performance in a similar fear conditioning paradigm in mice (Lu and 
Wehner, 1997; Smith and Wehner, 2002). Aniracetam was solubilised by 
sonication in a sonic water bath. NBQX was delivered at 15mg/kg (i. p. ), a dose 
which has been shown previously to disrupt expression of a conditioned 
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response in mice (Mead et al., 1999), NBQX was directly solubilised in vehicle 
by vortex mixing. Dosage times were based on those described in the studies 
cited above: aniracetam-treated mice were dosed 30 mins prior to the start of 
the stress session, whereas NBQX was injected 15 mins prior to the start. All 
other non-treated groups of WT and TASTPM mice were vehicle-injected prior 
to the novel cage stress session. 
Novel cage stress 
Novel cage stress was applied to WT and TASTPM mice, and NBQX-treated 
TASTPM mice. This was performed as described in Section 3.1.2. In brief, 
mice were individually placed for lh in novel clean cages, half the size of the 
home cage. Food, water, bedding and play tube were not available. Non- 
stressed mice were handled for control purposes; they were lifted by the tail 
from the home cage and replaced into the home cage at corresponding times to 
the start and finish of the lh stress session. At the end of the session, stressed 
mice were replaced in their home cages, the number of faecal boli was 
recorded, and the novel cages were thoroughly cleaned with standard 
disinfectant to remove olfactory scent markers. 
To determine emotional reactivity, unconditioned behaviours were manually 
scored during the first and final stress sessions. These included rearing (defined 
as total elevation of body rearing on hind legs without support of the forelimbs 
against the cage wall), grooming (defined as a single episode of grooming) and 
tail-rattles, an emotional aversive response exhibited by mice (defined as the 
tail being vigorously shaken). These unconditioned behaviours have been used 
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in previous investigations to assess stress reactivity in mice (Riittinen et al., 
1986; Gasparotto et al., 2007). Given an absence of activity in non-stressed 
mice in their home cages at times corresponding to the stress procedure, 
unconditioned behaviours were not scored in non-stressed mice. Unconditioned 
behaviours were analysed using a repeated measures ANOVA, with Stress 
Session as the within-subject factor (to compare performance during the first 
and last stress session) and Group as the between-subject factor. 
Physiological measures 
As with previous studies described earlier, body weight of all mice was 
recorded at two time points. First, prior to the stress/treatment period at 4 
months of age and, second, following the stress/treatment period at 5.5 months 
of age. Body weight results were compared using a repeated measures 
ANOVA with Age as the within-subject factor and Group as the between- 
subject factor. As mentioned above, defecation number was counted at the end 
of each stress session throughout the treatment period for all mice in the 
stressed groups. Results were analysed using a repeated measures ANOVA 
with repeated Stress Session as the within-subject factor, and Group as the 
between-subject factor. 
Locomotor activity 
To determine whether the drug/stress treatments had any effects on the 
locomotor activity of WT or TASTPM mice, performance of all mice was 
tested 24h following the final treatment and/or stress session, see figure 4.2. 
The test was conducted as described in Section 3.1.2; briefly, mice were 
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individually placed in one of eight identical test chambers (13 x 17 x 20 cm) 
for 30 mins and activity (distance moved in cm) was videotaped and 
subsequently measured automatically by Ethovision software. Locomotor 
activity performance was assessed two ways. First, as activity over six 5 min 
time intervals to determine habituation to the novel environment, analysed 
using a repeated measures ANOVA with Time as the within-subject factor and 
Group as the between-subject factor. Second, overall total ambulation over the 
30 mins trial was tested by comparing total activity using a one-way ANOVA 
with Group as the between-subject factor. 
Short-term memory test 
Short-term memory performance was assessed using CFC identically to that 
described above in Experiment 1; details on the timing of the trials are 
summarised in figure 4.2. During the 10 min memory acquisition trial activity 
(distance moved, cm per minute) of all mice was compared using a repeated 
measures ANOVA with the Time as the within-subject factor and Group as the 
between-subject factor. Performance across the memory retention and 
extinction trials was assessed using a repeated measures ANOVA with the 
Trial as the within-subject factor and Group as the between subject factor. 
Extinction indexes were calculated, as described above in Experiment 1, and 
values for all groups were compared to 0 using a one-samples t-test. 
To determine any effects of repeated injection on cognition in WT and 
TASTPM mice, memory performance of 5.5 month non-injected mice from 
Experiment I and 5.5 month old vehicle-injected mice from Experiment 2 was 
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compared. Activity during the memory acquisition trial was analysed using a 
repeated measures ANOVA with Minutes as the within-subject factor and 
Strain and Injection as the between-subject factors. In addition, performance 
throughout the memory retention and extinction trials was compared using a 
repeated measures ANOVA with Trial as the within-subject factor and Strain 
and Injection as the between-subject factors. 
Immunohistochemistry 
48h following the final CFC extinction trial, mice were killed and their brains 
were removed. Half brains were used to quantify levels of ß-amyloid in the 
four groups of TASTPM mice (non-stressed, stressed, aniracetam-treated and 
NBQX-treated TASTPM mice). The method of section preparation and 
analysis for Experiment 2 was identical to that described above in Experiment 
1. The number of representative examples for each ROI in Experiment 2 were 
as follows: hippocampus (6-9 examples), thalamus (7-10 examples), 
retrosplenial cortex (6-10 examples), corpus callosum (6-10 examples) and 
caudate putamen (6-10 examples). The mean percentage of each ROI covered 
in ß-amyloid was compared between the four TASTPM groups using a one- 
way ANOVA with Group as the between-subject factor. In addition, to 
determine effects of 5 weeks of vehicle injection on ß-amyloid levels, levels in 
5.5 month old TASTPM mice in Experiment I were compared to that of 5.5 
month old vehicle-treated non-stressed control TASTPM mice using an 
independent samples t-test. Morphology of ß-amyloid plaques in the 
retrosplenial cortex was manually assessed (as described in Section 3.2.2), 
levels of dense-core and diffuse plaques were compared between the four 
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groups of TASTPM mice from Experiment 2 using a one-way ANOVA with 
Group as the between subject factor. 
Levels of SC35 protein expression were quantified in all mice in Experiment 2 
(non-stressed and stressed WT and TASTPM, aniracetam- and NBQX-treated 
TASTPM mice). Brains were sectioned identically to that used for ß-amyloid 
assessment described above, and stained following a previously described 
protocol (Meshorer et al., 2005). Stained sections were scanned using the 
Nanozoomer Digital Pathology slide scanner at x40 magnification. To assess 
levels of SC35 expressed representative portions of ROIs were delineated 
directly onto the images using the NDP Digital Slide Viewer (Hamamatsu, 
Japan). To ensure consistency, all effort was made to ensure the representative 
portions were taken in the same place in the brain between animals. Details of 
the portions taken for analysis are listed below. Hippocampal functional 
regions, CAI, CA3 and dentate gyros were studied; each ROI was delineated 
as 5000µm2. For the retrosplenial cortex all portions were 0.1mm2 (figure 
4.3A), until the corpus callosum splits at Bregma 
-2.7mm, after which portions 
were 0.05mm2 adjacent to the corpus callosum. For the caudate putamen, a 
0.1mm2 portion was taken in the centre of the ROI between Bregma 1.10mm 
and 
-0.82mm (figure 4.3C), and between Bregma -0.94 to -3.88mm, 0.05mm2 
portions were taken in the centre of the ROI. For the corpus callosum a 
0.013mm2 portion was taken until this ROI splits at Bregma 
-2.70mm2 (figure 
4.3A & Q. For the thalamus, a 0.05mm2 portion was taken between Bregma 
- 
0.22mm and 
-0.82mm below the ventricles (figure 4.3C), a 0.1mm2 portion 
was taken between Bregma 
-0.94mm and -2.06mm beneath the hippocampus 
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(figure 4.3A), a 0.05mm2 portion was taken adjacent to the hippocampus 
between Bregma 
-2.18mm and -3.28mm (figure 4.3B) and a 0.015mm2 portion 
was taken between Bregma 
-3.40mm and -3.88mm next to the hippocampus. 
Example portions available and analysed for each ROI were as follows: 
retrosplenial cortex (5-10 portions), corpus callosum (6-11 portions), caudate 
putamen (5-10 portions), thalamus (5-11 portions), dentate gyrus (5-8 
portions), CAI (5-8 portions) and CA3 (5-8 portions). 
Within the portions delineated the intensity of the cellular stain was manually 
scored as one of three levels of intensity: high expression scored 3 (figure 
4.4A), medium expression scored 2 (figure 4.4B) and low expression scored 1 
(figure 4.4C). Mean intensity scores in all ROIs, for each mouse, was 
calculated to provide an "intensity read-out". The intensity read-out was 
compared between the six groups of mice using a one-way ANOVA with 
Group as the between-subject factor. 
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Figure 4.4. SC35 expression intensity criteria for scoring. Images captured 
in the mouse retrosplenial cortex at x40 magnification to demonstrate SC35 
stain intensity. A. Low intensity if SC35, nuclei are fully transparent, some 
evidence of cellular expression, receiving an intensity score of I. B. Medium 
intensity of staining, most nuclei are partially transparent, with evidence of 
strong cellular SC35 immunoreactivity, receiving an intensity score of 2. C. 
High expression of SC35 with heavy nuclear staining, almost non- 
transparent, receiving an intensity score of 3. D. Negative control section, no 
evidence of specific SC35 immunoreactivity. 
As with the (3-amyloid studies described above, SC35 expression from 5.5 
month old TASTPM mice in Experiment I was compared to that of 5.5 month 
old vehicle-treated non-stressed control TASTPM mice from Experiment 2; 
this was to determine any injection-related changes in SC35 expression using 
an independent samples t-test. Due to either loss of tissue when sectioning or 
insufficient portions of each RO1 available for analysis, number of subjects in 
each group was as follows: non-stressed WT (n=6-7), stressed WT (n=8), non- 
stressed TASTPM (n=7-8), stressed TASTPM (n=7-8), aniracetam-treated 
TASTPM (n=7-8), NBQX-treated TASTPM (n=6-8) and non-injected, non- 
stressed TASTPM mice from Experiment I (n=6). 
. 
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4.3. Results 
Experiment 1 
Short-term memory performance 
Age and strain-dependant changes in performance in the CFC test were 
compared in WT and TASTPM mice at 4 and 5.5 months of age. During the 
memory acquisition trial all mice, at both ages studied, demonstrated a decline 
in activity throughout the trial (P < 0.0001) indicating successful memory 
acquisition. There was an overall difference between WT and TASTPM mice 
(P 
= 
0.009) and a trend towards a difference between the two age groups, 4 and 
5.5 months old, but this did not reach statistical significance (P = 0.05). There 
was, however, no Strain X Age interaction, figure 4.5A&B. 
When analysing performance during the memory retention and extinction tests 
of WT and TASTPM mice, between the two ages, there was an overall 
significant effect of repeated trial (P = 0.006) and an overall difference 
between the two strains (P < 0.0001), but there were no global differences 
between the two age groups. There was, however, nearly a Trial X Strain X 
Age interaction (P 
= 
0.05). A multiple comparisons test revealed no differences 
in memory retention in WT and TASTPM at any age and no groups 
demonstrated extinction, except 5.5 month old WT mice where there was a 
trend towards a decline in immobility from the memory retention to the final 
extinction trial (P 
= 
0.066). In addition, 5.5 month old WT mice had a 
significantly lower level of immobility than age-matched TASTPM during the 
final extinction trial (P = 0.041), a difference which was not detected in mice 
one month younger, at 4 months of age. Also, there was a trend towards an 
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age-related difference in immobility levels when comparing 4 and 5.5 month 
old WT performance during the final extinction trial (P = 0.08), figure 4.6A. 
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Figure 4.5. Contextual memory acquisition, Experiment 1. A. Mcan (± 
SEM) activity (distance moved, cm) over the 10 min trial for 4 month old 
WT (4m WT, n=8) and TASTPM mice (4m TASTPM, n=8). B. Mean (± 
SEM) activity over 10 min trial for 5.5 month old WT (5.5m WT, n=7) and 
TASTPM mice (5.5m TASTPM, n=8). All mice demonstrated a decline in 
activity throughout the trial (P < 0.0001) indicating successful conditioning. 
Overall there was a significant difference between WT and TASTPM mice (P 
= 
0.009) and non-significant trend towards a difference between the two ages 
studied (P = 0.05), but no Age X Strain interaction 
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Extinction indexes were calculated to determine differences in immobility 
levels between memory test trials for each group. Both 4 and 5.5 month old 
WT mice exhibited significant (P < 0.05) extinction between the memory 
retention and final extinction test (Extinction), 4 month old TASTPM showed a 
trend towards significance (P = 0.062), but 5.5 month old TASTPM mice did 
not show any extinction. Instead, 5.5 month old TASTPM mice exhibited a 
significant increase in immobility (P 
= 
0.018). WT mice at 4 months of age 
were the only group to exhibit extinction between the memory retention trial 
and first memory extinction trial (Extinction 1, P<0.0001). None of the 
groups demonstrated extinction between the first and final extinction trial 
(Extinction 2), figure 4.6B. 
Brain glutamate levels 
Glutamate levels from the frontal cortex and hippocampus of WT and 
TASTPM mice were compared at two ages, 4 and 5.5 months of age. There 
was no significant difference with age, or between the two strains, and no 
Strain X Age interaction for either brain region, table 4.1. 
Experiment 2 
Physiological measures 
Body weight for all mice in Experiment 2 was recorded prior to (at 4 months of 
age), and following the stress/treatment period (at 5.5 months of age) for the 
six groups, non-stressed WT, stressed WT, non-stressed TASTPM, stressed 
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TASTPM, aniracetam-treated TASTPM and NBQX-treated TASTPM mice. 
All mice demonstrated a change in body-weight over time (P < 0.0001) and 
there was an overall difference between the six groups (P = 0.001). There 
appeared to be a difference in weight-gain between non-stressed WT and 
TASTPM mice but this did not reach statistical significance (P = 0.05) and 
there was no observed effect of repeated stress, or drug-treatments. 
WT TASTPM 
4 months 5.5 months 4 months 5.5 months 
Frontal 10.60 11.76 11.26 12.47 
cortex (1.39) (0.82) (0.66) (0.64) 
Hippoazmpus 11.41 11.04 11.06 10.45 
(0.86) (0.44) (1.11) (0.62) 
Table 4.1. Brain glutamate levels, Experiment 1. Mean (± SEM) 
glutamate (nmoles per mg tissue) in frontal cortex and hippocampus of 4 
month old WT (n=8) and TASTPM (n=8), and 5.5 month old WT (n=7) and 
TASTPM (n=8). There was no effect of Age, Strain, or a Strain X Age 
interaction for either frontal cortex or hippocampal glutamate levels. 
Defecation was counted at the end of each novel cage stress session for the 
three stressed groups: stressed WT and TASTPM, and NBQX-treated 
TASTPM mice. Changes in defecation levels over the stress period for all mice 
did not change over time, but there was an overall difference between the three 
groups (P < 0.0001). A multiple comparisons test revealed a significant 
difference between stressed WT and TASTPM mice (P < 0.0001) and between 
stressed TASTPM and NBQX-treated TASTPM mice (P = 0.044), figure 4.7. 
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Figure 4.7. Novel cage stress, Experiment 2. Mean (± SEM) defecation 
count for stressed WT (n=8), TASTPM (n=8) and NBQX-treated TASTPM 
mice (TASTPM (NBQX), n=8) over the 20 novel cage stress sessions. There 
was a difference in defecation counts between stressed WT and TASTPM 
mice (P < 0.0001) and stressed TASTPM and NBQX-treated TASTPM mice 
(P 
= 
0.044). 
Unconditioned behaviours during stress exposure 
To determine changes in unconditioned behaviours between the three stressed 
groups (stressed WT and TASTPM, and NBQX-treated TASTPM mice) in 
response to novel cage stress, rearing, grooming and tail-rattles were counted 
during the first and last stress exposure. Overall, there was a difference in tail- 
rattles and rearing comparing performance during the first session with last 
stress session (P = 0.034 and P=0.025 respectively), but there was no 
difference in grooming over time. There was no difference between the three 
groups in unconditioned behaviours, table 4.2. 
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First stress session 
Tail Groom Rear 
WT 0.14 7.43 22.43 
(0.14) (0.65) (5.48) 
Final stress session 
Tail Groom Rear 
0.00 7.14 30.00 
(0.00) (0.74) (8.80) 
TASTPM 9.71 5.43 11.00 
(5.68) (0.97) (4.10) 
TASTPM 12.25 9.00 22.25 
(NBQX) (7.30) (2.83) (4.88) 
0.00 5.43 24.57 
(0.00) (1.09) (11.56) 
0.00 6.75 39.88 
(0.00) (1.78) (10.37) 
Table 4.2. Unconditioned behaviours throughout the novel cage stress, 
Experiment 2. Mean (± SEM) tail-rattles (Tail), grooming sessions (Groom) 
and rearings (Rear) for the first and last novel cage stress expressed by 5.5 
month old stressed WT (WT, n=7), stressed TASTPM (TASTPM, n=7) and 
NBQX-treated TASTPM (TASTPM (NBQX), n=8). Tail-rattles and rearings 
changed over time (P < 0.05), whereas grooming sessions did not. There was 
no difference in unconditioned behaviours between the groups tested. 
Locomotor activity 
Locomotor activity was assessed following the novel cage stress/treatment 
period to determine any effects of these manipulations on habituation to a 
novel environment and total activity over 30 mins. Overall, all mice 
demonstrated habituation (P < 0.0001) and a difference between all groups 
nearly reached statistical significance (P = 0.079). However, a multiple 
comparisons test did not reveal any between-group differences and there was 
no difference in total activity throughout the 30 mins, table 4.3. 
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LMA habituation LMA 
0-5mins 5-10nwns 10-15mins 15-20mms 20-25mins 25-30nins Total activity WT 869.98 736.38 738.07 729.51 692.95 657.53 4424.42 (Non-stressed) (83.23) (46.06) (75.88) (72.31) (49.77) (80.81) (353.72) 
WT 1015.09 761.16 670.97 793.02 659.79 678.33 4578.36 (Stressed) (76.30) (70.91) (50.79) (51.40) (75.58) (83.22) (355.41) 
TASTPM 751.98 566.21 617.34 514.19 560.33 483.47 3493.52 
(Non-stressed) (71.75) (43.29) (48.52) (38.64) (42.36) (58.98) (250.62) 
TASTPM 916.43 727.66 675.03 632.24 654.01 613.90 4219.27 (Stressed) (57.12) (91.19) (57.83) (59.25) (75.33) (79.82) (374.46) 
TASTPM 917.54 685.75 732.75 672.91 723.26 720.12 4452.33 (Aniracetam) (63.79) (59.08) (83.75) (89.40) (66.92) (74.55) (392.93) 
TASTPM 918.91 742.27 733.25 722.44 634.10 739.17 4490.13 
(NBQX) (66.60) (57.84) (77.41) (65.85) (57.79) (59.84) (337.13) 
Table 4.3. Locomotor activity, Experiment 2. Mean (± SEM) habituation 
to the locomotor activity (LMA) chamber across six 5 min time intervals, and 
mean (± SEM) total activity (distance moved, cm) over the 30 min trial, for 
non-stressed WT (n=7), stressed WT (n=8), non-stressed TASTPM (n=8), 
stressed TASTPM (n=8), aniracetam-treated TASTPM (n=8), and NBQX- 
treated TASTPM (n=8). All mice exhibited a decline in activity throughout 
the trial (P < 0.0001), but there was no significant difference between groups 
in habituation, or total activity throughout the trial. 
Short-tem memory tests 
All groups of mice were subjected to memory acquisition of CFC following the 
stress/treatment period at 5.5 months of age. All mice, demonstrated a decline 
in overall activity (distance moved, cm) (P < 0.0001) indicating successful 
acquisition of contextual fear. There were no between-group differences. 
Moreover, there was no difference in activity throughout this trial when 
comparing memory acquisition of non-injected and injected, WT and TASTPM 
mice from Experiments I and 2. 
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When assessing changes in immobility across the memory retention and 
extinction trials, there was an overall effect of repeated Trial in all mice (P = 
0.038), but no significant difference between the six groups (P = 0.073), figure 
4.8A. A multiple comparisons test revealed a trend towards a difference 
between non-stressed WT and NBQX-treated TASTPM mice only, but this did 
not reach statistical significance (P = 0.05). As with memory acquisition, there 
was no difference between WT and TASTPM non-injected and injected mice 
with regard to performance across the memory retention and extinction trials. 
Extinction between memory trials was assessed in each group by the 
calculation of extinction indices. "Extinction", the difference between the final 
memory extinction trial and memory retention was significant in the stressed 
WT mice only (P = 0.031). "Extinction 1", calculated by subtracting 
performance during the memory retention trial from the first extinction trial, 
showed no statistical significance in any group studied, although, non-stressed 
TASTPM mice demonstrated an non-significant trend towards an increase in 
immobility (P 
= 
0.05). Finally, "Extinction 2", the difference between the first 
and final extinction trial, was significant in stressed WT mice only (P = 0.049), 
but did not quite reach statistical significance for non-stressed TASTPM mice 
(P 
= 
0.05) figure 4.88. 
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Immunohistochemical quantification of Q-amyloid 
Levels of ß-amyloid were quantified using immunohistochemistry in the 
retrosplenial cortex, hippocampus, corpus callosum, caudate putamen and the 
thalamus. There was no difference in mean percentage of area covered in ß- 
amyloid between the four groups of TASTPM mice, in any of the ROls 
studied. To assess any effects of five-weeks of repeated vehicle injection on 
TASTPM j3-amyloid levels, vehicle-treated non-stressed TASTPM from 
Experiment 2 were compared to age-matched non-injected TASTPM mice 
from Experiment 1. Injection had no effect on brain P-amyloid levels in the 
ROIs studied, table 4.4. Furthermore, there was no difference in numbers of 
dense-core or diffuse plaques in the retrosplenial cortex of the four groups of' 
TASTPM mice. 
'1'ASTPM nice 
Experiment I Experiment 2 
Non-stressed Non-stressed Stre. %ed Aniracetam NBQX 
Corpus 0.087 0.048 0.061 0.060 0.047 
callosum (0.030) (0.019) (0.020) (0.015) (0.014) 
Caudate 0.005 0.004 0.006 0.006 0.009 
putamen (0.002) (0.001) (0.001) (0.002) (0.003) 
Hippoeantpus 0.125 0.077 0.113 0.096 0.141 
(0.007) (0.023) (0.027) (0.012) (0.041) 
Retrosplenial 0.191 0.114 0.142 0.132 0.156 
cortex (0.032) (0.047) (0.055) (0.052) (0.047) 
Thalamus 0.151 0.087 0.111 0.078 0.098 
(0.026) (0.026) (0.032) (0.027) (0.040) 
Table 4.4. ß-amyloid pathology, Experiment 2. Mean (± SEM) percentage 
area covered in (3-amyloid for each ROI studied in non-stressed 5.5 month 
old TASTPM mice from Experiment I (n=6-8) and non-stressed (n=7-8), 
stressed (n=7-8), aniracetam-treated (n=7-8) and NBQX-treated (n=7-8) 
TASTPM mice from Experiment 2. There was no difference in P-amyloid 
levels between the four treatment groups, or any effects of repeated injection 
in non-stressed TASTPM mice when comparing non-stressed TASTPM mice 
from Experiments I and 2. 
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SC35 expression 
Levels of expression of SC35 protein was manually quantified in all groups of 
mice, both WT and TASTPM, results are expressed as a mean "intensity read- 
out" as described above in Section 4.2, where high expression scores 3, 
medium scores 2 and low scores 1. There was an overall difference between all 
groups in the caudate putamen (P < 0.0001), thalamus (P = 0.035), 
hippocampal dentate gyrus (P < 0.0001), CAI (P < 0.0001) and CA3 (P = 
0.001) but not in the retrosplenial cortex (P = 0.05). There was no detectable 
effect of 5 weeks of novel cage stress on SC35 expression in the ROIs studied 
in either WT or TASTPM mice. Non-stressed TASTPM mice showed 
significantly lower SC35 expression compared to non-stressed WT mice in the 
caudate putamen (P = 0.042), dentate gyros (P = 0.003), CAI (P = 0.002) and 
CA3 (P 
= 
0.003). Moreover, stressed TASTPM had a lower SC35 expression 
compared to stressed WT mice in the caudate putamen (P = 0.030) and dentate 
gyros (P = 0.022), table 4.5. There were no differences when comparing the 
expression of SC35 in all ROIs, between non-stressed and aniracetam-treated 
TASTPM mice, or between stressed and NBQX-treated TASTPM mice. 
As with the ß-amyloid studies, expression of SC35 in 5.5 month TASTPM 
mice from Experiment I were compared to age-matched non-stressed 
TASTPM mice in Experiment 2 to determine any effects of repeated injection; 
there was a significant difference between the two groups in the corpus 
callosum only (P = 0.012), where injected mice had lower SC-35 expression. 
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WT TASTPM 
Non-stressed Stressed Non-stressed Stressed Aniracetam NBQX Non-injected 
Retroplenial 2.70 2.75 2.30 2.17 2.08 2.22 2.20 
cortex (0.08) (0.06) (0.24) (0.16) (0.23) (0.25) (0.07) 
Corpus 2.00 1.94 1.53 1.72 1.65 1.70 $ 2.23 
callosum (0.19) (0.10) (0.19) (0.18) (0.16) (0.17) (0.11) 
Caudate 2.27 
purarnen (0.14) 
2.27 * 1.61 # 1.60 1.54 1.48 1.34 
(0.11) (0.20) (0.14) (0.17) (0.12) (0.08) 
Thalamus 2.37 2.40 1.74 1.96 1.95 1.87 1.59 
(0.08) (0.07) (0.19) (0.16) (0.22) (0.19) (0.05) 
Dentate 2.63 2.48 1.73 # 1.76 1.76 1.82 1.92 
gyrus (0.11) (0.10) (0.18) (0.11) (0.20) (0.19) (0.11) 
CAI 2.74 2.60 "" 1.76 2.04 1.96 1.98 2.03 
(0.08) (0.07) (0.19) (0.16) (0.21) (0.20) (0.03) 
CA3 2.73 2.58 1.88 2.03 2.07 2.13 2.01 
(0.08) (0.08) (0.17) (0.09) (0.17) (0.22) (0.06) 
Table 4.5. SC35 expression, Experiment 2. Mean (± SEM) intensity score 
(± SEM) for expression of SC35 in all ROIs studied for non-stressed WT 
(n=6-7), stressed WT (n=8), non-stressed TASTPM (n=7-8), stressed 
TASTPM (n=7-8), aniracetam-treated TASTPM (n=7-8), NBQX-treated 
TASTPM mice (n=6-8) form Experiment 2, and non-stressed, non-injected 
TASTPM mice from Experiment 1 (n=6). SC-35 expression was significantly 
lower in non-stressed TASTPM, compared to non-stressed WT mice (*P < 
0.05, **P < 0.01) and in stressed TASTPM compared to stressed WT (*P < 
0.05). There was a significant reduction in SC-35 expression in the corpus 
callosum of injected non-stressed TASTPM mice compared to non-injected 
TASTPM mice only (5P = 0.012). 
4.4. Discussion 
A previous study by our group demonstrated how the TASTPM mouse 
developed a short-term memory deficit at 5.5 months of age, which was 
prevented with pre-exposure to repeated mild stress (Pardon et al., 2009). The 
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aim of the studies described above were to, first, further investigate age-related 
changes in memory performance in TASTPM mice and how these correlate 
with changes in levels of the excitatory amino acid glutamate. Second, given its 
interaction with stress, memory systems and AD, AMPAr signalling was 
targeted pharmacologically to either prevent or mimic the beneficial effects of 
repeated mild stress on AD-associated pathologies exhibited by TASTPM 
mice. 
No detectable changes in short-term memory retention were found between 4 
and 5.5 months of age in TASTPM mice. However, consistent with other 
studies described previously in this thesis, a short-term memory extinction 
deficit appears to develop in TASTPM mice between 4 and 5.5 months of age 
- 
a time point known to correlate with increasing brain ß-amyloid levels (Pardon 
et al., 2009), but we found no age-related changes in brain glutamate levels. In 
the investigations described above, stress was incapable of affecting AD- 
associated pathologies in TASTPM mice, and manipulations of the AMPAr 
signalling had little effect on these factors. 
The first experiment dealt with investigating changes in short-term memory 
performance that occur between 4 and 5.5 months of age in TASTPM mice. 
Although, here, we were not able to replicate the age-related short-term 
memory retention deficit in TASTPM mice as observed in our previous study, 
5.5 month old TASTPM mice did have a lower level of memory retention as 
compared to younger 4 month old TASTPM mice (immobility, sec, 129.66 ± 
6.20 vs. 154.13 ± 4.49). Despite this difference not reaching statistical 
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significance it may indicate a decline in memory performance over time, as 
demonstrated previously (Pardon et al., 2009). In addition, a short-term 
memory extinction deficit appeared to develop between the ages of 4 and 5.5 
months of age in TASTPM mice which is consistent with findings described in 
Chapter 3. Given we know of an age-related increase in brain ß-amyloid levels 
in TASTPM mice between these two ages, these changes in cognitive function 
add support to the hypothesis that ß-amyloid can influence memory 
performance in such mice (for review, (Morgan, 2003)). The method by which 
ß-amyloid can modulate memory performance in not fully known, but cell loss 
due to its local neurotoxic effects is one possibility (see Section 1.1.2. and 
references therein). Indeed, cell loss has been observed as a later-stage 
pathology in (3-amyloid over-expressing mouse models (see Section 1.2.3 and 
references therein), which may be at least partly responsible for memory 
deficits observed in such mice. Evidence exists demonstrating lower 
neurotransmitter levels, possibly a downstream event of cell loss, in ß-amyloid 
overexpressing transgenic mice, including the main excitatory amino acid 
transmitter, glutamate (Marjanska et al., 2005; von Kienlin et al., 2005; Oberg 
et al., 2008), findings which support the known lowered brain glutamate level 
observed in clinical AD (Hyman et al., 1987). Contrary to these observations, 
TASTPM mouse brain glutamate levels were no different to those of WT mice 
and did not change with age. One possible explanation for this discrepancy 
may be that changes in glutamate are strain-dependant and that different 
mutations expressed in various transgenic mouse models may alter the 
aggression, or form of the pathology (for instance, leading to varying degrees 
of neuronal cell loss). Another possibility is that between 4 and 5.5 months of 
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age is still considered an early stage of (3-amyloid pathology, and it is likely 
that if a drop in glutamate levels was to occur in the TASTPM mouse brain, it 
would be easier to detect during the later stages of the pathology. The lack of 
changes in glutamate levels in young TASTPM mice indicate that the changes 
observed in the functioning of memory systems, for instance the development 
of a memory extinction deficit, do not necessarily correlate directly with levels 
of this neurotransmitter. It is worthy of note that our study employed HPLC to 
measure glutamate 
-a technique which allows only the determination of tissue 
glutamate content, as opposed to extracellular glutamate levels which can be 
measured by microdialysis. Using microdialysis could, therefore, be a potential 
follow-up study given it can provide more information on the functional 
neurochemistry of TASTPM mice brains. 
Experiment 2 aimed to determine to what extent repeated mild novel cage 
stress exerts its effects on TASTPM mice through glutamatergic signalling. 
Studies have shown that exposure to stressors enhance glutamatergic 
transmission (Moghaddam, 2002; Quinton and Yamamoto, 2007) and blocking 
such transmission prevented the effects of stress on physiological responses, 
such as hyperthermia (Iijima et al., 2007). More direct links between the 
stressor we use, and glutamatergic function exists; for instance, one hypothesis 
is that novel cage stress affects mice through enhancing exercise and elevating 
stimulation through enrichment, both requiring glutamatergic function (Leung 
et al., 2006; Segovia et al., 2006). Despite the connection between brain 
glutamate levels and memory performance being shown not to correlate in the 
current study, there is evidence in the literature demonstrating that blocking 
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glutamatergic transmission can interfere with performance in memory-based 
paradigms, such as fear conditioning (Schulz et al., 2001). Given that stress is 
widely believed to interact with memory performance in rodents (see Section 
1.3.1 and references therein), it is possible that glutamate transmission is, at 
least, partially responsible for underlying stress and memory interactions. As 
described in Section 4.1, glutamate signalling through AMPAr receptors 
appears to be a plausible candidate. It is important to note at this point, 
however, that although we targeted AMPAr, which are believed to be involved 
in memory systems and stress responses (see Section 4.1) other glutamate 
receptors such as the N-methyl-D-aspartic acid (NMDAr) are still active. Like 
the AMPAr, NMDAr have been shown to be involved in conditioned memory, 
as receptor antagonists impair memory performance (Mathur et al., 2009) and 
are believed to play a role in the stress response (Schasfoort et al., 1988). 
Therefore, although we targeted a key glutamate receptor in these studies, 
glutamate signalling could continue through alternative pathways such as the 
NMDAr. 
We exposed a group of TASTPM mice to novel cage stress, the hypothesis 
being that exposure to novelty regularly elevated glutamate transmission, thus 
providing a beneficial stimulus to protect memory systems against decline. 
Half of these stressed TASTPM mice were pre-treated with the AMPAr 
antagonist NBQX to reduce AMPAr signalling due to elevated glutamate 
release during the stress session. Consistent with previous findings, defecation 
level throughout the stress procedure, indicative of emotional reactivity to 
novelty, was higher in TASTPM than WT mice (see Section 3.2). Interestingly, 
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pre-treatment with NBQX appears to have lowered the defecation number, 
indicative of a lowered emotional reactivity in this group. If this was indeed the 
case we would have expected some changes with unconditioned behaviours 
exhibited during stress exposure, however, there was a lack of any significant 
effect of NBQX-treatment on such behaviours. It is possible that a lack of 
effect may be due to weak statistical power given the large variability within 
groups; during the first stress session, mean body rears was over double for 
NBQX-treated TASTPM mice compared to control TASTPM mice, but this 
was not statistically significant. 
In terms of the long-term effects of stress, with or without NBQX exposure, on 
short-term memory function, there was no difference as neither group 
demonstrated a memory retention deficit, and both groups exhibited the 
memory extinction deficit. The absence of an effect of NBQX on memory 
performance is not consistent with a previous study demonstrating the drugs 
ability to disrupt conditioned memory behaviours in mice at the same dose 
(Mead et al., 1999). One major difference between these two studies is that the 
authors administered the drug 15 mins prior to behavioural testing, whereas 
there was a two day wash-out period in our study, which was designed so as to 
investigate the downstream behavioural effects of stress exposure. NBQX may 
only, therefore, affect memory performance during the period in which it was 
present in glutamatergic synapses. Re-addressing the hypothesis with the 
evidence described and presented above it seems clear that elevated signalling 
through AMPAr during the novel cage stress exposure is unlikely to be 
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important in the mechanism linking the stressor with the previously described 
beneficial effects. 
A separate group of non-stressed TASTPM mice were assigned to two 
different treatment groups; one was exposed to repeated administration of the 
AMPAr positive modulator aniracetam. Despite not being statistically 
significant, there appeared to be a slight increase in locomotor activity in the 
aniracetam-treated group compared to the controls. Although there was no 
gross effect of aniracetam treatment on memory retention, control mice 
demonstrated increased memory from the memory retention to the first 
extinction test and a drop in memory expression between the first and the final 
extinction test, neither of which was demonstrated by the aniracetam-treated 
TASTPM mice. The reason for these differences between the two groups is not 
clear; previous studies using the same dose showed that the drug was capable 
of improving memory performance in mice (Lu and Wehner, 1997; Smith and 
Wehner, 2002). However, as with the NBQX group, the wash-out period 
between the two studies was different, but the results presented above do 
indicate that aniracetam, although incapable of affecting short-term memory 
retention, may affect the complex processes underlying extinction of memory 
in TASTPM mice. Expression of memory extinction represents an active form 
of relearning (for review, (Cammarota et a1., 2007)) and is therefore different 
from memory retention, which is simply expression of a conditioned response. 
Aniracetam may be capable of disrupting the systems which deal with 
extinction only, indeed, disruptions in glutamate transmission have been linked 
to changes in the expression of memory extinction (Kim et al., 2007). It is 
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possible that daily increases in glutamate transmission, induced by repeated 
aniracetam exposure, are capable of affecting memory extinction performance 
of TASTPM mice (a process we know to be deficient from an early age) but 
had no effect on memory retention performance. Interestingly, it has been 
previously shown that normal AMPAr function is required for memory 
extinction, but not memory acquisition (Dalton et al., 2008). The absence of a 
stress effect on extinction, or memory retention, suggests that the links between 
glutamate and the stress response are weak, as was found with the NBQX study 
described above. An interesting point arising from Experiment 2 is that 
although stress had no effect on memory retention or extinction in TASTPM 
mice, it appears to have facilitated normal extinction behaviour in WT mice 
(used as a control group in the above experiments). 
Consistent with findings from Chapter 3, stress was incapable of changing P- 
amyloid pathology in 5.5 month old TASTPM mice as determined by 
immunohistochemistry and neither NBQX nor aniracetam was capable of 
changing ß-amyloid levels. Interestingly, although clinically available drugs 
targeting the glutamatergic system to prevent excitotoxicity were not originally 
aimed at lowering ß-amyloid pathology, some evidence exists to show that the 
NMDAr antagonist memantine may be capable of lowering ß-amyloid levels 
(for review, (Rogawski and Wenk, 2003)), although to our knowledge no such 
evidence exists linking AMPAr and ß-amyloid production. As aniracetam 
enhances signalling through glutamatergic pathways and NBQX reduces 
signalling, it is surprising that altering the levels of neuronal firing, over a5 
week period had no effect on ß-amyloid levels given neuronal activity is 
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thought to be positively correlated to ß-amyloid secretion (Kamenetz et al., 
2003). This evidence is contradictory, however, to the notion that 
environmental enrichment can attenuate brain ß-amyloid levels (Lazarov et al., 
2005), a treatment which likely leads to elevated brain activity. 
SC35 is a serine-arginine rich splicing factor, the expression of which is 
elevated during states of stress (Meshorer et al., 2005). Stress-induced 
elevation of SC-35 leads to the alternative splicing of AChE to a variant 
expressed in stress states (Meshorer et al., 2005). This alternatively spliced 
read-through AChE (ACNE-R) is thought to be neuroprotective against ß- 
amyloid and is under-expressed in the brains of AD sufferers (Berson et al., 
2008). SC35 is also capable of changing the flop: flip ratio of AMPAr (Crovato 
and Egebjerg, 2005), to a formation associated with reduced signalling 
following activation by glutamate. This, overall, would suggest that stress- 
induced SC35 may reduce glutamate transmission through this system, but may 
also provide neuroprotection through enhanced expression of AChE-R. There 
were differences between WT and TASTPM mouse base-line expression of 
SC35; in all cases TASTPM mice had lower SC35 expression. Interestingly, 
AChE-R has been shown to be lower in the AD-affected brain, indicating a 
possible link existing between lower SC35 expression in the presence of ß- 
amyloid (Berson et al., 2008). The absence of a stress effect on SC35 in either 
strain was unexpected; this may have been due to the length of time following 
the last stress session to death (I I days), although studies have demonstrated a 
long-term, rather than just acute, elevation of SC35 following stress (Meshorer 
et al., 2005); it is worthy of note that the current study and this cited study used 
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two different stressors, the later being the more severe cold water stress. To our 
knowledge there have been no studies investigating the effects of mild stressors 
on SC35 expression. There was no detectable effect of the glutamatergic 
treatments on SC35 expression in TASTPM mice, suggesting that AMPAr 
function does not directly feedback to the expression of SC35. 
Potential confounding factors should be addressed in relation to studying SC35 
in these mice, including the stressful nature of the behaviour tests used. For 
instance, the intensity of the learning trial during the contextual fear 
conditioning memory test; all mice, including non-stressed mice, were exposed 
to footshocks known to induce a classic stressful response (Baez et al., 1996), 
also, mice were exposed to novelty during the locomotor activity tests. These 
manipulations after the treatment period may have dampened any subtle 
changes to SC35 expression which may have changed with the various 
treatments. Another possible factor is that all mice were exposed to a daily 
injection, which likely elicits a stress response and, therefore, may lead to 
unwanted changes in SC35 expression in this study. However, only one 
injection-associated change was observed between non-injected and injected 
TASTPM mice in the above studies, a decrease in corpus callosum SC35 
expression in injected mice. This drop in SC35 expression was contrary to 
what we expected, which would have been an increase in expression in injected 
mice that would have likely experienced this daily stressor. In general, injected 
mice had little change in SC35 levels, which was consistent with the finding 
that repeated injection had no detectable effect on either memory performance 
in WT and TASTPM mice, or ß-amyloid levels in the brains of TASTPM mice; 
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this indicates SC35 expression, memory systems and ß-amyloid pathology are 
no directly correlated in this study. 
These studies aimed to investigate the role of glutamate signalling, first on age- 
related changes in memory performance and, second, on the stress-induced 
changes in AD-associated pathologies in TASTPM mice. It appeared that 
behavioural changes and increases in brain ß-amyloid that occur in young 
TASTPM mice did not correlate with changes in brain glutamate levels. 
Furthermore, both enhancing glutamatergic signalling through AMPAr to 
mimic repeated stress exposure, or decreasing signalling during stress 
exposure, were incapable of modulating gross AD-associated pathologies. 
Taken together, these studies indicate that glutamate levels and signalling 
through AMPAr, despite being clinical targets for AD therapy, had little 
influence on early pathological changes in TASTPM mice and appeared not to 
underlie the changes that occur with exposure to repeated mild stress. 
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CHAPTER 5 
GENERAL DISCUSSION 
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5.1. Reviewing the aims and hypothesis 
As described in detail in Chapter 1, a variety of tools are available to study 
AD-like pathology preclinically, one of which is the 0-amyloid over- 
expressing transgenic mouse model. A growing body of clinical and preclinical 
evidence indicates that a link exists between emotional stressors and AD- 
associated pathologies. While most preclinical studies imply that relatively 
severe stressors exacerbate 0-amyloid-associated pathology in transgenic 
mouse models, a study by our group found that a repeated mild stressor 
improved AD-associated pathology in double transgenic TASTPM mice 
(Pardon et al., 2009). This thesis aimed to, first, optimise a behavioural 
paradigm to determine memory performance in TASTPM mice. Once this, 
along with other tests to assess AD-like pathology in TASTPM mice were set 
up, they were employed to describe the progression of pathology in the mild- 
to-moderate stages of ß-amyloid pathology in TASTPM mice and how such 
pathologies are affected by novel cage stress. With these studies, the time-point 
at which optimal effects of repeated mild stress on TASTPM mice were 
observed was investigated further in order to identify underlying mechanisms, 
specifically, the involvement of signalling through the AMPAr 
-a major 
component of the glutamatergic neurotransmitter system. 
5.2. Summary of key findings 
Contextual fear conditioning was a suitable test to study both short- and long- 
term memory in mice. Using this test, along with various other assessments of 
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pathological burden, our studies indicated that novel cage stress was beneficial 
with regard to AD-associated pathologies in TASTPM mice. The most robust 
effect was observed between 4 and 5.5 months of age when TASTPM mice 
developed a short-term memory deficit during a time corresponding to rapidly 
increasing brain 0-amyloid levels. Novel cage stress prevented this memory 
impairment and lowered ß-amyloid load. This time-point was subsequently 
used to investigate the role of glutamate signalling via the AMPAr in this stress 
effect. It appears, from the studies detailed in this thesis, that AMPAr activity 
was not directly involved in this link between repeated mild stress and AD-like 
pathology in TASTPM mice, described in more detail below. 
5.3. Early AD-like pathology in TASTPM mice, and effects of novel cage 
stress 
As discussed in detail in Chapter 3a short-term memory extinction deficit 
developed in TASTPM mice between 3 and 4.5 months of age. Short-term 
memory retention remained intact in TASTPM mice until 5.5 months of age, 
whereas long-term memory retention remained intact in TASTPM mice at all 
ages studied. Repeated mild stress reversed the short-term memory retention 
deficit, but had no effect on long-term memory retention. Interestingly, stress 
had no effect on the seemingly robust short-term memory extinction deficit, but 
appeared to enhance long-term memory extinction in the oldest group of 
TASTPM mice only, at 6.5 months of age. It is likely that these differences in 
short- and long-term memory performance, with or without stress, in TASTPM 
mice, arises from the nature of the memories involved which are thought to be 
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held in different brain areas (Wiltgen et al., 2004), as discussed in Section 
3.2.4. 
In vivo measures of pathological burden through MRI revealed that stress was 
capable of modulating pathological markers, confirming this technique as a 
potential method to study disease status in mice. Pre-exposure to repeated mild 
stress lowered brain 0-amyloid levels in 5.5 month old TASTPM mice, which 
correlated with the improved short-term memory performance. Collectively, 
the results from the above studies confirm that environmental manipulations 
are capable of modulating early pathological changes in 3-amyloid- 
overexpressing transgenic mice, but unlike the majority of previous studies 
looking at exposure to more severe stressors (see Section 1.4) a milder stress 
procedure appears to attenuate, rather than potentiate, AD-like pathology. 
Mild stressors are generally thought to be beneficial in normal aging through 
activation of adaptive response pathways leading to anti-aging effects, a 
process called hormesis (for review, (Rattan, 2004)); it is therefore possible 
that in the studies described throughout this thesis, repeated novel cage stress 
provided sufficient hormesis, which was protective against the pathological 
insults in TASTPM mice. Alternatively, these positive effects detected may 
simply be due to elevated levels of physical exercise known to occur during the 
novel cage stress exposure (Pardon et al., 2004; Pardon et al., 2005). Indeed, as 
described in Section 1.4.2., enhanced exercise is believed to be beneficial to 
AD-like pathology in both clinical (Fratiglioni et al., 2004) and preclinical 
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studies (Adlard et al., 2005), as well as general aging (Castillo-Garzon et al., 
2006). 
5.4. The role of glutamate signalling 
As described in Section 4.1, neuronal signalling through AMPAr is important 
in the stress response, plus AMPAr activity is lower in (3-amyloid 
overexpressing mice (Chang et al., 2006). Such evidence presented altered 
AMPAr function as a likely candidate linking stress and AD-like pathology in 
TASTPM mice. A further link emerged from the literature, i. e. that the splicing 
factor SC35 elevated during states of stress is capable of lowering AMPAr 
signalling, and inducing the expression of a variant of the acetylcholinesterase 
enzyme, thought to be protective against (3-amyloid related insults. We, 
therefore, investigated whether a pharmacological attempt to increase AMPAr 
signalling was capable of mimicking stress, and if blocking AMPAr function 
during stress could prevent its positive effects, whilst also looking at whether 
these treatments, or stress itself, was capable of affecting SC35 expression. 
Neither treatment gave rise to significant changes in memory performance, or 
brain ß-amyloid burden. It appears from these studies that AMPAr activity 
plays little role in the beneficial effects of novel cage stress on TASTPM mice, 
it is possible, however, that AMPAr signalling could modulate pathological 
markers which were not tested here. Other potential mechanisms underlying 
this link are discussed in Section 5.6 
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5.5. Subjective scoring of rodent behavioural studies 
Some of the key findings in this thesis came from behavioural paradigms 
which had subjective endpoints. It has been recognised that "manual" scoring 
of animal behaviour data, for instance immobility associated with a fear 
conditioning paradigm, can vary between investigators and this can lead to 
variations in the outcomes of studies (Pham et a]., 2009). The nature of 
behavioural scoring, for example, what an investigator considers to be an 
immobile animal, will inevitably vary between laboratories, thus making 
comparisons in behavioural results across groups difficult. In the investigations 
described in this thesis, all behavioural experiments involving subjective 
scoring of immobility behaviour were scored blind by the same investigator 
using consistent scoring criteria. To ensure internal consistency existed, the 
performance during one behavioural experiment (comparing CFC memory 
retention in non-stressed and stressed TASTPM mice) was re-scored using the 
same criteria after a gap of over one year and with several studies intervening 
between scorings. Results were compared using a two-way ANOVA with 
Stress and Scoring (first vs. second scorings) as the between-subject factors, 
using Tukey's post-hoc test for multiple comparisons. There was no effect of 
Stress, and no difference between the two scores, for either group, (see table 
5.1). This provides evidence that all studies conducted within this thesis are 
consistent for the same observer, and therefore, effectively comparable to each 
other. 
203 
TASTPM mice 
Non-stressed Stressed 
First 150.90 158.53 
scoring (8.14) (6.08) 
Second 140.77 152.37 
scoring (7.30) (5.28) 
Table 5.1. Within-experimenter consistency in behavioural scoring. Mean 
immobility (sec, ± SEM) during a CFC memory retention trial for non- 
stressed (n=7) and stressed (n=7) TASTPM mice. There was no difference in 
immobility between non-stressed and stressed mice during either score, and 
there was no overall difference between the two scores. 
However, behavioural data from such experiments scored by a different 
investigator could give rise to different values in such experiments, as 
described previously (Pham et al., 2009). Such differences likely arise from 
subtle variations in the subjective criteria of behavioural scoring; for instance, a 
total lack of mobility maybe easily scored equally by all investigators, but 
smaller, more subtle body movements require a decision to be made by the 
investigator as to whether or not this is to be considered "immobility". In order 
to test this using a behavioural study described in this thesis, immobility scored 
by myself for a CFC memory retention study (comparing immobility of WT 
and TASTPM mice), was compared to that of another experienced investigator. 
To compare the subjective outcomes from these different observations I re- 
scored the immobility for this experiment, strictly abiding by the second 
investigator's scoring criteria. All data were analysed using a two-way 
ANOVA with Strain and Scoring as the between-subject factors, and Tukey's 
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post-hoc test was used for multiple comparisons. The key findings of this 
analysis were as follows: first, there were significant differences between my 
original scores and the second investigator's scores (P < 0.0001); second, 
adopting the scoring criteria of the second investigator gave data that were not 
significantly different between the two scorers (table 5.2). Overall, this limited 
investigation into the nature of immobility scoring demonstrates the well 
known subjective nature of behavioural analysis (Pham et al., 2009), and that 
through adopting another investigator's criteria, differences in the dataset can 
be apparent. 
WT TASTPM 
Experimentor 1 Score 1 118.40 153.39 
(11.66) (5.41) 
Score 2 62.37 102.08 
(15.93) (6.02) 
Ezperirrentor 2 58.97 102.33 
(17.15) (4.70) 
Locomotor activity 219.22 100.38 
(42.74) (11.52) 
Table 5.2. Comparing behavioural scoring between two investigators. 
Mean immobility (sec, ± SEM) and locomotor activity (distance moved, cm) 
of WT (n=7) and TASTPM mice (n=8) during the CFC memory retention 
trial. Experimenter 1 used their original scoring criteria (score 1) and adopted 
that of Experimenter 2 (score 2). There was no difference in immobility 
between WT and TASTPM mice using any scoring criteria. There was a 
significant difference between Experimenter I's Score I and Score 2 (P < 
0.0001) and Experimenter I's Score I and Experimenter 2's scores (P < 
0.0001). There was, however, no difference in scores between Experimenter 
I score 2 and scores by Experimenter 2. 
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On comparison of the scoring criteria employed, it appeared that the difference 
between the two investigator's scores was largely due to the exclusion of minor 
head movements as part of the immobility behaviour in the original scorings. 
The fairly low intensity footshocks (0.4mA) administered throughout the 
behavioural studies described in this thesis lead to a behaviour expressed as 
immobility rather than a more clear-cut freezing, which would be easier to 
quantify. Thus, small movements, such as head twitches, can lead to different 
end-scores. Locomotor activity can be used as a "back-up" measure to support 
immobility scores as one expects an inverse relationship between the two 
measures. Indeed, in the study outlined above locomotor activity (total distance 
moved during the trial) does match the outcome of the immobility scores; 
generally there was higher ambulation in the TASTPM compared to the WT 
mice, although this did not reach statistical significance, table 2. This is not, 
however, an ideal measurement of conditioned fear; for example, it scores a 
complete 360° rotation of the mouse on the spot, as inactivity, which is clearly 
not the case. It has been recommended that to standardise behavioural 
measurements, such as those described above, one could rely on automated 
analysis software capable of discriminating immobility from mobility in 
laboratory rodents (Pharr et al., 2009), this may present a solution to this well 
known issue. 
Indeed, efforts were made by our group to attempt to set-up an automated 
measure of fear-related immobility in the mouse, but the results were not fully 
convincing, and problems were likely due to similar issues associated with 
automated measures of locomotor activity during these tests, described above. 
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Whether or not one includes small behaviours, such as minor head twitches, in 
their scoring of mouse immobility, it is clear that the measure of immobility, 
used consistently throughout this thesis, was a fear-response which relied on 
the memory of prior footshock administration, as demonstrated in the initial 
method optimisation (described in Section 2.1). 
Together the comparisons of scorings summarised above highlight the 
importance of every experimenter within a research group adopting the same 
rigid set of criteria for behavioural scoring and if all studies are scored 
consistently by the same experimenter, then results should remain accurate and 
comparable, ensuring the same behavioural process is measured. Standardising 
behavioural scoring between laboratories to allow for cross-laboratory 
comparisons is largely unrealistic; although using an automated analysis tool 
may help. 
Indeed, with the benefit of hindsight, modifications to the execution of other 
methodologies described within this thesis could be made to improve the 
output. For instance, problems arising from the nature of brain sectioning, part 
of the immunohistochemistry procedure, lead to different numbers of 
representative sections for analysis being available between studies; this, 
therefore, made direct comparisons of ß-amyloid pathology between studies 
impossible. Another potential issue that is worthy of note was the intensity of 
the CFC memory test. Exposure to footshocks is itself a stressor (Baez et al., 
1996), and such shocks may impact on the effects of pre-exposure to 5 weeks 
of repeated novel cage stress. Lowering the number of footshocks administered 
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during the CFC training trial, for instance, may reduce stress experienced by 
the mouse, therefore making the test more appropriate for these experimental 
conditions. It is important to reflect on such potential issues surrounding this 
body of work, and work similar to this, to improve experimental rigor for 
future studies. 
5.6. Future directions 
To expand on the studies detailed in this thesis, it is important to establish the 
changes which occur in the mouse with exposure to novel cage stress. An in 
vivo approach, such as microdialysis, to measure extracellular levels of various 
neurotransmitters during novel cage exposure could provide a clearer picture of 
how stress mediates its effects on TASTPM mice. For instance, using this 
technique, acetylcholine has been shown to be elevated during emotional 
arousal (Imperato et al., 1991). If, indeed, acetylcholine levels are found to be 
elevated during novel cage stress exposure this system would be a potential 
target as an underlying mechanism. However, information on neurotransmitter 
levels would need to be coupled with knowledge of the state of the receptor 
and signal transduction systems; studies into protein expression using 
techniques such as Western blotting to determine receptor expression would 
provide a more complete picture of the changes which occur following novel 
cage stress exposure. 
We know from previous studies that novel cage stress induces elevated levels 
of activity in mice (Pardon et al., 2004), which provides an indication that this 
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acts as an enriching stimulus. Brain-derived neurotrophic factor (BDNF), a 
protein which supports cell survival, is known to be elevated following 
exercise (for review (Cotman and Berchtold, 2002), and is believed to protect 
neurons against the neurotoxic effects of ß-amyloid-overexpression in 
transgenic mouse models of AD (Um et al., 2008). It is possible that increases 
in activity during novel cage stress lead to elevated BDNF expression, and 
subsequent heightened neuronal survival, therefore, giving rise to a positive 
end-point. As it is generally accepted that BDNF is elevated during states of 
environmental enrichment (Adlard et al., 2004) and is protective against AD- 
associated insults (Um et al., 2008), this would be an appropriate target to 
study the beneficial effects of repeated mild, novel cage stress. 
Many research groups have recently focused on effects of corticotrophin 
releasing factor (CRF), a component of the stress response pathway and HPA 
axis, which appears to play a key role in the modulation of AD-like pathology 
with stress. For example, CRF administered to ß-amyloid-overexpressing 
transgenic mice mimicked the negative effect of acute severe stress (Kang et 
al., 2007) and evidence suggests that CRF receptors mediated the 
phosphorylation of tau protein following acute stress (Rissman et al., 2007). 
CRF signalling thus appears the appropriate target if one was to study the 
negative effects of a severe stressor. It is unlikely, however, that the beneficial 
effects of the repeated mild stress procedure described in this thesis would have 
the same neurochemical consequences as acute severe stress which adversely 
affects AD pathology. 
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There are, clearly, several possible mechanisms which may underlie the 
beneficial effects of novel cage stress on AD-like pathology in TASTPM mice; 
whether these effects are due to altered neurotransmitter signalling, improved 
cell survival due to up-regulation of neuroprotective agents, or due to an event 
directly part of the stress response, is yet to be determined. 
5.7. Conclusion 
A better understanding of the effects of lifestyle factors on the development of 
neurodegenerative disorders, such as AD, will improve our recognition of those 
at risk of developing the disorder. Moreover, discovering pathways underlying 
such links may open novel therapeutic avenues. In the studies described 
throughout this thesis, repeated mild stress seems to be beneficial to AD-like 
pathology in ß-amyloid-overexpressing mice. This effect appears to be 
dependent on the pathological status of the animal, the type of memory tested 
and the methods by which they are studied; therefore such considerations are 
important when planning future studies into this area. Signalling through 
AMPAr appears to not play a key role in this beneficial effect, but further 
studies, as described above, should elucidate the underlying mechanisms. 
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